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ABSTRACT
Dengue is a major public health problem in many parts of the tropical developing world.
Dengue is caused by infection with one of four serotypes of dengue virus (DENVI-4), which
are arboviruses belonging to the Flaviviridae family. Although most DENV infections are
asymptomatic, mild, or self-limited, a proportion of dengue fever cases result in clinically
apparent disease that varies in severity from mild undifferentiated fever through to more
severe syndromes, primarily dengue haemorrhagic fever (DHF) and dengue shock syndrome
(DSS).
The main work described in this thesis was to examine molecular epidemiology of DENV
over the last 10 years in southern Vietnam (1999-2008) and to document DENV molecular
epidemiology in the 2007 dengue outbreak in Dong Thap province, a Mekong Delta province,
southern Vietnam. A further purpose was to assess the utility of two commercial NS I antigen
test kits, Platelia NSI-ELISA and NSI-Lateral Flow Rapid (NSI-LFRT), for early diagnosis
of acute dengue infection in relation to immune status, DENV-reactive measurable IgM/lgG,
viraemia level, and duration of illness prior to patient specimen collection.
Sequence analyses of Vietnamese DENV-l and DENV-2 revealed that these viruses
comprised significant genetic diversity. DENV-2 exhibits 3 distinct genotypes,
American/Asian, Asian I and Cosmopolitan. DENV-I viruses have become predominant in
Vietnam since 2006, and circulate as 6 distinct lineages within genotype I. The most striking
finding of this work was the replacement ofDENV-2 genotype in the context of serotype shift
occurring in southern Vietnam; both of which were temporally linked to increased disease
incidence. The American! Asian genotype which has circulated in HCMC and surrounding
provinces since at least 1987 was displaced by the DENV-2 Asian I genotype preceding the
change in serotype from DENV-2 to DENV-I. However, negative selection appears to be the
major evolutionary factor impacting DENV population dynamics.
Evaluation of the diagnostic accuracy for the two commercial NS I test kits consistently
showed that viraemia level in acute phase NS l-positive patients is higher than in NS 1-
negative patients. NS I sensitivity was also greater in patients with primary infection.
xiv
Proportion ofNS1 positivity was generally greater in DF cases. Duration of fever time prior to
patient blood samples collected also contributes to NS I sensitivity. Both DENY-reactive IgG
and IgM were negatively correlated with NS 1 sensitivity, but IgG showed stronger influence
on NS 1 positivity rate. NS 1 sensitivity is also different in individual infecting serotypes;
DENY-2 consistently shows lower positive NS1 results for both test kits. Overall, NS1-LFRT
was modestly less sensitive than Platelia NS1-ELISA but importantly, both P1atelia NS1-
ELISA and NS1-LFRT retain extremely high specificity of 100%.
With a large number of whole DENY genome sequences generated in this study, it is a
massive contribution to the DENY genome data in GenBank. In addition, results presented in
this study contribute to current knowledge of the DENY genetic diversity which is of a
fundamental importance in vaccine or drug designs. Results from the evaluation of the utility
of NS 1 antigen as a diagnostic marker provide further information of the strength and the
weakness of the current NS 1 antigen detection assays.
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Charter I. Introduction
Chapter 1
1. Introduction
Chapter I. Introduction
1.1. History
1.1.1. The term "Dengue"
Epidemics of dengue fever (OF) have occurred in Africa, Asia, Europe and the Americas,
since the first was described in 1780 in Philadelphia [1-3]. Patients with DF showed some or
all of the following symptoms: fever, headache, severe muscle pain, joint pain, nausea,
vomiting, rash, thrombocytopenia, haemorrhagic manifestations and restlessness. According to
the Oxford English Dictionary, the word "dengue" originated in West Indian Spanish as dinga
(from kidingapopo - dislike of movement by affected patients). In Spain, "dengue' was
initially used in Madrid in 1801 to describe a fatigued appearance in patients with syndromes
such as bone and joint pains, haemorrhage, and jaundice [1, 3].
1.1.2. Discovery of vector and virus
In 1903, Graham described experiments in which he claimed to show that dengue was
transmitted by mosquitoes and was caused by protozoa inhabiting red blood cells and closely
resembling the plasmodia of Malaria [4]. Many subsequent studies conducted have attempted
to confirm that the protozoa described by Graham were the agent of dengue, but all were
unsuccessful. Although Graham's interpretation of the agent causing dengue erred, his results
regarding the mechanism of transmission in dengue were valuable and well-grounded. In
1906, Ashburn and Craig experimentally infected nine volunteers with mosquitoes and two
volunteers with an intravenous injection of filtered and unfiltered dengue blood [4]. This
research confirmed the role of mosquito vectors in dengue transmission and conclusively
proved that a causative agent was ultramicroscopic in size. However, the real agent causing
dengue was not identified until 1943-1944. During World War II, dengue assumed
considerable military importance because of its tendency to occur in massive outbreaks
affecting large numbers of men. Japanese scientists first identified the virus in 1943 [5] and
were quickly followed by the U.S researchers - Sabin and his co-workers. Using active cross
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immunity tests in human volunteers (he inoculated one strain of DENY into volunteers, re-
infected these volunteers with the same strain/or a different strain within intervals of several to
18 months, then recorded the level of protection or developed disease result) or a dermal
neutralization test with viruses diluted in convalescentlhealthy sera in human volunteers, Sabin
showed that of infected sera sent from Hawaii (n=I), New Guinea (n=4) and India (n=2); the
Hawaiian strain, one of the four New Guinea strains, and the two Indian strains belonged to
one group, while the other three New Guinea strains belonged to another different antigenic
group. Thus, two antigenic types of dengue virus were identified in 1944-1945 [6]. By 1956-
1958 two more serotypes of the virus were identified through the outbreak in Manila in 1953
by Hammon [5] and every outbreak of the disease since then has been related to a virus
belonging to one of the four serotypes. Herein, DENY-I, -2, -3 and -4 refer to dengue serotype
1,2,3, and 4.
1.1.3. Global expansion of the dengue as a disease of public importance
The first known epidemic of dengue hemorrhagic fever (DHF) occurred in Manila,
Philippines, in 1953 - 1954 [7]. The disease subsequently spread throughout Southeast Asia
and became one of the ten leading diseases causing hospitalization and death in children in at
least eight tropical Asian countries [8]. In the early 1970s, dengue was reintroduced to the
Pacific islands after an absence of more than 25 years [2]. The large dengue epidemic in Cuba
in 1981 caused by DENY-2 led to -10,000 DHFIDSS cases and 158 deaths [9]; since then,
dengue epidemic transmission has intensified in the Americas [8]. Interestingly, there are no
records of DHF outbreaks in Africa, though surveillance is weak in most of this continent [2].
Within four decades, dengue has become a major international public health problem,
particularly in tropical and sub-tropical areas. It has been estimated about 50 million DENY
infections occur annually around the world producing at least 500,000 cases of DHF [10]. The
case fatality rate is as high as 5% in places with less clinical experience of the disease or
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where resources are limited [10]. In addition, dengue is not only problematic in
endemic/epidemic areas but is also an important problem amongst international travelers.
Dengue was the second most common vector-born infection, after malaria, in travelers [II].
1.1.4. Major Dengue outbreaks in Vietnam
Dengue is hyper-endemic in Vietnam and occasionally epidemic; at times, a certain serotype is
more prevalent than the other serotypes. Dengue was first recorded in northern Vietnam (Ha
Noi and Hai Phong) in 1959 and in the South in 1960. The first epidemic of DHF appeared in
southern Vietnam in 1963 resulting in 331 DHF children being hospitalized, of whom 116
died. From 1963 - 1994 the Ministry of Health recorded 1,577,452 cases and 12,942 deaths
[12]. During the last 30 years, epidemic peaks of dengue have occurred regularly at 3-4 year
intervals [1975, 1978179, 1983, 1987, high endemic between 1988 and 1997, then outbreak in
1998, 2001, and 2005; according to Pasteur Institute HeMe, http://www.pasteur-
hcm.org. vn/english/]. The first nationwide outbreak occurring in 1983 resulted in ~ 150,000
DHF cases of which 1,795 died. After an interval of three years, the second nationwide
outbreak occurred in 1987 which was the most severe with ~ 354,517 DHF cases and 1,566
deaths with DENV-2 being the predominant serotype [13]. A widespread DHF epidemic in
1998 affected 19 provinces in southern Vietnam and resulted in ~120,000 DHF cases and 342
deaths; most of which were caused by DENV-3 [14]. Since 1999 the dengue control program
for southern Vietnam has been based at the Pasteur Institute, HeMe. Dengue is a notifiable
disease in Vietnam and the Pasteur Institute collates this data on an annual basis. Virus
surveillance is also conducted by isolation of viruses from blood samples submitted by city,
district and provincial hospitals. Fig.I.! depicts dengue epidemics and death toll in southern
Vietnam from 1963 to 1998 and other major outbreaks that occurred in 1983, 1987 and 1998.
Serotype prevalence in southern Vietnam from 1987 to 2007 and disease incidence between
and 1996 and 2007 is described in Fig.!.2.
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Fig.l.1. Dengue epidemics and number of deaths in southern Vietnam from 1963
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1.2. Burden of dengue
1.2.1. In other countries
The relative burden of dengue can be estimated by use of DALYs (disability-adjusted life
years - the number of healthy years of life lost due to premature death or disability, measured
by DALY/year/million people). The average loss to dengue in Puerto Rico (1984-1994) is
similar to the losses to meningitis, hepatitis, or malaria in the Latin American and Caribbean
region (loglO DALY, 2.8 versus 3.1, 2.5 and 2.9, respectively [15]. Estimates ofDALYs with
respect to dengue in Thailand suggest it is of the same order of importance as hepatitis (DENV
DALY: 4.27x103/million people, Hepatitis DALY: 5.56xl03/ million people, 2000) [16].
However, this result may not reflect the true burden of dengue. Dengue surveillance programs
usually give an account of notified or hospitalised dengue cases and do not capture data on
non-hospitalised cases or cases that do not present to health care facilities. A prospective study
in Thai children suggested that non-hospitalised dengue patients represented about 44 - 73%
of the total DALYs lost to dengue each year [17].
1.2.2. In Vietnam
Few systematic studies of the economic impact of dengue in Vietnam have been conducted.
Aside from the incidence data reported by the Pasteur Institute-HCMC for the southern
provinces, the only other information on disease burden information is from hospital records.
In recent years, the number of dengue patients admitted to the Hospital for Tropical Diseases
(HTD) in HCMC has been increasing and all four serotypes of dengue virus have been
detected (Fig.1.3). Recently, the number of adults hospitalised with DHF has increased to
-60% of all dengue patients at the HTD (Fig.1.4). However, the overall burden of DSS has
remained much higher in children (Fig.1.S). The basis for this trend towards adults with
dengue is unknown. One possible explanation is migration of dengue nalve adults from the
North to the South creating a large pool of susceptible adults.
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1.3. Dengue diagnosis
Accurate and timely diagnosis of dengue can play an important role not only in clinical
management, but also in surveillance activities and outbreak control. Laboratory approaches to
the diagnosis of dengue consist of virus detection, virus antigen detection, and identification of
virus-specific antibodies. In the early acute phase of illness from day one to day five, direct
virus detection via viral isolation and genomic nucleic acid amplification (peR) can be useful
tools. At the end of the acute phase, serological assays for the detection of virus-specific IgM
antibodies are the method of choice.
1.3.1. Virus detection
1.3.1.1. Virus isolation
The intrathoracic inoculation of mosquitoes or intracranial inoculation in suckling mice are
systems for the isolation of the dengue virus, but because of the particular skill and special
facilities required these methods are rarely used. Virus isolation in cell cultures is the
alternative method. The mosquito cell line C6/36 (clone obtained from Ae. albopictus) is the
8
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host cell of choice for virus isolation. Virus isolation generally requires from one to two weeks
and is usually carried out in research or reference laboratories rather than hospital settings.
1.3.1.2. RNA genomic amplification
The high sensitivity, specificity, and rapid detection of minute quantities of viral RNA are
advantages of the RT-peR technique. Many real-time RT-peR assays utilizing TaqMan or
SYBR Green have been developed [18, 19]. SYBR Green is a double stranded DNA binding
dye. It has an undetectable fluorescence when it is in free form, but once bound to dsDNA, it
emits fluorescence, and therefore it is not a specific signal to target DNA sequence. TaqMan
real-time peR offers greater specificity via the sequence-specific hybridization of probes.
During a TaqMan assay, a specific probe labeled with two different dyes hybridizes within the
region of specific amplification. When the two dyes are close together (intact oligonucleotide
probe), one of the two dyes (for example TAMRA or BHQI) acts as a quencher for the second
dye. The 5' exo-nuclease activity of Taq polymerase degrades the hybridizing probe leading to
the separation of these two dyes in the reaction mixture resulting in a fluorescent signal. The
amount of fluorescence measured in a peR mixture is proportional to the amount of specific
peR product. The advantages of real-time TaqMan RT-peR over conventional RT-peR are
speed, quantitative measurement, high sensitivity and specificity, and lower contamination
rates relative to nested peR assays. The relative high price of probes and real-time thermal
cyclers is a disadvantage of this technique.
1.3.2. Detection of viral aotigen NSl (oon-structural proteio 1)
In vivo, the existence of viral NS 1 was first reported in the sera of primary dengue cases [20].
Studies conducted afterwards have shown that this viral protein appears in the bloodstream
from day one of the acute phase of illness to day nine with no significant difference in NS 1
concentration between primary and secondary patient specimens (0.04 - 2.0 ug/ml in primary
sera and 0.01 - 2.0 ug/ml in secondary sera) [21]. The NS 1 protein can also be detected in
9
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patient sera until day 18 after the onset of symptoms [22]. This protein could be detected even
when viral RNA was not detected by RT-peR or in the presence ofIgM antibodies [21, 22].
In the bloodstream, NSI levels varied amongst individuals (ranging from 0.07f.lg Iml to
several ug/ml, up to l Sug/ml) [20]. Mean plasma levels of NS 1 were highest in the first few
days of illness and reached a peak at day 3 [23].
Recently, commercial assays for the detection of DENV NSI have been developed. NSI assay
kits from different manufactures have been evaluated in several settings for the diagnosis of
acute dengue [24-30]. Detection of dengue NSI antigen in acute-phase serum has been shown
to be more sensitive in patients with primary infection than patients with secondary infection
[25,27].
1.3.3. Detection of virus-specific antibodies
A variety of serological assays have been used to detect anti-DENY antibody. These
tests include the haemagglutination-inhibition test, complement fixation test, plaque reduction
neutralization test (PRNT), and enzyme-linked immunosorbent assay (ELISA). Of these tests,
only the ELISA assay is widely used in diagnostic laboratories in endemic countries.
1.3.3.1. IgM antibody-capture ELISA (MAC ELISA)
The IgM antibody-capture ELISA has been widely used for routine dengue diagnosis. Briefly,
patients' total IgM are captured in a microplate coated with anti-u chain antibodies (specific to
human IgM). Dengue antigens (usually pooled culture supernatant from DENVI-4) are
overlaid on the captured IgM. Antigens bound by DENV-specific IgM are detected by
monoclonal or polyclonal DENV antibodies labeled with an enzyme (e.g. horseradish
peroxidase). In the presence of a substrate, an enzyme-dependent color-change reaction
occurs. The optical density (OD) is measured by a spectrophotometer. All steps of this assay
are illustrated in Fig.l.6. A diagnosis of acute dengue can be made if IgM sero-conversion
occurs between acute and convalescent sera, or there is evidence of a rising level of IgM
10
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between paired specimens. Generally, in primary infection, IgM level rises rapidly then peaks
two to three weeks after the onset of fever [31]. Anti-DENV IgM levels remain positive longer
in patients with primary infections compared to patients with secondary infections [31]. IgM
in anamnestic (secondary) responses appears at a lower level [31, 32]. In both primary and
secondary infections, anti-DENY IgM declined after days 15-30 and became undetectable in
the majority of patients by day 60 [31].
I Optical density reading
D
Coloured substrateI Substrate added I
~
DENV antigen
Total patient's!gM
Anti-u chain
Microplate
Fig.l.6. Diagram of MAC-ELISA for anti-DENY antibody detection
1.3.3.2. ELISA assays for detection of IgG
Two approaches are used to detect DENV-reactive IgG. The DENV IgG capture ELISA is
used to detect DENV-reactive IgG in human plasma/serum based on the similar principle
described above but the micro-plate is coated with human anti-y chain antibodies instead of
anti u-chain. A positive IgG antibody-capture ELISA result indicates either current or recent
Flavivirus infection, which in countries such as Vietnam usually means dengue. A second
approach for detecting DENV-reactive IgG is to use an indirect ELISA assays (Fig.1. 7) in
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which the micro-plate is coated with recombinant E proteins or purified virions. Dilutions of
plasma/serum are overlaid and any bound IgG is detected with a conjugated detector antibody.
The four-fold increase in titre of IgG antibody level in convalescent samples over acute
samples is indicative of acute dengue [33]. Indirect ELISA assays are useful for
seroprevalence studies. In secondary infection, IgG rises quickly and appears at high levels for
two to three weeks then slowly declines over 3-6 months [8].
Optical density reading
I Substrate added I
~
Coloured substrate
DENV specific IgG
DENVs antigen
(e.g.recombinant E protein)
Microplate
Fig.1.7. Diagram of indirect IgG ELISA for DENV antibody detection
1.4. Clinical features and management of Dengue
1.4.1. General characteristics
Dengue is an acute systemic viral infection. After an incubation period of about 3-7 days,
DENV infections can result in a variety of clinical outcomes. Most DENV infections are
clinically inapparent while a number of patients may present with classic Dengue fever (DF)
or develop severe/potentially life-threatening dengue hemorrhagic fever (DHF) or dengue
shock syndrome (DSS) [10]. Hepatomegaly and increased liver enzymes are commonly
observed in severe dengue [34, 35]. Increased disease severity is also associated with high
viraemia level and secondary infection [36, 37]. Symptoms caused by DENV infection may
last from 3 to 10 days, with an average of 5 days [8]. Viraemia levels was also correlated
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with duration of symptoms [38]. Symptoms of dengue include, but are not limited to, fever,
retro-orbital pain, muscle pain (myalgia) and joint pain (arthralgia), sometimes abdominal
pain, severe headache and hemorrhage. Hemorrhagic manifestations may present in a variety
of forms such as petechiae (pinpoint round red spots that are the results of blood leaked from
capillaries into the skin, Fig.l.8), purpura (larger red spots of bleeding into the skin, Fig.l.9)
or less frequently, gingival or gastrointestinal hemorrhage.
The time for virus clearance from the bloodstream is 5 to 7 days after the onset of fever, and
this coincides with defervescence [36, 37]. Laboratory findings include increased aspartate
transaminase (AST) and alanine aminotransaminase (ALT), leucopenia and thrombocytopenia.
Platelet count at admission in those who later developed DHF was significantly lower than in
those who did not develop DHF. It is also shown that aspartate transaminase (AST) and alanin
aminotransaminase (ALT) were greatly raised, sometimes at 10 times greater of the upper
normal limit [39] and associated with poor prognosis [40,41] and AST in DHF patients was
higher than DF [42]. Vascular leakage of plasma in DHFIDSS patients is a critical point of
differentiation from patients with milder disease.
Fig.1.8. Petechiae in DHF patient in acute phase Fig.l.9. Purpura in DHF patient in acute phase
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1.4.2. World Health Organization (WHO) Classification
The WHO Dengue classification scheme (Fig. 1.10), although under revision [3, 43, 44], is
used to categorize patients with dengue.
Unusual No shock
[GradeI, II
Dengue shock
syndrom
Grade ill, IV
Dengue virus infection
I
Asymptomatic II Symptomatic
iDengue haemorrhagi~
. fever I
r
fever
Without
haemorrhage haemorrhage
OF OHF
Fig.1.10. Schematic of the WHO classification for dengue
Asymptomatic fever may be the most common manifestation of dengue. A prospective study
of dengue infections in 4 to 16-year-old students in Bangkok, Thailand, found that 87% of
students were either asymptomatic or minimally symptomatic and were absent from school
only one day [45]. Symptomatic dengue can vary from undifferentiated fever, dengue fever
(OF), to dengue haemorrhagic fever (DHF). Criteria for OHF diagnoses include all symptoms
of OF - fever and hemorrhagic manifestation, plus thrombocytopenia (lower than
lOO,OOO/mm3) and evidence for plasma leakage. Plasma leakage can be detectable by either
elevated haematocrit (packed-cells volume/whole blood volume) which is defined as ~ 20%
increasing over the baseline (or a similar drop after volume replacement treatment), low
plasma protein level (normal level: 7g1dl), or clinical signs such as pleural effusion (an
abnormal accumulation of fluid in the pleural space) or ascites (excess fluid in the peritoneal
cavity) or thickening of the gallbladder.
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The severity of DHF is divided into four grades. In grade I and II, plasma leakage is mild to
moderate, and patients usually recover with or without intravenous fluids. The difference
between grade I and grade II is that in grade I patients manifest haemorrhage after a tourniquet
test (positive result for tourniquet test) but we can see spontaneous bleeding in grade II.
Grades III and IV are dengue shock syndrome (DSS). Intense and sustained abdominal pain,
persistent vomiting; rapid change from fever to hypothermia, with sweating and prostration
(absolute exhaustion), restlessness and accompanied with markedly decreased platelet count
are the first warning signs of shock. Patients with DHF grade III have incipient shock with
signs of circulatory failure manifested by rapid, weak pulse with a narrowing blood pressure
of ~ 20 mm Hg or profound hypotension (systolic pressure is less than 90 mm Hg in five year
olds or old patients) and cold extremities/clammy skin and restlessness. Grade IV is the most
severe status in DHF. Plasma loss is critical, resulting in profound shock with undetectable
blood pressure and pulse.
1.4.3. Clinical management
There is no specific anti-viral drug to treat DENV infection, although these are in development
[46, 47]. The mainstay of care is supportive treatment with oral and when necessary
intravenously administered fluids. Patients with cardiovascular shock require urgent fluid
replenishment, sometimes with large amounts of intravenously administered fluids. Without
fluid transfusion, cardiovascular shock is life-threatening. Mortality in DHF/DSS patients can
be as high as 10-20 % without appropriate treatment [48, 49]. Hospitals with a good triage
system, well-trained staff and enough essential equipment and intravenous fluids can reduce
mortality from DSS to as low as ~0.2 % [50-52]. Patients recover rapidly after appropriate
volume-replacement therapy. The absence of fever for 48 hours, stable haematocrit, platelet
count greater than 50,000/mm3, and return of appetite are the first signs of recovery. Around
the defervescence phase, macular rash (normally described as small white bumps on an area of
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red skin, Fig.l.11) appears and lasts for several days and may be accompanied by itching or
scaling.
Fig.1.11. Macular (recovery) rash in an adult
patient in the defervescence phase
1.5. Current hypotheses for dengue pathogenesis
It is believed that many factors contribute to DENV infection outcome. Chief amongst these
are host immune status, inherent virus virulence, age, host genotype and nutritional status.
1.5.1. Inherent virus virulence
1.5.1.1. Epidemiology observations
Several studies have suggested that viral virulence has an influence on infection outcome. For
example, epidemiological studies have suggested the DENY -2 American genotype viruses are
not associated with DHF even in secondary infection [53], whereas DENV-2 Asian viruses are
more potentially associated with DHF [54-56]. Evidence for capacity of DENY -2 Asian
genotype to cause DHF has been revealed in four countries, there, the "native" American
genotype that has been associated with mild disease has gradually been displaced [54]. The
two major DHF epidemics in Cuba also associated with DENY-2 Asian genotypes; Asian 2 III
the 1981 [55] epidemic and American/Asian (Am/As) in the 1997 epidemic [56]. A
phylogenetic study of DENY-3 in Sri Lanka revealed that the introduction/emergence of the
new clade of subtype III, which originated in the Indian subcontinent, coincided with the DHF
outbreak in 1989 [57].
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I.S.1.2. In vitro studies of viral traits
Full genome sequencing of DENY-2 American and Asian genotypes revealed distinct
nucleotide changes in E (encoding residue 390), 5', and 3' un-translated regions (UTR) [58].
The E390-Aspreduced virus output in monocyte-derived macrophage [59] and E390-Hiseffected
neurovirulence in suckling mice [60]. In vitro experiments have shown that the Southeast
Asian genotype can out-replicate the American genotype. The Southeast Asian genotype
(American/Asian and Asian 1) generates higher virus output than the American genotype in
human dendritic cells [61] and disseminated more efficiently than its American counterpart in
mosquitoes [62, 63]. These observations have led to the hypothesis that SE-Asian genotype
viruses are more virulent than the American genotype.
1.S.2. Infection status in dengue pathogenesis
The 1981 Cuban epidemic provided a "natural experiment", in which the introduction of a
dengue serotype 2 mainly related to DENY-2 New Guinea 44 virus [55] - after dengue
serotype 1 epidemic in 1977 - was associated with the dramatic increase of cases of DHFIDSS
[64]. Secondary infections were demonstrated in almost 98-99% of individuals experiencing
DHFIDSS [64]. The 1997 DENY-2 epidemic in Santiago de Cuba, mainly related to Am/As
genotype [56], provided other epidemiologic support for the association between secondary
infection and DHF, and its effect can last for as long as 20 years [9,64]. A leading hypothesis
to explain DHF in secondary infection is that the pre-existing antibodies augment heterotypic
virus uptake into mononuclear cell lineages through Fcy receptors. This hypothesis is based on
the premise that heterologous antibody-virus complexes can enter cells bearing Fcy receptors
more efficiently. Animal models and in vitro experimental results suggested that enhancing
antibody leads to a greater proportion of infected mononuclear cells. For example, after six
weeks to six months of initial infection with DENY-1, 3, and DENY-4, primates challenged
with DENY-2 had DENY-2 viraemia at significantly higher titres compared to monkey's with
17
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primary infection [65]. In vitro, dengue replicates at higher titres in cultured human monocytes
in the presence of heterotypic antibody or homotypic antibody at subneutralising
concentrations than in cultures treated similarly but without flavivirus antibody [65]. This
phenomenon is called antibody-dependent enhancement (ADE).
Since dengue virus exists as four distinct serotypes; people living in dengue endemic areas can
be exposed to more than one serotype during their lifetime. Individuals who have experienced
dengue develop serum antibodies that can neutralize the infecting serotype but weakly or not
at all heterologous serotypes. The presence of non-neutralising Abs elicited by the previous
infection is believed to increase virus replication and account for DHF in secondary infection.
Non neutralising Ab may also account for DHF in first infection of infants born to Dengue
immune mothers [66, 67]. However, not all DHFIDSS cases are related to secondary infection;
in one study, about 20% of DHFIDSS cases occurred in primary infection [68]. ADE can not
wholly explain this phenomenon; primary DHFIDSS cases have been reported sporadically in
Thai children [69] as well as in travelers [70].
1.5.3. Role ofDENV-NSl in pathogenesis
1.5.3.1. NSl biology
NSl, a 46-50 kDa glycoprotein, was originally described as a soluble complement-fixing
antigen in infected cell cultures [71]. When newly synthesized, NSI is trans-located in
endoplasmic reticulum (ER) and exists as a water-soluble monomer then followed by a rapid
dimerization before it passes through the Golgi apparatus [72, 73]. In infected cells, the NSI
protein is expressed as 2 discrete forms: an intracellular-dimer membrane-associated form
(mNSI) [72, 73] and a secreted-hexamer form (sNSl) in mammalian cells [74]. Dengue NSI
is expressed on the infected cell surface via a glycosyl-phosphatidylinositol (GPI) anchor [75].
The co-localization ofNSI with ds-RNA replicative form within infected-cell is suggestive of
the role of NSI as a cofactor for viral replication [76]. Avirutnan and others have shown that
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NS1 binds to many uninfected-cell types including sets of mammalian and human peripheral
blood cell lines through glycosaminoglycans heparan sulfate and chondroitin sulfate E [77].
1.5.3.2. Role of DENV-NSI in pathogenesis via in vivo and in vitro observations
Several studies have suggested NS I may play a role in the pathogenesis of dengue. sNS I
levels in dengue patient plasma correlated with viraemia levels and were higher in patients
with DHF than in those with OF [23, 78]. High NSI level (of 600ng/ml) on presentation
predicted the subsequent development of OHF with a sensitivity of 72% and a specificity of
79% [23]. sNSI is believed to contribute to dengue pathology by activating complement
which is enhanced by polyclonal and monoclonal antibodies against NSI [78]. Plasma SC5b-9
levels in OHF patients were higher than in OF patients; and large amounts of NS 1 and
complement activation products (C5a, SC5b-9) were present in pleural fluids from OSS
patients [78]. Moreover, secreted DENV NSI differentially attaches to some types of
endothelial cells such as lung and liver but not intestine or brain endothelium of mouse
tissues suggesting that the discriminatory vascular leakage that occurs in severe dengue
infection may be related to the relative ability of endothelial cells in different tissues to
bind soluble NS I [77]. These observations suggest a possible role for NS I in the pathogenesis
of vascular leakage in OHF/DSS patients.
1.5.4. Role of host genetic background
Previous studies have shown that several host genetic factors can contribute to clinical
outcome. For example, variations in the HLA-A locus were associated with susceptibility to
OHF while HLA-DRBI and TNF genes were shown to be negatively associated to OHF [79].
However, genetic mechanisms of underling the DENV-host interaction remain largely
unknown; this could be due to the ,limitations in sample size and study design in previous
studies. Recent developments in biology such as high-throughput sequencing, microarray,
genome-wide association studies, and bioinformatics advance the understanding of host-
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pathogen interactions [80-82]. In dengue particularly, microarray analyses of gene expression
have revealed that some aspects of the host response can be used as potential biomarkers of
disease severity (e.g. IP-IO and I-TAC) and some can be used to control dengue viral
replication (for example, over-expression of viperin reduced virus replication) with
implications for drug therapy [83].
1.6. Vectors and Transmission
1.6.1. Mosquito biting behaviors and breeding habits
Aedes mosquitoes Aedes aegypti, Aedes albopitus, and to a much lesser extent, Aedes
polynesians are the main vectors of DENV transmission. In Vietnam Aedes aegypti plays a
major role in dengue transmission; it is highly anthropophilic (human-preferring) lives around
human habitations or indoors. Aedes aegypti is primarily a daytime feeder and mainly bites in
the morning and late in the afternoon in covered areas. Female mosquitoes prefer to lay eggs
in stagnant clean water such as artificial water containers, e.g. discarded tyres, water jars. The
mainstay of dengue prevention programs is vector control. The fight against dengue in terms
of mosquito eradication is complicated firstly due to mosquito resistance to commercial
aerosol sprays [8] and secondly, A. aegypti eggs can withstand months of desiccation [8].
Furthermore, mosquito eradication programs work best with community involvement and this
is not always sustainable.
1.6.2. Transmission
Mosquito dispersal and survival rate have an important role in transmission. Mosquito flight
depends on environmental conditions such as climate and geography; it can be 50 - 160 meter
in distance [84], its dispersal sometimes can be as far as -360 meters in natural open
environment [85]. Importantly, human movements such as travel or transportation results in
considerable contribution to mosquito global spread [7]. The transmission cycle of DENV by
mosquitoes begins when an uninfected female Aedes aegypti bites an infected individual(s)
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and ingests blood containing DENV. DENV replicates in the mosquito midgut then
disseminates to the rest of the body and infects other organs including the salivary glands -
this period is called the extrinsic incubation period (EIP). Infectedmosquitoes transmit DENV
to susceptible individual through their saliva. The extrinsic incubation period is influenced by
the ambient temperature, humidity, virus strains and mosquito strains [63, 86]. Female
mosquitoes can pass viruses to the next generation of mosquitoes through trans-ovarian
transmission (TOT) in the laboratory setting [87] and in nature also [88-93]. However, the role
of this transmission pattern in maintenance of dengue in nature is still controversial [94-96].
1.7. Dengue virus
1.7.1. Virus structure
Dengue virus exists as four serotypes [DENV-l (10735nt), DENV-2 (10723nt), DENV-3
(10696nt), and DENV-4 (10653nt)] and belongs to the genus Flavivirus, family Flaviviridae.
DENV-l and DENV-2 were first isolated in 1944 [5,6]. DENV-3 and DENV-4 were isolated
in Manila, the Philippines in 1956 [5]. The mature dengue virion is icosahedral (having twenty
equal sides or faces), and is approximately 50 nm in diameter [97]. The RNA genome is of
approximately 10.7 kb in length, surrounded by a nucleocapsid (or core protein-C) and
covered by a lipid envelope containing the envelope (E) and membrane proteins (M)
(Fig.1.U).
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Fig.1.12. Dengue virus structure. (A): Sectional structure.
(OHhttp://www.sciencecentric.com/images/news/dengue virus 1440 1440.jpg)
(B): Outer and inner dengue virus tructure (Source: Marlade Institute)
1.7.2 Genome organization
The viral genome is a positive single-stranded RNA, has a 5'cap but it lacks a 3' poly - A tail.
The 5' (~97nt) and 3' UTRs (~450nt) play an important role in viral replication [98]. Colona
et al [99] generated a panel of chimeric infectious clones in which they introduced the E-390
substitution and the 5' and 3' UTRs of DENV-2 American genotype (Iquito strain) into the
backbone of the SE Asian genotype (16681-strain, Asian 1 genotype) singly and in various
combinations. The 5' and 3' -terminal and E-390(ASn~Asp)mutations give a larger reduction of
virus output compared to the E-390(Asn~ASP)mutation only. The genome contains an open
reading frame of 10,176; 10,173; 10,170 and 10,161 nucleotides in length in DEN-1.-2,-3, and
4, respectively, which encodes a precursor polyprotein of 3,392; 3,391; 3,390 and 3,387 amino
acids. The gene order of the 3 structural and 7 nonstructural proteins from the 5'terminus is C
- PrMIM - E and NS1- NS2A - NS2B- NS3 - NS4A - NS4B - NS5 (Fig. 1.13). The ten proteins
are formed by cleavage of the precursor polyprotein by host and viral proteases during co- and
post translational phase.
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Fig.1.13. Genome organization of Dengue virus. C, prM and E encode
structural protein. NS 1 to NS5 encode nonstructural proteins.
1.7.3. Dengue structural proteins
The capsid (C) protein is ~ 12-14 kDa, positively charged and rich in lysine and arginine
residues (27%), contains 114 amino acids. During infection, the C protein localizes to the
nuclei of infected cells [100]. There are two forms ofM protein; prM in the immature DENV
particles is a glycoprotein precursor (18.1-19 kDa, 166 amino acids) that is cleaved to M
protein (7-9 kDa, 75 amino acids). prM protein forms a prM-E heterodimer to prevent the E
protein from undergoing low-pH induced conformational changes prior to virion maturation
[101]. The 55-60 kDa E protein (493-495 amino acids), which is exposed on the surface of the
virion is associated with a number of biologic activities including haemagglutination [102],
receptor binding [103], and low-pH mediated endosomal fusion [104]. The E protein is also
the major antigenic target of the humoral immune response and neutralising antibodies map to
this protein [105, 106]..
1.7.4. Dengue non-structural proteins
Of the 7 nonstructural proteins, thelOO kDa NS5 protein (899-900 amino acids) is the RNA-
dependent RNA polymerase required for viral replication [107]. The 67 to 70 kDa NS3 protein
(618 to 619 amino acids) possesses multiple enzymatic activities and in complex with NS2B it
catalyzes the cleavage of NS2A-NS2B-NS3-NS4A and NS4B-NS5 sites in the polyprotein
[108]. NS3 also contains NTPase-helicase on that is essential for virus replication [109].
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Functions of the four small non-structural proteins - NS2A (18-22 kDa and 218 amino acids),
NS2B (13-15 kDa and 130 amino acids) and NS4A (16.0-16.4 kDa and 150 amino acids),
Ns4B (27- 28 kDa and 248-249 amino acids) - remain poorly defined. The 46-50 kDa NSI
protein consists of 352 amino acid, it is expressed in infected cells in both membrane -
associated (mNSl) [72] and secreted (sNSl) forms [74], and possesses both group specific and
type specific determinants [110]. NS 1 is also attributed to playa role in pathogenesis [23, 77,
78].
1.8. Molecular evolution in dengue viruses
1.8.1. Genetic diversity
Genetic variation in DENY may result from multiple factors [111]. First, DENY replication
relies on an error-prone RNA-dependent RNA polymerase resulting in roughly 1 error per
genome per round of replication [112, 113]. Second, recombination facilitated by a co-
infection of a single host (mosquito or human) could also drive this genetic diversity [114].
Recombination has been observed within a DENY serotype. Worobey et al [115] performed a
diversity analysis of 71 published dengue virus sequences and found 7 recombination
sequences which were comprised of hybrid gene regions with conflicting evolutionary
histories.
Genetic diversity is an inherent characteristic of DENY illustrated by the existence of 4
distinct serotypes. In each serotype, there are multiple genotypes (with up to 8% difference in
the nucleotide sequence) that can be distinguished via sequence analysis of all or part of the
genome. Phylogenetic studies revealed 4 distinct genotypes in DENY-1 (1 sylvatic and 3
human lineages, [116, 117]); 6 genotypes in DENY-2 (5 human lineages and 1 sylvatic
lineage, [118-120]); 4 human-associated genotypes in DENY-3 [118, 121]; and 4 genotypes in
DENY-4 (3 human lineages and 1 sylvatic lineage, [122]). Additionally, virus populations
within infected hosts are not homogeneous but consist of different variants described as
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forming a quasi species population [123, 124]. The extent of sequence variation differed
amongst patients [123] and varied between mosquito and human hosts (125). It was revealed
that intra-host genetic variation was significantly lower in severe dengue cases than classical
DF [126].
1.8.2. Serotype/Genotype/Clade turnover in DENV evolution
A common viral feature in endemic settings is the phenomenon of serotype turnover [118,
127]. Thus, in areas with four serotypes co-circulating, a certain serotype is more prevalent
than the others for a period of time and then is gradually replaced by another. The mechanism
underlying this shift is unknown. It could be due to stochastic factors or it is probably related
to the level of herd immunity that is reached in the affected population [128].
In addition to serotype turnover, genotype/clade shift is also a feature of DENV evolution in
endemic settings. This phenomenon has been observed in all 4 serotypes [118, 129-131] . For
example, lineage replacements have been observed in DENV-l genotype I [118] and DENV-3
genotype II in Thailand during a long sampling study of 30 years [132].
Many factors contribute to phylogenetic shifts. They may be due to stochastic factors (such as
the oscillation of mosquito population vectors, changes in weather/climate [130, 132] or
associated with selection pressure [129] or it was related to herd immunity [118, 128]. For
example, the observed lineage replacement in DENV-4 in Puerto-Rico during the sampling
time of -18 years (1981-1998) was associated with adaptive selection in NS2A gene [129].
However, the replacement of DENV-l genotype I, lineage A by DENV-I genotype III
lineages (B and C) in Myanmar (between 1998 and 2000) was attributed to seasonal variations
(dry season and monsoon) [130, 132). Additionally, introduction (gene flow) of a "foreign"
genotype/clade can alter genetic structures. For example, the DENV-2 Southeast Asian
viruses that are fitter than the native lineage [61-63] have spread over the Americas and
displaced the American genotype in at least four countries [54). Also, the Cosmopolitan
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genotype effectively replaced Asian 2 in the Philippines in 1998 [133], and a lineage of
DENV-3 genotype III replaced the resident in Sri Lanka in 1989 [57]; both of which were
associated with the emergence ofDHF cases.
1.8.3. Selection pressure on DENV viruses
Analyses of selection pressure on DENV population have shown that the overall pressure
impacting on DENV is of purifying selection [118, 122, 125, 132], which is the process that
decreases the prevalence of deleterious mutations diminishing individual's capacity to fitness,
practically expressed as ratio of non-synonymous substitution rate (dN, amino acid changed)
and synonymous substitution rate (dS, amino acid unchanged), with dNldS <1. However,
there was some evidence for positive selection pressures (the process that increases the
prevalence of adaptive traits, dN/dS> 1) which differed among serotypes, genotypes and viral
proteins [129, 134-136].
1.9. Purposes of this thesis
Understanding the evolution of DENV and whether there is an association between viral
genotype and epidemic potential or disease severity is of fundamental importance for vaccine
and drug development. Although many studies of the molecular epidemiology of DENV have
been conducted, there has been limited research at the level of the entire virus genome.
Conventional approaches focusing on DENV genome segments to study epidemiology and
genetic relationships may not have the sensitivity to accurately reflect the epidemiological and
evolutionary dynamics ofDENV. This shortcoming can be addressed using a robust process of
whole genome sequencing, which in general has become a genomic cornerstone for
understanding pathogen biology [137]. Potentially important questions in dengue
epidemiology and pathogenesis could be answered with the sensitivity given by a whole
genome sequence, e.g. can the molecular fingerprint given by the genome sequence be used to
understand virus transmission patterns better?
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High-throughput sequencing of DENV genomes has been used to provide a higher resolution
for studying recombination, phylogenetic dynamics, comparative sequence divergence and the
association between viral genetics and pathogenesis [58, 136-139]. However, a number of
important questions about the role of viral virulence in pathogenesis have not been answered
such as, (I) is there a particular gene or variant of a gene associated with disease severity? and
(2) is clinical outcome associated with a particular DENV genotype or lineage? Furthermore,
although the occurrence oflineage replacement is one of the most intriguing aspects of DENV
molecular epidemiology, its mechanistic basis is unclear. In particular, it is uncertain whether
such lineage replacement events reflect large-scale epidemiological processes that are
independent of viral genotype, such as random population bottlenecks, caused by large-scale
declines in mosquito numbers during the annual dry season [130, 132], or differences of viral
lineages in fitness such that one is able out-compete another [54, 61-63], including as
mediated by cross-immunity. Differentiating between these two mechanisms is of central
importance because it enables predictions to be made on the future course of DENV evolution.
Dengue is endemic in Vietnam, with local outbreaks consecutively occurring in different
areas, and a continual increase in disease incidence over the last decade, yet little is known of
what drives epidemic dynamics, and how the DENV viral population is evolving. We
hypothesise that (1) the recent increased in dengue incidence is associated with change in the
phylogenetic structure of the DENV population and (2) the genetic diversity revealed by the
genome sequence of DENV can be used to explore aspects of transmission dynamics in time
and space. These questions are addressed in Chapter 3 and Chapter 4.
Further, while awaiting specific drugs or vaccines for dengue, an early, sensitive, and accurate
diagnosis for dengue is helpful for clinical management, research activities and disease
surveillance. The NSI protein has the potential to be a valuable diagnostic marker. However,
further evaluations of commercial assays in different ethnic groups and virus serotypes are
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needed. There also remains a practical question about the utility of NS I as a prognostic marker
for dengue shock syndrome. In addition, the impact of the IgM response on the sensitivity of
NSI detection is still controversial [21, 22, 24, 27, 29, 140]. Previous studies have also
shown that NSI sensitivity differed in infecting serotypes [25, 29]. We hypothesise that
different sensitivity in relation to infecting serotypes may be caused by the differential binding
of mAbs used in capture and detection to the target epitope(s) on NSI in different serotypes.
Therefore, the aim of Chapter 5 and 6 of this thesis is to address the following questions; 1)
how does the sensitivity of NS 1 detection differ amongst DENV serotypes circulating in
Vietnam; 2) is this difference in sensitivity influenced by host infection status andlor viral
factors, and 3) what is the specificity of NSI assays for the diagnosis of acute DENV
infection?
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Chapter 2
2. Subjects and Methods
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2.1. Study subjects
2.1.1. Patients with acute dengue
Acute dengue patients (adults and children) were recruited from 3 referral hospitals in HCMC
and 1 provincial hospital in Dong Thap (Dong Thap Hospital, herein abbreviated as DTH).
Acute dengue virus infection was confirmed by serology and/or RT-PCR and/or NSI-ELISA
and/or virus isolation. There were 3 main study groups from which patient samples were
collected: a} DENCO study in HCMC (Children's Hospital #1, Children's Hospital #2 and
Hospital for Tropical Diseases - abbreviated as HTD), samples were collected between 2006-
2007 ; b) FG study (DTH), samples were collected between 2006-2007; and c) MD, OF, FL,
FR studies in HCMC (HTD), samples were collected between 1999-2008. Severity of dengue
was defined according to WHO classification (refer to section 1.4.2. in Chapter I). All study
procedures were approved by the Hospital for Tropical Diseases Ethics Committee (DENCO,
MD, OF, FR and FL), the Children's Hospital #1 Ethics Committee (DENCO), the Children's
Hospital #2 Ethics Committee (DENCO}, Dong Thap Hospital Ethics Committee (FG) and the
Oxford Tropical Research Ethics Committee UK (OXTREC) (All studies).
2.1.2. Control group
Patients with other acute febrile illness (OF!) including other viral infections (from DENCO
study), malaria, enteric fever, Japanese encephalitis or leptospirosis from other studies in HTD
were used as a control group for assessment of the specificity of the NS 1 antigen test kits.
2.1.3. Inclusion and exclusion criteria for patient recruitment
The study inclusion criteria were: clinical suspicion of dengue with a history of fever less than
72 hrs (FG, FR studies) or 7 days (DENCO, MD, FL studies), or dengue shock syndrome (OF
study); and written informed consent obtained. Patients were excluded who had dual acute
infections (e.g. meningitis plus dengue), or no laboratory evidence of acute dengue (except for
the control group defined above), or a lack ofinfonned consent.
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2.1.4. Sample coUection
A 2-3ml venous blood sample from dengue patients collected in EDTA anticoagulant-
containing tubes at the enrollment day (admission samples) and hospital discharge day
(convalescent samples) were sent to the Oxford University Clinical Research Unit at the
Hospital for Tropical Diseases for serologic, virologic, NSI diagnostic investigations and
genome sequencing. These samples were centrifuged to separate the cells and the plasma.
Each cell pellet or plasma was aliquoted into 3 aliquots and stored at -20°C for further
experiments.
2.2. Methods
2.2.1. Methods for viral amplification and sequencing
2.2.1.1. RNA extraction
RNA extraction from plasma or plasma-derived culture was carried out with Qiagen viral
RNA extraction (Qiagen, Cat. No 52906). The procedure was performed according to the
manufacturer's instructions. For TaqMan RT-PCR, as an internal control, an amount of 10-102
copies/reaction of single-stranded positive sense RNA virus [Equine arteritis virus (EAV)]
was added to each patient's plasma sample prior to extraction. Viral RNA was eluted in 60~1
of elution buffer. RNA was stored at minus 80°C until use. For whole genome amplification,
no internal control was used.
2.2.1.2. cDNA synthesis
Viral RNA was subjected to cDNA synthesis by using either random hexamers or specific
reverse primers, or a combination of random hexamers and specific reverse primers.
a. cDNA generation using random hexamers
Random hexamers (Cat #1034731, Roche, Lewes, UK) of 50A26ounit equal to 2 mg in dry
form were reconstituted with IOOO~1of distilled water to give a concentration of 2mg/ml, and
then diluted to a working solution of lng/ul. A mixture of I4~1 of Ix First-strand buffer
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(Invitrogen) containing a standard amount of viral RNA, 2J.ll random hexamers and a mixture
of O.S mM deoxyribonucleotide triphosphates (dNTPs) (Cat #03622614001, Roche) was
incubated at 65°C for 5 min and immediately chilled on ice for at least 1 min. A mixture of 6
J.ll of l x First-strand buffer containing 5mM dithiothreitol (DTT, 0.1 M), 20 units of RNase
inhibitor (40U/J.ll, Cat #10777-019, Invitrogen) and 100 units of SuperScript III Reverse
Transcriptase (200U/J.ll, Cat #18080-094, Invitrogen) was added to make up a reverse
transcription volume of 20 ul. The content was pretreated at 2SoC for 5 minutes. cDNA was
synthesized at 50°C for 60 min. The reaction was inactivated by heating at 70°C for 15 min.
cDNA would then be used for TaqMan RT-PCR.
b. cDNA generation using specific reverse primers
cDNA was generated similarly to the above procedure but using a working concentration of
of each specific reverse primers (DENV-2 Reverse
AGAACTGGCY AAAATGCTCACC,
TGGTCGTAGTGCCA YGATGT,
position: 4170-4191; DENV-2 Reverse
I:
2:
3:8438-8457 and DENV-2 Reverse
CACCATTCCATTTTCTGGCG, 10684-10704; in which Y stands for CIT nucleotide) instead
of random hexamers without pre-treatment at 2SoC. cDNA would be used for whole genome
amplification in 3 fragments
c. cDNA generation using combination of random hexamers and specific reverse primers
For genome sequencing conducted with the Broad Institute, cDNA was generated using lng/ul
random hexamers and 2J.lM specific reverse primer of fragment 14 of each dengue serotype
(DENV-l R14: AGAACCTGTTGATTCAACAGCAC, DENV-2 R14:
AGAACCTGTTGATTCAACAGCAC, DENV-3 R14: CATTTTCTGGCGTTCTGTGC). The
procedure for cDNA generation is shown in Table 2.1.
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Volume (J..I.I) Final
Mix 1 (working concentration) (For 1 reaction) concentration
5x First-strand buffer 2 lx
Random hexamers (Ing/ul) 2 G.Ing/u!
(and/or) R specific primer (2j..1.M) 2 0.2j..1.M
dNTPs (1OmM) 1 0.5mM
Viral RNA (template) 5
dH20 up to 14
Mix well and briefly centrifuge. Heat mixture at 65°C for 5 min and
Quickly chill on ice for at least I min. Add mix 2 into mix I
Final
Mix2 Volume (j..I.l) concentration
5x First-strand buffer 2 Ix
DTT(O.IM) 1 5mM
RNase inhibitor (40U/j..I.l) 0.5 20 U
Superscript III reverse transcriptase
(200U/j..I.l) 0.5 100 U
dH20 up to 6
Run at 25°C for 5 minutes followed by 50°C for 1 hour, then inactivate
the reaction at 70°C for 15 minutes
Table 2.1 cDNA synthesis procedure. For 14 fragment amplification strategy, a
combination of random hexamers and specific reverse primer (R 14) of each dengue
serotype was used. For 3 fragment amplification strategy, only specific reverse
primers were used. For TaqMan RT-PCR, only random hexamers were used.
2.2.1.3.Dengue serotyping by TaqMan RT-peR amplification
a. Standard curve establishment
The standard curve was generated using serial dilutions (106-10-1) of a linearized plasmid
containing the cloned target amplicon (177 nt in NS5 gene). Results were expressed as cDNA
equivalents per milliliter of plasma. Viraemia level was estimated from a eros-over threshold
(Ct value) calculated using quantitative RT-PCR
b. Primers and probes
Oligonucleotide primers and fluorescence-labeled probes used for DENVs serotyping were
adapted from Laue [18]. DENV specific primers and probes are shown in Table.2.2.
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Oli2;O name Ollgonucleotide sequence Position
Denv-l F Primer ATCCATGCCCACCAYCAATG 9960 - 9980
Denv-I R Primer CAGGGATCCACACCAYTGATC 10100 - 10121
Denv-2 F Primer ACAAGTCGAACAACCTGGTCCAT 9937 - 9941
Denv-2 R Primer GCCGCACCATTGGTCTTCTC 10095 - 10113
Denv-J F Primer TTTCTGCTCCCACCACTTTCAT 9719 - 9741
Denv-3 R Primer TGGCGTTGGATGCYAGTCT 9915 - 9934
Denv-4 F Primer GYGTGGTGAAGCCYCTRGAT 9587 - 9607
Denv-4 R Primer AGTGARCGGCCATCCTTCAT 9744 - 9764
Den-l-probe-ver2 5'-FAM TCAGTGTGGAATAGGGTTTGGATAGAGGAA 3'TAMRA
DEN-2
Vers4LNA. 5'-FAM GTTTTgTCTTCCATCCA 3' BHQ-l
Den-3-probe-ver2 5'-FAM AAGAAAGTTGGTAGTTCCCTGCAGACCCCA 3'TAMRA
Den-4-probe-ver2 5'-FAM ACTTCCCTCCTCTTYTTGAACGACATGGGA 3'TAMRA
EAV F Primer CATCTCTTGCTTTGCTCCTTAG 1847-1869
EAV R Primer AGCCGCACCTTCACATTG 1962-1980
5'-Cy5CGCGCTCGCTGTCAGAACAACA TTATTGCCCAC
EAV Probe AGCGCGJ'BHQ-3
Table 2.2 DENVs Oligonucleotide primers, fluorescence-labeled probes used for
serotyping and EAV primers and probes used as internal control. Y stands for CIT
nucleotide, R for AlO. F: forward; R: reverse; EAV: Equine Arteritis virus
(causing systemic infection in equids)
c. peR Amplification procedures
Four III cDNA generated with random hexamers as described above were added to 21 III of
amplification reaction containing a final concentration of lx HotstarTaq buffer, 2.5 mM
MgCh, 0.4 mM dNTPs, 0.6 IlM of each sense and anti-sense primer and 0.2 IlM probe
corresponding to each serotype, and one unit HotstarTaq (Qiagen). The amplification reaction
was pretreated at 95°C for 15 min then run for 45 cycles of 95°C for 30s, 600e for 30s and
ire for 30s. The internal probes for three dengue serotypes 1, 3, and 4 were labeled with two
fluorescence dyes: FAM reporter dye (5-carboxyfluorescence) and TAMRA quencher dye (N,
N, N', N'tetramethyl-6-carboxyrhodamine). The DENV-2 probe contained LNA (locked
nucleic acid) residues and was labeled with FAM reporter dye and BHQ I (Black Hole
Quencher 1). The PCR procedure and conditions are described in Table 2.3.
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TaqMan RT -PCR procedure
Reagents (working
concentration) ul/reaction Final concentration
DENV FW Primer (10 J..I.M) I.S 0.6J..1.M
DENV RV Primer (10 J..I.M) I.S 0.6J..1.M
EAV FW Primer (10 J..I.M} I.S 0.61lM
EAV RV Primer (10 J..I.M) I.S 0.6J..1.M
MgCh (2SmM) 2.S 2.S mM
lOx HotstarTaq Buffer 2.5 Ix
dNTPs (10mM) 1 O.4mM
DENY Probe (1IlM) S 0.21lM
EAV Probe (S 11M) 1.S 0.31lM
HotstarTaq (SVIIll) 0.2 1 Vnit
cDNA 4
H2O up to 25 J..I.l
TaqMan RT -PCR conditions
Number of cycles r Time
1 9SoC 15 min
9SoC 30 sec
4S 60°C 30 sec
noc 30 sec
Table 2.3 TaqMan RT-peR procedure and conditions
2.2.1.4. DENV-2 whole genome amplification in 3 fragments and shotgun sequencing at
the Sanger Institute
a. Amplification strategy
DENV -2 genome was amplified in 3 overlapping fragments. The first amplicon was 4,179
base pairs (bp) covering S 'VTR/C/M/EINS IINS2A and one-third of NS2B. The second
amplicon (4,448 bp) had 180 nuc1eotides overlapping the first amplicon that spanned from
NS2A1NS2B to the first one-third ofNS5. The last amplicon (2,349 bp) covered the last two-
thirds of NSS and 3 'VTR with 100 nucleotides overlapping the second amplicon. The
amplification strategy is shown in Fig.2.1.
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A
5' NS2B NS4A 3'
~llrc~l~p~~II--~E'----r~N~sjr-IINwS~2A"I-'----7,N~S3.----r-'I~N~S4~B~I----~NSN5~--'I~1
Fl (4,179bp) B F3 (2,349 bp) I
E2 (4 448 bp)
Fig.2.1 Schematic of the DENV RNA genome amplification strategy. (A) shows the
genome organization and (B) is RT-PCR strategy for 3 overlapping fragments with
length indicated in each block. F=fragment
b. Oligonucleotide primer design
To design primers for 3 overlapping fragments, 35 DENV-2 whole genomic sequences
available from GenBank were aligned using AlignX (Vector NT! suit 7.1). Primer design
software (http://frodo.wi.mit.edu/cgi-binlprimer3/primer3 www.cgi) was used to design 3
pairs of oligonucleotide primers. These primers would generate 3 overlapping DNA fragments
(namely amplicon 1, 2 and 3) covering 99.7 % of the DENV-2 genome. Oligonucleotide
primers for whole genome amplification in 3 fragments are shown in Table 2.4.
Oligo Melting Product size
name Oligo sequence Position TO in base_pairs
Fl ACGTGGACCGACAAAGACA 13-31 50.8
RI AGAACTGGCYAAAATGCTCACC 4170-4191 54.5 4179
F2 CCCCACTGHTYTTRACATCC 4010 - 4029 50.9
R2 TGGTCGTAGTGCCAYGATGT 8438 - 8457 52.3 4448
F3 CGYAACATTGGAATTGAAAG 8356 - 8375 49
R3 CACCATTCCATTTTCTGGCG 10684- 10704 55 2349
Table 2.4 Oligonucleotide primer sequences used for amplification of DENV-2
in 3 overlanninz frazments. (Y= CIT. R= AlG and H= AlC/T nucleotide)
c. DENV2 whole genome amplification conditions
PCR amplicons were generated with High Fidelity Taq polymerase (Cat #11732650001,
Roche). A mixture of dNTPs (O.4mM), forward and reverse primers (0.2IlM of each), Sill of
eDNA, plus 0.38 units of enzyme (Tgo and Taq DNA polymerase) in a 25 III PCR reaction
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including 10 x High Fidelity Taq buffer and 1.25 f..I.lDMSO was run for 35 cycles. To amplify
each fragment, thermo cycling began at 94°C for 2 min, followed by 10 cycles with different
PCR annealing temperature conditions according to the primer pairs' characteristics. Fragment
1 and 2 underwent 54°C annealing temperature, and 57°C for fragment 3. Elongation was
achieved at rrc for 3 min. For the last 25 cycles, after each cycle, 5s of elongation were
added. PCR products were analysed by 1% agarose gel electrophoresis. The remaining PCR
products were stored at -20°C for shipment to the Sanger Centre (UK). Whole genome
amplification procedure and thermo cycling conditions for DEN V-2 are shown in Table 2.5.
Whole 2enome amplification in 3 fragments procedure
Reagents (working concentration) ul/reaction Final Concentration
FW Primer (10 J.1M) 0.5 0.2 )JM
RV Primer (l0 J.1M) 0.5 0.2J.1M
DMSO 1.25 5%
IOx HiFiTaQ Buffer 2.5 Ix
dNTPs (1OmM) 1 O.4mM
HiFi TaQ (5Uhtl) 0.2 1 unit
eDNA 2
H2O up to 25 III
Whole genome amplification in 3 fra2ments conditions
Step r Time Number of cycles
Pretreat 94°C 2 mins 1
Melting 94°C 15 sec
Annealing" 54°C 30 sec 10
Extension tr c 3 mins
Melting 94°C 15 sec
Annealing" 54°C 30 sec 25
3 mins, plus Ss
Extension rrc after each cycle
Final extension rrc 7 mins 1
B: 57°C for the third fragment
Table 2.5 Whole genome amplification procedure and thermo-
cycling conditions for DENV -2 in 3 overlapping fragments
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d. Shotgun sequencing and sequence assembly
The 3 amplicons of the DENV-2 whole genome were subjected to shotgun cloning and
sequencing at the Sanger Institute, Cambridge UK, according to the Sanger protocols. The
amplimers were first purified then kinase treated. Small Insert Libraries were conducted as
described in Finishing Library
http://www.sanger.ac.uklTeams/Team53/psub/methods.shtml and
http://www.sanger.ac.uklTeams/Team53/psub/reference/vectorinfo.shtml.
Methods at
Libraries were constructed using pUC19 SmaI-CIP (Q-BIOgene Cat#CVPSM029) then
transformed to an E. coli host.
dJ. Purification of peR products
Each PCR amplimer was resuspended ID 9 J.lI dye mix (available at the Biochemical
Development, Team 53, Sanger Institute), loaded on a 0.8% low-melting point agarose gel
with one-track gap between each amplimer, run at 5V for 16hrs or 25V for 2hrs in TE buffer
(if running at 25V, after 1 hour, the running buffer was changed). Desired fragments separated
by electrophoresis were excised from the gel. The agarose piece was melted at 65°C. When the
agarose gel completely melted it was then cooled at 42°C and an aliquot of AgarAce
(Promega) was added according to this ratio: l.25 U (5J.lI)of AgarAce for 200 J.lIof agarose
gel. Then the content was incubated at 42°C for 30 mins. DNA was collected by phenol
extraction and then ethanol precipitation (as described in Finishing Library Methods). DNA
was recovered in 5J.lITE. Because the amount of each amplimer yielded in 3 individual PCR
reactions was different, a different volume of each amplicon was used to give a roughly equal
molar concentration. To assess this, 0.5 J.lIof each amplicon was suspended in 4 J.lIdye mix
then run on 0.8% high gelling temperature (HGT) agarose gel in IxTBE buffer at 70V for 40
minutes. They were roughly equivalent in molarity based on the appearance in the agarose gel.
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This process avoided misrepresentation and also normally yielded a random collection of
fragments. The mixed-3 amplicon was made up to 50 J.l.Iwith di-distilled water.
d2. Library construction
Amplicons were treated with kinase (Polynucleotide Kinase, Cat #174645, Roche, Germany)
to transfer the phosphate group from ATP to the 5' -hydroxylated terminus of amplicons
(phosphorylation) as follows: 16 J.l.Iof mixed-3 amplicon mixture, 2 J.l.Iof l Ox kinase buffer,
1 J.l.lof hnM ATP and 1 J.l.IT4 polynucleotide kinase was incubated at 37°C for 15 minutes,
then 65°C for 10 minutes to denature enzyme. It was then chilled on ice and poured back to
the main tube. The mixture was sonicated at full power for 2-3 mins then 1 J.l.Iof the sonicated
amplicons was analysed on a 0.8% HGT agarose gel to ascertain the sonication was successful
Amplicons were treated with Mung Bean Nuclease (Amersham, 156U/J.l.l)to produce blunt
ends (6 J.l.Iof lOx Mung Bean buffer, 0.3 J.l.Iof Mung Bean nuclease was added then incubated
at 30°C for 10 minutes). Then 141 J.l.IH20, 20 J.l.Iof 1M NaCl, I J.l.Ipellet paint and 560 J.l.I
cold ethanol was added to the mixture and incubated at -20°C overnight or -70°C for 30
minutes for ethanol precipitation. DNA was recovered in -10 J.l.lTE then run onto LMP
agarose gel to yield a set of fragments in a similar size. The excised fragments of 0.8 -1.2 kb
were purified again as described above and subjected to ligation using ready-to-use pUCI9
SmaI-CIP (40ng/J.l.l) (3 J.l.Iof DNA solution, 0.3 J.l.IofpUCl9, 0.4 ul IOx ligase buffer and 0.3
J.l.IT4 DNA ligase (Roche, 5U/J.l.l)then incubated at 12-14°C overnight). The content was then
made up to 50 ul by 0.5 x TE and proteinase K treated (I J.l.I)at 50°C for I hr.
d3. Transformation
Transformation was achieved with BioRad genepulser system set at 1.9 kV, 200 ohms, 25 J.l.F;
E. coli DHIOB (Invitrogen) served as host for pUCI9 SmaI libraries. Ten J.l.Iof 10% glycerol
were transferred to a pre-chilled eppendorf tube then 0.2 J.l.llibraries and 40 J.l.lelectro
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competent cells were added. All the content was mixed well and transferred to a pre-chilled
0.1 em gap electroporation cuvette and shocked by the genepulser set as described above.
Five hundred I.d of SOC medium [10 ml SOB medium (2% tryptone, O.S% yeast extract,
10mM NaCI, 2.S mM KCI) plus 200 III of 20% glucose] were immediately added and
incubated at 37°C for 1 hr, then SOIlIof each IPTG (40mg/ml) and X-gal (SOmg/ml) were
added. Volumes corresponding to 0.02 III and 0.04 III libraries were plated on TYE (lOg of
Bacto Tryptone, Sg of yeast extract, 8g of NaCl, IS g of Bactor Agar per liter) - ampicillin
plate (lOOllglml). Recombinant pUC plasmids presented as white colonies based on blue-
white selection. Ideally, the number of clones picked must provide adequate coverage
spanning the entire genome and be equally representative for the PCR amplimers being
sequenced in 8 - 10 times. To meet these criteria, this condition should be satisfied: C=N.r/G
(C=Coverage, N: Number of reads, r: Mean read length, G: Length of the genome) [141]. In
each shotgun library, between 96 and 192 clones with the average read length of O.S- 1.2 kb
were picked. Subsequently, plasmid DNA was harvested in 96-Well Miniprep as described at
http://www.sanger.ac.uklTeamslTeamS3/psub/methods.shtml. in which pellet cells were
suspended in GTE (SOmM glucose, 2S mM Tris-HCI (pHS), 1 mM EDTA) with RNaseA
(1.2ml of SOmglml RNaseA to 100ml GTE), SDSINaOH (0.2M NaOH, l%SDS), and 3M
KOAc. Biochemical development is
http://www.sanger.ac.uklTeamslTeamSllMicroPrep.shtml
described at
and
http://www.sanger.ac. uklTeams/TeamSlIvacsol.shtml?:decor=printable. DNA was re-
suspended in SO III ddH20. Double-stranded DNA was dideoxy sequenced using universal
primer (M13F) (S'-TGTAAAACGACGGCCAGT-3') and reverse primers (pUC19R)
(S'GCGGATAACAATTTCACACAGGA-3') according to the Sanger automated ABI 3700
sequencer system (http://www.sanger.ac.uklTeams/seguencing/). Sequence assembly was
40
Chapter 2. Subjects and Methods
performed by Team 2I-Sanger using Gap4 program. The incomplete sequences or thin
coverage was solved by walking peR.
2.2.1.5. Whole DENV genome amplification and sequencing in collaboration with the
Broad Institute
In collaboration with the Broad Institute, a second whole genome amplification approach was
deployed for amplification ofDENV genomes in 14 overlapping fragments (Fig.2.1). DENV-
1, -2, and DENV-3 genome were first amplified in 14 overlapping fragments in the first round
peR (conducted in the OUeRU). Each fragment was ~ 2 kb in length. This peR strategy
created 2-3x physical coverage for each nucleotide site. The fourteen amplimers were pooled
in one tube and shipped to the Broad Institute - USA. Each genome was dispensed into one
quadrant of a 384-well plate containing peR amplification reaction for second round peR
with M13-tailed primer pairs. The amplification strategy for the whole genome in 14
fragments is illustrated in Fig.2.2. The process of amplification (at OUeRU) and sequencing
strategy (at the Broad Institute) is illustrated in Fig.2.3. All primer sequences (designed by the
Broad Institute) for DENV-I, -2, and DENV-3 are shown in Table 2.6 (A), (B), and (e),
respectively. peR procedure and conditions are respectively shown in Table 2.7.
Dengue genome
14 overlapping fragmentsl 1
Fig.2.2. Schematic of RT-peR amplification strategy for the DENV genome in
14 overlapping fragments (designed by the Broad Institute). Each amplimer is ~
2kb in length ranging from 1.901 (fragment 4) to 2.213 kb (fragment 13).
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Oxford Clinical Research Unit- HTD
Dengue RNA
Dengue <:DNA
mRoundPCR
Pooled sst round=-=--=- -=. pCp. produeU
- -- ---I>---
Dengue eDNA
14 x 1st RooodPCR Amplicons
-2kb each = 2X ~ysical coverage
Transfer to]
PrWuction
Sequendni
Sanger Sequencing
Bidirectional M13 sequencmg
of each product
Fig.2.3. Procedure of whole genome amplification (WGA) in 14 fragments (Oxford Clinical
Research Unit-HTD) and whole genome sequencing (WGS) ofDENVs (The Broad Institute).
DENV-l Forward Primer
AGTTGTTAGTCTACGTGGACCG- -
TTCTAGCCATACCYCCAACAGC
AGCACATGCCATAGGAACATCC
TGAGACCCAGCATGGAACYGT
ICYTGGACCA TGAAAATAGGAATAGG
CATATGGYTGAAATTGCGTGACTC
;----- --
ATGGACTTGCAATGGGYATYATG------
AGTGYTATGGGACACACCYAG
GCYCAAGCTAAAGCATCACARG-- ----
CACGCYCAYTGGACAGAAGCAAA
TCYGAACAAGGAGGAARAGCCTA
r- - - ----
AAA YTGAGGTGGTTTGTGGAGAGI-'-- __ - -- --
A GTGGAA CCA GA GGT A GCCAAC-- -
ATYCCCATGGTCACACAAATAGC---- --
DENV-l Reverse Primer
lAYCACGA '!:._GTARCTCTCACCAA _1.!:3073
Regio!_1
CTTCCACATTTGAGTTCTCTRCC
AYTTGGGTGTAGGAGTCACGCA~ ------
YAGCACCGGAAGCCATGTTGTT
i-- --
ATRGTTCCA TCATCTTGGA CCTC
1-- -AACACCTCGTCYTCAATCTCTGG
TGCTTCTGTCCAATGRGCGTGRT
TCCACACTGGCCATCCATARCA
AAGGCGAGAAGTGGAACTCCTA
TCYACCACACTTGGCATGTARG- --
TCTGTTGTCCRAAGGGTGTGGT
ACGGCTGAACAGATRGCATTAGC
GGTTTTTACATCCCCACGATGG
AGAACCTGTTGATTCAACAGCAC
261-2469
856-2953
1873-4060,
2289-4380
2917-5070
3849-5995
4525-6678
5015-7116
:5975-8145
6476-8627
,7754-9918___,
8368-10465
8573-10735
Table 2.6.(A) Oligonucleotide primer sequences used for DENV-l
amplification in 14 fragments. (Y stand~ for CIT and R for A/G nucleotide)
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DENV-2 Forward Primer DENV-2 Reverse Primer Re_g_ion
A GTA GTTA GTCT A CGTGGACCG GATCCRAAATCCCARGCTGTGTC 1-2207
CAGA TCTCTGA TGAA TAACCAACG GATCCRAAATCCCARGCTGTGTC 87-2207
CCAGAAGACATAGA YTGTTGGTG TRCCTGCATGATTCCTTTRATGTC 619-2718
TGCCCAACACAAGGRGAACCYA ATCTTCCATGTRTCATTGAGTGC 1156-3056
. --
ATGGTGCARGCYGATAGTGGTT TAGGCTCCRTCTTCCAGTTCRG 2410-4589 .._
YATGACAGGAGACATYAAAGGAATC CTTCCARCCTCCTCCATAYGATA 2685-4773
ATGCTYAGGACCCGAGTAGGAA AGRCAAGCTGCTATRTCATTTCC 3541-5645
GCA TGGAARGTGAGYTGCACAA TATTCRCCRTCAATGGCATCCAC 3967-6089
GTYACAAGGAGTGGARCATATGT AGRA GGGGA A CTCCRA TGTCCA 4984-7106
GCAGCYGGGATTTTYATGACAG GTYTCTCCTRTGTTGCCAGTTC 5446-7592
--
AGATGGYTGGAYGCTAGGATCTA TARTGCCATGAYGTTTCATGCTC 6301-8450
CTAGA WCCAATACCYTATGATCC GTGATTCTTGTGTCCCAKCCTG 7288-9197
GTGACA TAGGGGARTCRTCACC GTARTCTGTGTATTCCTCATTGCC 8003-10215
GCCATATTCACYGATGAGAACAAR AGAACCTGTTGA TTCAACAGCAC 8800-10723
Table 2.6.(B) Oligonucleotide primer sequences used for DENV-2 amplification in
14 fragments. (Y stands for err, R for AJG, W for A IT and K for G/T nucleotide)
DENV -3 Forward Primer DENV-3 Reverse Primer Region
TGGACCGACAAGAACAGTTTC GGCTTTGTCTCCAATTCCAA 16-2086
GCATGATTGTGGGGAAGAAT TGTCGACCTGATTCCGCACA 468-2593
AGCCCTATTTCTTGCCCATT GTGAA GACTCCGAA CCCGTA 844-2904
TTTCATGCATTGTGATAGGA GGGTTTGCTTTTGCCAAGTG 2358-4508
ATGGAGTGTGCGGAATCAGG TCTCCATCCTCCTCCGTATG 2568-4765
ACATGATTGCAGGGGTTCTC ATTGCCTGAATTCCATGAGC 3561-5560
TGGAGAACAGCCACCCTGATT TCACCCCTCCTCATGAGTTC 3962-6138
GTGGGGGTTGGAGTACAAAA TTGCTTGTCTTGGGGAGTTC 4619-6769
CATTGAAAGGGCTCCCAA TA TCCAGCAGCTGTCCTTTTTT 5217-7240
GATGTCTCAAGCCAGTGATT CACACTTTTCAGGTGGAAGA 5796-7985--
GAGACCTAGGTGGCTTGATG A TGGTAA GCCCACGTTTTGTA 6289-8479
CCCTAGCCACAGGACCAATA GTTCTCGAGGTCTGCCTTCG 7404-9469
CATGCCAACTGTGATTGAGC CAAA TGGCTCCCTCTGACTC 8119-10263
ACGAAACCATGGGATGTGGT CATTTTCTGGCGTTCTGTGC 8546-10679
Table 2.6.(C) Oligonucleotide primer sequences used for DENV-3
amplification in 14 fragments. CY= err and R= AJG nucleotide)
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Procedure for Whole Genome Amplification in 14 fragments
Reagents J,.Ll/reaction Final concentration
FW Primer (10 JlM) 0.5 0.2 JlM
RV Primer (10 JlM 0.5 0.2 JlM
DMSO 1.25 5%
lOx HiFiTaq Buffer 2.5 Ix
dNTPs 10mM I O.4mM
HiFi TaQ(5U/Ill) 0.2 I unit
cDNA 2
H2O UP to 25 III
PCR conditions for Whole Genome Amplification in 14 fragments
T' (C) Time Number of cycles
94 2 mins 1 cycle
94 30 sec
60 1 min 25 cycles
72 2 mins
72 10 mins 1 cycle
4 hold
Table 2.7 Amplification procedure and thermo-cycling conditions for
DENV whole genome in 14 overlapping fragments
2.2.2. Methods for serological assays
2.2.2.1. IgMlIgG capture ELISA procedure
Serological testing was performed for paired plasma samples (collected -5-7 days apart).
Plasma was diluted 1:100 in diluents [0.1% BSA in lxPBS (8g NaCI, 0.2g KCI, 1.44g
a. Coating plates
100 ~l per well of anti-human ~ (DakoCytomation, Cat # A0425) or anti-human y chain
[Sigma, Cat # I 2136) diluted I :2000 in 0.05M coating buffer (I carbonate bicarbonate buffer
tablet (Sigma)/lOOml dH20, pH 9.6; filter through 0.22 urn filter)] was dispensed into 96-well
ELISA Plates (Nunc Immuno plate, Cat # 442404) and incubated at 4°C overnight (16-20 hrs).
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b. Blocking plates
Plates were washed 3 times with washing buffer (lml Tween20/2000ml PBS), and then 200lli
of blocking buffer (3% BSA in lxPBS) was added to each well of the plate, incubated at room
temperature (RT) for I hr, and washed 3 times with washing buffer.
c. ELISA assay
Briefly, 100 III plasma/sera diluted at 1:100 (in diluent) were dispensed into each well of a
plate and the plate was incubated at RT for 2 hrs. After washing 6 times, 100 III per well of
DENVs antigen mixture of four serotypes (supplied by Venture Technologies, Sarawak,
Malaysia) diluted at 6:10 in PBS were added and incubated at 4°C overnight. After incubation
plates were washed 6 times and 100J,1lof mAbs (specific for DENV or lEV E protein, supplied
by Venture Technologies, Sarawak, Malaysia) diluted at 1:5 in diluent were added to wells,
then incubated for I hr at RT. After incubation the plate was washed 6 times before 100 III of
conjugate solution (Polyclonal Rabbit Anti-Mouse immunoglobulins/HRP, Dako Cytomation,
Cat # P0260) diluted I :2000 in diluent were dispensed into each well and incubated at RT for
I hr in the dark. After incubation, the plate was washed 6 times and 100 III of substrate
solution [1 tablet of Buffer with urea (Sigma Fast™), 1 OPD tablet (Sigma Fast™), 20ml
dH20] was added to each well; colour development was stopped with 50 III of stopping
solution (10% H2S04). The optical density was read at 490 nm on a spectrophotometer.
Positive controls (positive control sera), negative controls (negative control sera) and
background (positive sera and PBS instead of DENV antigen) in triplicate were run together
with samples on each plate. The ELISA assay is summarised in Table 2.8.
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Assay
procedure Reagent added J.1Iper well Incubation to Time
1- Coating plate Anti-human (j.t/y) 100JJI 4°C 16-20 hrs
3x washing with washing buffer
2- Blocking plate Blocking buffer 200JJI RT I hr
3x washing with washing buffer
Diluted plasma 100JJI RT 2hrs
6x washin_g_
DENVs antigen 100JJI 4°C 16-20 hrs
6x washing with washing buffer
DENVsmAb-E 100JJI RT Ihr
6x washing with washing buffer
3- ELISA Conjugate
solution 100JJI RT/dark Ihr
6x washin_g_with washing buffer
Substrate
solution 100JJI RT/dark 30 min
Stopping
solution 50JJI
Reading absorbent at 490 nm
Table 2.8 IgM/lgG capture ELISA procedure. RT: Room temperature
d. Calculation and interpretation of results
Negative control value (O~e) was defined by mean OD value of 3 negative controls minus
mean OD of 3 background wells (ODs). The assay cut-off (ODeo) was defined as 5x ODNe.
The sample ratio (Rg) was calculated by taking the sample OD (ODs) minus mean background
(ODa) and dividing by the assay cut-off [I.e.: Rs = (ODs - ODs)/ ODeo]. The interpretation of
results was as follows: - IfRs < 0.8, result was interpreted as negative
- If Rs > 1.2, result was interpreted as positive
-IfRs from 0.8 - 1.2, result was interpreted as equivocal
2.2.2.2. NSl antigen-capture ELISA
a. Assay procedure
The Platelia Dengue NS 1 Ag kit is a one step sandwich - format microplate enzyme
immunoassay for the qualitative or semi-quantitative detection of DENV-NSI antigen in
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human plasma or serum. Tests were carried out according to the manufacturer's instructions.
Briefly, 50 ,.d of plasma or control sera [including cut-off (in duplicates), one negative and one
positive control sera] were incubated directly and simultaneously with 50 III of diluent and
100 III of diluted conjugate at 37°C for 90 min in microplate wells. The plate was washed six
times with l x washing solution (TRIS-NaCI - pH 7.4, 1% Tween 20), then Immune-
complexes were detected by using a color development reaction [160Il1, Mix of TMB
Substrate Solution (citric acid and sodium acetate pH 4.0, H202 - 0.015%, and DMSO - 4%),
and TMB Chromogen (0.25% of 3,3' ,5,5' tetramethylbenzidine)]. After 30 mins of incubation
in the dark at RT, the enzymatic reaction was stopped by 100 III of 1N sulfuric acid solution.
The OD was read at dual 450/620 nm. The presence ofNSI antigen was based on comparison
of the OD of the sample with the cut-off of control. All samples were tested in a single well.
b. Calculation and interpretation of results
The sample ratio (Rs) was expressed by the following formula: R, = ODsiODco, where
- ODs: Optical density (OD) obtained on the sample
- ODco: Cut-off value corresponding to the mean OD values of the duplicate control
wells, and which must be >0.2.
Result interpretation:
* If sample ratio was <0.5: sample was non-reactive for dengue NSI antigen, and
interpreted as negative
* If sample ratio ranged between 0.5 and 1.0: sample was considered equivocal for
dengue NS 1 antigen, and interpreted as equivocal.
* If sample ratio was >1.0: sample was reactive for dengue NS 1 antigen, and
interpreted as positive.
2.2.2.3. Dengue NSI Lateral Flow Rapid Test (NSI-LFRT) (Bio-Rad Laboratories)
The NSI-LFRT is an individual test for qualitative detection ofNSl antigen in human plasma
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or serum, marketed by Bio-Rad Laboratories as Dengue NSI Ag STRIP. The assay is based
on the principle of lateral flow immunochromatography. Tests were performed according to
the manufacture's instructions. Briefly, 50 IIIplasma was diluted in 1 drop of migration buffer
(dropper and migration buffer are provided in the test kit) in the test tube. The NSI strip was
vertically placed in the test tube and the result was read after 15min. Tests were interpreted as
positive if the Test Line and Control Line appeared clearly. If the Test Line appeared in faint
colour, the strip was read after a further 15 min. The test was considered positive if the Test
Line appeared clearly at this time. Tests were considered valid if the Control Line appeared
clearly, otherwise it must be repeated.
2.3. Result analyses
2.3.1. Sensitivity, Specificity, Positive predictive value (PPV) and Negative predictive
value (NPV) calculation
Sensitivity was calculated by: TP/TP+FN (TP: True positive, FN: False negative)
Specificity was calculated by: TN/TN+FP (TN: True negative, FP: False positive)
NPV was calculated by: NPV= TN/TN+FN
PPV was calculated by: PPV= TPITP+FP
2.3.2. Sequence analysis
2.3.2.1. Building maximum likelihood (ML) phylogenetic tree
In collaboration with Dr Eddie Holmes (Penn State University - State College-Pennsylvania,
USA), Maximum Likelihood (ML) phylogenetic trees for DENV complete CDS were inferred
for each of the serotype data sets using the PAUP* package (PAUP* version 4.0blO, Swofford
2003). Aligned sequence data set in nexus format was run in PAUP to calculate likelihoods
using 56 different models of evolution. In each case, the best-fit model of nucleotide
substitution was identified by MODELTEST [142] as the general time-reversible (REV or
OTR) model. In all cases, (GTR+I+f) model was determined. OTR indicates unequal base
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frequencies (1tA "* 1tT "* 1tC "* 1tG) and all 6 substitution types occurring at different rates (A-
G, C-T, A-C, A-T, G-T, and G-C). I is the proportion of invariant sites and r is the gamma
distribution indicating mutation rates are different among-sites. A bootstrap re-sampling
process (1,000 replications) using the neighbor-joining method was used to assess the
robustness of individual nodes on the phylogeny. All reference sequence data used in this
study are available from GenBank: (shown in List I, Appendix 2). All complete sequences
were manually aligned using the Se-AI program (http://tree.bio.ed.ac.uklsoftware/seaIQ. ML
tree for 266 DENV-2 E sequences was performed at the phylogeny section, OUCRUNN
using the PAUP* package also. Neighbour joining (NJ) phylogenetic trees were inferred for
DENV-2 EINSI and NS5 and DENV-3 E sequences using MEGA version 4 (Tamura, Dudley,
Nei, and Kumar 2007).
2.3.2.2. Estimate of dN/tIS at every codon site
To understand what codon sites are under positive or negative selection, selection pressures at
every codon site across genes were measured as the ratio of nonsynonymous (dN) to
synonymous substitutions (dS) expressed as dNldS using Fixed Effects Likelihood (FEL). The
FEL method is a maximum-likelihood method available at Datamonkey Web-server, HYPHY
package (http://www.datamonkey.orgl) [143]. The procedure includes 3 phases. In phase I,
nucleotide model from the time-reversible class (GTR or REV) that fits the input aligment
data set and NJ tree will be determined. The "best-fitting" model can be determined
automatically or by a model selection procedure. In phase 2, codon model was obtained by
crossing MG94 and the nucleotide model from phase 1 (MG94xREV) and global dNldS
(single dNldS for the entire tree) was estimated. Phase 3 will estimate site-by-site dNldS using
parameters from phase 1 and phase 2. In all cases, site with dNldS > 1 with a significance set
at P<O. 05 was declared to be under positive selection.
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2.3.2.3. Sequence divergence analysis
Sequence divergences in nucleotide and amino acid sequences were calculated as overall mean
p-distance (proportion of nucleotide difference amongst compared sequences) using MEGA
version 4 [123, 136].
2.3.3. Statistical analysis
Indices of sensitivity, specificity, negative predictive value (NPV) and positive predictive
value (PPV) with 95% confidence intervals (CIs) were assessed for Platelia-NSI and NSI-
LFRT DIAGNOSTIC TESTS. All statistical analysis was performed by using Intercooled
Stata 9.2 (Stata, College station, TX, USA). Significance was assigned at P<O.05 for all
parameters. The distribution of categorical variables was analysed using the Fisher's exact
test/Pearson chi square test to compare proportions between/amongst groups. The Mann-
Whitney U test/Kruskal-Wallis was used for comparing continuous, non-parametric variables
between groups (e.g. viraemia level, day of illness).
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3.1. Introduction
DENV, like other RNA viruses, lack efficient proofreading or mismatch repair system and
therefore exhibit a degree of genetic diversity within DENV serotypes. Differences in viral
genotype can affect viral virulence and this can be reflected by disease phenotype or by fitness
in the mosquito vector or can also impact on susceptibility to neutralization by pre-existing
anti-DENY antibodies. For example, replacement of DENV-2 American viruses with Asian
viruses (Am/As genotype) in the Americas is associated with an increased prevalence of DHF
[54]. In vitro, DENV-2 Asian viruses have greater replicative potential in Aedes mosquitoes
and human dendritic cells than American lineage viruses [61]. Furthermore, DENV-2
American viruses are neutralized by anti-DENV-I antibody more effectively than Asian
DENV-2 lineages [144]. The ongoing evolution of DENV has inevitably led to viruses with
different biological characteristics, therefore a better understanding of DENV diversity and
how this changes through time, is central to both vaccine design and drug development efforts.
Continuous sampling and phylogenetic analyses of viruses prevalent in dengue endemic
regions has revealed patterns of evolutionary processes which encompass continuous inter-
serotype change and intra-serotype lineage (clade) replacement [122, 130] even including
whole genotypes [133]. Viral lineage turnovers have been temporally associated with changes
in serotype [118]. Many factors contribute to phylogenetic replacement; they may be
stochastic factors such as the oscillation of mosquito populations, changes in the weather [130,
133], or under the impact of selection [129]. Changes in herd-immunity might also drive
serotype lineage replacement. Preexisting antibody at a certain level may be favorable for
specific strains of virus in sequential infection [128] and consequently these strains obtain
advantages in replication in human and mosquito host [61], and therefore become more
successful in transmission than others.
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Although dengue is hyper-endemic in Vietnam with the most prevalent DENV serotype
changing over time, identification of how serotype/genotype prevalence patterns change with
time in this setting and how Vietnamese strains relate to their regional counterparts remains
poorly understood. The aim of the work described in this chapter is to document changes in
DENV serotypes and genotypes in and around HCMC over the last 10 years and their
relationship to disease incidence. Rather than focusing on a single gene in isolation, we carried
out an expansive genomic approach, utilizing the complete coding region sequences of 386
DENV from 3 prevalent viral serotypes sampled in and around HCMC. We were particularly
interested in better understanding the population of DENV-2 viruses as these were the most
prevalent when this study began. The selection pressure acting on DENV-I, -2, DENV-3, and
sequence divergence were also investigated.
3.2. Methods
3.2.1. Study subjects
All viral sequences were directly obtained from plasma samples (n= 150) or from viral cultures
that had undergone ~ 3 passages in vitro (n=44). Patients were recruited into prospective
studies at HTD (2001-2008) and Children's Hospital #1 (CH#I), Children's Hospital #2
(CH#2) (2006-2007). Inclusion criteria were: a) children «15 years) with suspected "mild"
dengue (MD study at HTD) or b) children with severe disease (DHF grade III and IV, DF
study at HTD) or c) children with suspected dengue with less than 7 days of illness (DENCO
study at HTD, CH#1 and CH#2) and d) adult patients with suspected dengue and less than 3
days of fever (FR study at HTD). Exclusion criteria were patients with signs and symptoms of
other acute infectious diseases or lack of written informed consent.
3.2.2. Strategy for sampling viral genomes
For better documenting changes in DENV, especially in DENV-2, from the time when it was
less significant in causing clinical disease to when it became the most prevalent viral
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serotype in patients, a strategy for recovery of DENV-2 sampled from 1999 to 2005 was made
by retrospectively amplifying DENV-2 from dengue patient samples collected in HTD.
Retrospective specimens were grouped by period of sampling for the purposes of showing the
ratio of successful recovery (1999-2000, 2001-2002, 2003-2004 and 2005). Number of
amplification attempts in each period was as follows: 100% in 1999-2000 (5/5), 34% in 2001-
2002 (20/59),46% in 2003-2004 (99/213) and 40% in 2005 (22/55). There is a bias in some
of our sampling; for example no viruses from the 1999-2000 period (n=5) were successfully
recovered or there was a low rate of success e.g. only 10% (6/59) in the 2001-2002 period.
Overall (1999-2005), 21% (70/332) of DENV-2 viruses were retrospectively recovered.
Details of virus sequence recovery rate are summarised in Chart 1.
r·""·'-·--"-·"·"-"··-"·..""·_.·····~·········-···-·__.. _. ":
! Samples selected I
L "_ ,,_ _..._'I"'''' .
•
Retrospective samples
MD MD MD and DF
(1999-2000) (2001-2002) (2003-2004)
MD
(2005)
DENV-2WGA
attempted:
PCR (+):
DENV-2 (+):
'---..------"
DENV-2 genome
representative (%)
Prospective samples
DENCO FR
(1006-1007) (2007-2008)
96 (42%) 53 (100%)
27 (51%)
Chart 1. Strategy of sample selection for DENV-2 whole genome sequencing. Showing is
sample selection strategy for whole genome sequencing of DENV-2 sampled between
1999 to 2008 and possible biases caused by failure (1999-2000 period, n=O) or low
success rate in sample recovery (2001-2002; 10%, 6/59). Shown in the first box line is
total peR (+) and DENV-2 detected in each period. Numbers of DENV-2 attempted for
whole genome amplification and sequencing is shown in the second box line. % DENV-2
representative in each period is shown in the third box line at the bottom.
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3.2.3. Whole genome amplification and sequencing strategies
Two approaches were employed for genomic sequencing. In the first approach, PCR
amplification of the DENV-2 genome (n=54) from position 13 to 10,704 was performed in 3
overlapping amplimers (2.4kb, 4.5kb and 4.5kb). Details of oligonucleotide primers and
amplification strategy were summarised in Chapter 2. Amplification procedures and
conditions were performed as described in Chapter 2. An example of a DENV-2 whole
genome amplified in 3 overlapping PCR amplimers is shown in Fig.3.1. These amplimers
were then subjected to shotgun cloning in the pUC19 vector (described in Chapter 2).
5090
407230542036
Fig.3.1. A representative of DENV2
genome amplification results in 3
overlapping fragments. Lane 1 is 4.179
kb long; lane 2 is 4.448 kb long; lane 3
is 2.349 kb long; lane 4 is negative
control; lane 5 is Ikb ladder
In the second approach (n=332 viruses; 199 DENV-I, 102 DENV-2, 31 DENV-3), viral
genornes were first amplified in 14 overlapping fragments as described in Chapter 2. Genomes
were sequenced from position 1 to 10,735 (DENV-I), 10,723 (DENV-2) and 10,696 (DENV-
3). An example of a DENV-2 whole genome amplified in 14 overlapping PCR amplimers is
shown in Fig.3.2.
3054
2036
Fig.3.2. A representative result of DENV-2 WGA in 14 amplimers. The length of
these amplimers ranges from 1901 bp (lane 4) to 2213 bp (lane 13). Lane 15 is lkb
ladder.
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3.2.4. Additional strategy for partial coding sequencing in retrospective DENV-2 samples
Since the numbers of DENV-2 whole genome sequences between 200t-2005 and between
2006-2008 were rather small (n=70 and 86, respectively), further efforts to obtain sequence
information on DENV-2 viruses were made to compensate for this limitation. To this end,
partial sequence of DENV-2 viruses (177 nt, position 9,937-10,113; specific forward primer:
5'-ACAAGTCGAACAACCTGGTCCAT-3', specific reverse pnmer: 5'-
GCCGCACCA TTGGTCTTCTC-3') was obtained. PCR products were sent to Macrogen
Korea for double strand sequencing. This strategy covered 335 DENV-2 viruses sampled from
2001 to 2008 (2001, n=2; 2002, n=lO; 2003, n=75; 2004, n=51; 2005, n=29; 2006, n=89;
2007, n=66 and 2008, n=13).
3.2.5. Sequence analyses
Sequence alignments were manually constructed using Se-AI program
(http://tree.bio.ed.ac.uk/software/seaiD for the complete coding regions for 199 Vietnamese
DENV-l sequences (10,176 nt), 156 Vietnamese DENV-2 (10,173 nt) and 31 Vietnamese
DENV-3 (10,170 nt) data sets combined with genome sequences available in GenBank (352
DENV-t, including 176 Dong Thap strains; 368 DENV-2, including 38 Dong Thap strains;
and 203 DENV-3). ML tree for Vietnamese DENV-2 E sequences available from GenBank
was inferred using PAUP* under the assistance of the OUCRU phylogeny group. Sequence
alignments and analyses for the partial coding regions of 335 Vietnamese DENV-2 generated
in this study, Vietnamese DENV-2 and DENV-3 (E and EINS1) sequences available from
GenBank were constructed using MEGA (V4, Tamura, Dudley, Nei and Kumar- 2007).
Methods for building ML phylogenetic trees were described in Chapter 2.
3.3. Results
3.3.1. Sample data
The first dataset from dengue patients admitted to the study hospitals between 200 I to 2008
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comprised genome length sequences [nt 24-10715 in DENY-I; nt 32-10680 (the Sanger
project) or nt 23-10700 (the Broad project) in DENY-2 and nt 22-10673 in DENY-3] from
199 DENY-I, 156 DENY-2 and 31 DENY-3. The patients from whom these viruses were
sampled were resident in HCMC (n=292) or surrounding provinces (n=69). There were 25
patients where the address was unknown.
The second data set from dengue patients admitted to HTD between 2001 to 2008 comprised
sequences of 78 nt (NS52419- 2496) from 335 DENY-2. Of these, 244 patients lived in HCMC,
59 patients lived in neighboring provinces. The breakdown of sequences by time of sampling
and method of sequencing is summarised in Table 3.1.
HCMC 155 : 112 : 25 244 536------ --------- ---- --- ----- . -- .---- ---. -----I------------------i------------------ ----- ------ ------I---"-~-i
_Q~~~!_p_r~yj!1_~~~__ _____ ~~ l.__} ~---.l. 1 ~~____ 128
Unknown 16 i 7 i 2 32 57--------------------------- -----------------r-----------------l------------------ -----------------
I I
I I
Total 199 : 156 : 31 335 721
DENY-l DENV-2 DENY-3
(2006-2008) (2001-2008) (2006-2008)
DENV-2
(2001-2008)
Total
Complete CDS Partial CDS
Table 3.1 Table of number of sequences derived from genome sequencing (complete
coding sequence- CDS) and partial sequencing by serotype, time of sampling and
geographic location of the patients' home address.
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Shown in Fig.3.3 are HCMC and 13 provinces from which viruses were sampled and
sequenced. Number of viral genomes sequenced per year is shown in the table at the bottom.
Year 200 1 2002 2003 2004 2005 2006 2007 2008 Total
100Km
Fig.3.3. Map of patient distribution in
southern Vietnam. Map shows provinces
where dengue patients lived and from whom
viruses were sampled. Number labelling is
total patients sampled from that province.
Different levels of shading reflect the
intensity of sampling. Most patients were
living in HCMC when they presented with
dengue (74%, n=536/721). Patients from
surrounding provinces account for 18%,
(n=128/721). Patients with unknown address
were 8% of total (n=57/721).
Cambodia
Number of whole
3 3 35 25 9 138 100 73 386
2 10 74 51 29 89 66 14 335
3.3.2. Serotype shift events in DENV population in Southern Vietnam
Four DENV serotypes co-circulate in Vietnam. In this study, we documented DENV serotype
frequencies determined by TaqMan RT-PCR from 3,465 acute dengue plasma samples
collected from dengue patients admitted to HTD between 1999 and 2008, CH#1 and CH#2 in
2006 and 2007, and collated them to determine whether the patterns of serotype abundance
matched that seen in the Dengue Virus surveillance program conducted by the Pasteur
Institute (HCMC) (Fig.3.4). The predominant dengue serotype varied with time. Before 2000,
DENV-3 was dominant; in 2001, DENV-4 displaced DENV-3 and was the most prevalent
until 2002. DENV-4 was subsequently replaced by DENV-2 from 2003 - 2005, followed by
the emergence of DENV-1 since 2006 which has remained the most prevalent serotype until
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2008 (referred to Fig.1.3). This current serotype shift from DENV-2 to DENV-l was
associated with substantially increased DENV incidence (Fig.1.3 and Fig. 3.4). Shown in
Fig.3.5 are serotype shift events over the last 10 years deduced from patient samples admitted
to HTD, CH#1 and CH#2. Generally, our results of serotype prevalence (spanning from 1999-
2007) were in agreement with data courtesy of Pasteur Institute (Fig.3.4).
Fig.3.4. Disease incidence~ SID 2D
Q.
0
Q,) 400
Q. 15
0
0 3D00
0 100..... 2D0-Q,)u
C
5Q,)
'0 100'u
.E
and DENV
=:
Q
:;::= Vietnam from 1996 to 2007..
Q'
m;••
prevalence m
reported by the Dengue
I- Control Programme for the
20 provinces of Southern
VN (Pasteur Institute-
year based) .
• DENV-I • DENV-2 'DENV-3 • DENV-4
serotype
southern
Fig.3.5. Pattern of DENY serotype abundance in patients admitted to HTD, CH #1 and CH #2
over the last 10 years. The predominant dengue serotype changed through time, before 2000:
DENV-3; 2000-2002; DENV-4; 2003-2005: DENV-2; 2006 to up till now; DENV-I. Number
of total RT-PCR positive in each year is shown under the graph (n=3,465). Serotype
prevalence patterns from 1999-2007 match DENV surveillance data reported by the Dengue
Control Program for the 20 provinces of Southern Vietnam (Fig.3.4).
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3.3.3. Molecular epidemiology ofDENV-2
3.3.3.1. Sampling of DENV-2
Of 491 complete and partial DENV-2 coding sequences derived from patients admitted to
HeMe hospitals (as described in Table 3.1), 72% patients resided in HeMe (n=356), 20%
patients came from 11 surrounding provinces (n=96) and 8% patients were of unknown
address (n=39). Shown in Fig.3.6 is a map showing the distribution of sampled patients in
HeMe and other 11 provinces. The 156 DENV-2 complete genome sequences generated from
this project have been logged into public databases (http://www.ncbi.nlm.nih.gov/sites/entrez)
under the accession numbers shown in Appendix 3.
100Km
Fig.3.6. Map of southern Vietnam and
the distribution of residential addresses
of patients from whom DENV-2 viruses
were sequenced. Each number indicates
number of DENV-2 sampled in the
province/city. Patients derived from
HeMe accounted for 72 % (356/491).
Ninety-six patients came from 11 other
surrounding provinces (20%). Province
name is displayed in abbreviations and
italics
s
Cambodia
3.3.3.2. Phylogenetic analyses of DENV-2
The ML tree of 156 Vietnamese DENV-2 complete coding sequences (10,173 nt) generated in
this study plus 368 complete coding sequences available from GenBank (Accession numbers
shown in List 1, Appendix 2) is shown in Fig.3.7. The tree shows 2 distinct phylogenetic
relationships: the sylvatic strains from Asia and Africa (monkey or sylvatic mosquito or
human sera) and the human-related lineages defined as 5 genotypes (American, Asian 1, Asian
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2, AmlAs and Cosmopolitan genotypes). The Vietnamese strains fell into 3 phylogenetically
distinct groups referred to as Asian 1, Ami As, and Cosmopolitan genotypes. The Asian 1
genotype, of which 103 sequences from this study belonged, was first sampled in Vietnam in
2003. ML tree of these Vietnamese strains revealed that this genotype was genetically close to
Thai strains (e.g. ThD2_0078_01, ThD2_0017 _98). The Vietnamese AmlAs (n=51) genotype
clustered closely with Thai (ThD2_0284_90) and Chinese (China 04) strains. This lineage
split into 2 distinct groups: group A (n=31) consisted of virus sequences sampled between
2001-2005, whilst group B (n=20) comprised sequences sampled between 2001 and 2006.
When taken together, there was an obvious temporal structure in the tree; AmlAs genotype
was only sampled between 2001-2006 period and not thereafter whilst the Asian 1 genotype
(clustered closely to Thai strains) was first sampled only after 2002. Only 2 samples fell into
the Cosmopolitan genotype (2%). The Vietnamese Cosmopolitan strains were
phylogenetically related to Indonesian (BA05i, 2004) and Singaporean
(D2/SG/05K4155DK1I2005) strains.
To understand better whether DENV-2 Asian I genotype viruses circulated in and around
HCMC prior to 2003, we analyzed DENV-2 sequences available from GenBank and sampled
from HCMC and other provinces [n=59, 38 E gene sequences (1,485nt) (1995, n=l; 1996,
n=IO; 1997,n=9; 1998,n=8;2002,n=l; 2003,n=I;2004,n=2; 2005,n=3; 2006, n=l; 2007,
n=2) and 21 EINS1 sequences (240nt) (1987, n=2; 1995, n=2; and 1996, n= 17). GenBank
accession numbers are shown in List 2, Appendix 2]. The ML phylogenetic tree for E gene
sequences (Fig.3.8) and NJ tree for EINS1 sequences (Fig.3.9 in Appendix I) showed that all
viruses sampled prior to 2003 belonged to the AmJAs lineage (n=50), whereas viruses sampled
from 2003 onwards fell in Am/As (n=4) or Asian 1 (n=4) or Cosmopolitan genotypes (n=I).
As a further effort to understand whether Asian I genotype viruses circulated before 2003 and
whether Am/As viruses circulated after 2006, sequence length of 78 nt (NS52419-2496)of the
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DENV-2 genome from 335 patients enrolled into one of the previously described prospective
studies at HTD between 2001 and 2008 was analysed using NJ method. Phylogenetic analyses
of these short sequences clearly identified them as Am/As or Asian 1 or Cosmopolitan
lineages. NJ tree of these sequences is shown in Fig.3.10 in Appendix 1.
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100
Asian2 genotype
(New Guinea -1944)
86
100
100
American genotype
(Tonga, Peru, Puerto-
Rico, Colombia)
Asian! genotype
(Thai, Vietnam. VN
strains in this study are
highlighted in blue
(2003-2008). Appeared
in black is Vietnamese
strains that do not
belonz to this study)
IIA (2001-200S)]VN
I B (200 1-~006) strains
AmI As genotype
(Thailand, China,
Vietnam, Brazil,
the Caribbean,
Venezuela,
Nicaragua,
Colombia)
Cosmopolitan genotype
(SE. Asia, China, Taiwan,
Australia). Vietnamese
I strains in green -2006
~ Sylvatic DENV-2
Fig.3.7. ML tree of complete coding sequences from 156 Vietnamese DENV-2 in this
study and 368 DENV-2 strains from GenBank (grey). Tree contains 6 DENV-2 genotypes
labeled by genotype name. Branches with different colour indicate different genotypes.
Geographical distribution of these viruses in each genotype is also noted. Viruses are listed
by strain name. All Vietnamese Asian 1 viruses are in blue (2003-2008). Vietnamese
Am/As genotype (in red) divides in 2 distinct clades, 2001-2005 (A) and 2001-2006 CB).
Vietnamese Cosmopolitan genotype appears in green (n=2). Tree is rooted with sylvatic
DENV-2. Viruses listed in black are Vietnamese strains that do not belong to this study.
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98
98
Cosmopolitan genotype
(3 Vietnamese strains: 2006-2007)
AmiAs genotype
Vietnamese strains: 1995-2006)
American
genotype
Asian 1 genotype
(145 Vietnamese strains: 2003-2008)
100
100
Sylva tic genotype
Fig.3.8. ML phylogenetic tree of 72 E gene sequences (1,485 nt) available from
GenBank. Thirty-eight sequences were Vietnamese strains sequenced by other
investigators highlighted in red, 194 Vietnamese strains were generated in this
study (highlighted in black or blue). Sequences from other countries are
highlighted in grey. All Vietnamese E sequences available from GenBank
collected prior to 2004 fell in AmlAs genotype Cn=3J), sequences collected from
2004 onwards were defined as AmlAs (n= 2) or Asian 1 (n=4) or Cosmopolitan
(n= 1) genotypes. Bootstrap values are shown in main nodes.
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To summarise the temporal trend in lineage replacement, the relative prevalence of each
lineage was plotted against time in years for the period in which sampling was performed
(Fig.3.lt). Collectively, on the basis of complete and partial sequences from DENV-2
spanning more than 10 years and 550 patients, the results suggest the Asian 1 lineage was
probably an introduction that arrived into southern Vietnam between 2002 and 2003
(Fig.3.lt). This introduction was associated with increased DENV-2 prevalence (Fig.3.5).
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Partial CD Sa 2
Year 1987 1995 1996 1997 1998 2001 2002 2003 2004 2005 2006 2007 2008 Total
Partial CDSb
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10 75 51 29 89 66 13 335
[Complete
CDSc 3 3 30 25 9 59 20 7 156
Total
analvses 3 27 9 8 5 14 106 78 41 149 88 20 550
b: Sequences obtained from this studya: Sequences available from GenBank
c: Complete CDS generated from this study
Fig.3.lt DENV-2 genotypes detected in southern Vietnam and DENV-2 genotype
replacement between 1987 and 2008. Data were integrated by complete CDS (n=156)
and partial CDS (n=394 including 59 sequences available from GenBank) from 1987 to
2008 in and around HCMC. Number of complete CDS and partial CDS per year is
shown in the table under the graph.
3.3.3.3. DENV-2lineage replacement associated with increased DENV-2 incidence
The appearance of DENV-2 Asian 1 lineage viruses was associated with increased DENV-2
prevalence and disease incidence relative to previous years (Fig.3.12). For example, DENV-2
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incidence in 2003 (84 cases/lOO,OOOpeople) was 185% higher relative to 2002 (29
cases/100,000 people) and DENY-2 incidence in 2004 (150 cases/100,000 people) was 79%
higher compared to 2003.
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Fig.3.12. The association between DENV-2 Asian 1 introduction and increased DENV-2
incidence. Chart showing the appearance of DENV-2 Asian 1 genotype (2003) is associated
with increased disease incidence and DENV-2 incidence (2003-2004). Black bars indicate total
disease incidence, dot bars indicate DENY-2 incidence corresponding to numbers in left Y axis.
3.3.3.4. Selection pressure on DENV-2
To determine the extent of the selection pressure acting on DENV-2, an analysis of selection
pressures on individual genes amongst lineages was conducted on the data set of genome
sequences (CDS only) using Fixed Effects Likelihood (FEL) methods (HYPHY package
available at http://www.datamonkey.orgl). Selection pressure at nucleotide site was measured
by comparing the ratio of non-synonymous (dN) and synonymous (dS) substitutions per site
(dNldS). Sites where dNldS > 1 (dN> dS) is evidence for positive selection (the process that
fixes non-synonymous mutations that improve an individual's fitness). Sites or where dNldS
<1 is evidence for purifying (negative) selection (purifying selection decreases the prevalence
of nonsynonymous mutations that diminish an individuals fitness). Mean dNldS ratios across
66
Charter 3. Dengue virus evolution over the last tell years ill Southern V ictnam
genes were very low (ranging from 0.028 to 0.136, Table 3.2). The Capsid exhibited the
highest level of non-synonymous variation (dNldS = 0.136), implying that this gene was least
impacted by purifying selection. Generally, the major evolutionary theme was that of
purifying selection. However, 2 positively selected sites were detected in the NS5 gene at
position 634 and 644 (NS5634,NS5644,genome position 3125, 3135; Table 3.2). dNldS at these
sites were 2.0 and 4.8, respectively. Selection pressure amongst all genes and positively
selected sites in this DENV-2 dataset are summarised in Table 3.2.
Global Positively dNldSat P value
Gene Length (No ofaa) dNldS selected site selected site for site
Capsid 114 0.136
prM 166 0.063
E 495 0.041
NSI 352 0.082
NS2A 218 0.098
NS2B 130 0.028
NS3 618 0.041
NS4A 150 0.031
NS4B 248 0.039
NS5 900 0.059 634 2.0
0.02
644 4.77 0.001
Table 3.2 Selection pressure in DENV-2 viruses (n=156) on a gene-by-gene
basis. Mean dNldS of all genes is <1, ranging from 0.028 (NS2B) to 0.136
(Capsid). Two positively selected sites were discovered in NS5 gene (position
634 and 644) with dNldS of 2.0 and 4.8 respectively).
3.3.3.5. Sequence divergence between DENV-2lineages
Sequences were grouped by genotype using MEGA version 4 to explore sequence divergence
at the individual gene level. The overall mean sequence divergence (p-distance) between
genotypes was 8.2% in nucleotide sequence and 2.6% in amino acid sequence (complete
coding sequence) (Table 3.3). NS2A had the most divergent sequence with 10.8% difference
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at the nucleotide level and 5.2% at the amino acid level (Table 3.3). Capsid was the second
divergent sequence at amino acid level. At the nucleotide level, the second most divergent
gene was NS4B with 9.6% difference, but at the amino acid level, this was the least divergent
sequence (1.4%) (Table 3.3).
The relatively higher level of amino acid diversity in the NS2A and Capsid genes may suggest
that these genes were less constrained by purifying selection pressure than other genes. This is
compatible with the results shown previously in that these 2 genes exhibiting higher dNldS
ratio than the other genes (dN/dS = 0.136 and 0.096, Capsid and NS2A respectively).
Conversely, the high sequence identity in amino acid sequence in NS4B sequences may be
due to stronger functional constraints on this gene product. Sequence divergence at the
nucleotide and amino acid level amongst DENV-2 genotypes is shown in Table 3.3.
Length Mean divergence in
(No of amino Mean divergence in amino acid sequence
Gene acid) nucleotide sequence (%) (%)
Capsid 114 7.6 4.2
M 166 8.4 3.9
E 495 7.8 2.4
NSI 352 8.9 3.9
NS2A 218 10.8 5.2
NS2B 130 8.6 2.4
NS3 618 8 1.5
NS4A 150 9.4 1.8
NS4B 248 9.6 1.4
NS5 900 7.9 2.5
Complete
CDS 3391 8.2 2.6
Table 3.3 Sequence divergence between Ami As and Asian 1 genotypes in individual
genes and in complete coding sequence (CDS). Shown in bold is the gene with highest
divergence in nucleotide and amino acid sequence (NS2A -10.5% and 5.2%, respectively).
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3.3.3.6. Characteristics of the amino acid changes between the Am/As and Asian 1
lineages
ClustalW (MEGA version 4) was used to align amino acid sequences from Ami As (n=5l) and
Asian 1 (n=103) data sets. From a comparison of consensus amino acid sequences, a total of
41 amino acid changes were consistently detected between the 2 genotypes. Of them, 15
amino acid differences were associated with physicochemical properties. Eight of these
changes resulted in a charge difference and 7 resulted in a side chain difference (polar vs. non-
polar) (Table 3.4). Collectively, 5 of the 6 amino acid changes detected in structural genes
were localized in E gene and 4 of 9 amino acid differences detected in nonstructural genes
were in NS5.
Position Position AmlAs Asian I
in genome Gene in gene (VN) (VN) Typeof change
130 prM 16 R I (+), polar-s non polar
363 E 83 N K no charge-s (+)
483 E 203 D N (-) ~ no charge
506 E 226 T K no charge-s (+)
508 E 228 G E no charge-s (-)
626 E 346 H Y (+) ~ no charge
825 NSI 50 H Q (+) ~ no charge
855 NSI 80 S A no charge, polar ~ non-polar
1280 NS2A 153 S L no charge, polar ~ non-polar
1316 NS2A 189 A T non-polar ~ no charge, polar
2265 NS4B 22 E Q (-) ~ no charge
2626 NS5 135 T I no charge polar ~non-polar
2666 NS5 175 D N (+) ~ no charge
2687 NS5 196 T A no charge, polar ~ non-polar
3356 NS5 865 T A no charge, polar ~ non-polar
Table 3.4 Summary of consistent amino acid differences between Vietnamese Ami As and
Asianl genotypes. Eight substitutions related to charge change, 7 substitutions related to
side chain change.
E (Glutamic acid), D (Aspartic acid): Negative charge/polar amino acids.
H (Histidine), K (Lysine), R (Arginine): Positive charge/polar amino acids.
T (Threonine), N (Asparagine), S (Serine), Q (Glutamine), Y (Tyrosine), G (Glycine):
Neutral amino acids with polar side chains.
I (Isoleucine), L (Leucine), A (Alanine): Amino acids with non-polar side chains.
69
Chapter 3. Dengue virus evolution over the last ten years in Southem Vietnam
3.3.4. Molecular epidemiology of DENV-I
3.3.4.1. Sampling of DENV-I
One hundred ninety-nine DENV-1 genomes sampled from dengue patients admitted to
hospitals in HeMe were investigated. Five viruses were sampled in 2003 and 194 were
sampled between 2006 and 2008. Most patients resided in HeMe (155/199) and lived in 21
of 24 districts. Twenty-eight patients came from 10 provinces surrounding HeMe, and 16
patients had no recorded address. Shown in Fig.3.13 are HeMe and the provinces from
which DENV -1 infected patients were resident when they acquired dengue.
A
Cambodia
DENV-l map
/!... 100 Km 10Km • HTD
Fig.3.13. Distribution ofDENV-1 infected patients in southern provinces/HeMe VN .
Shown in (A) is the map showing the distribution of patients' addresses in HeMe (in
red) and 10 provinces from whom DENV-l viruses were sampled during admission to
HeMe hospitals (n=199). Labeled with numbers indicates amount of patients in each
city/province. Shown in (B) is a map showing the distribution of patient addresses in
HeMe accounting for 77.9% (1551199) of total patients. (HTD: Hospital for Tropical
Diseases)
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3.3.4.2. Phylogenetic analyses of DENV-1
DENV-I has become increasingly prevalent in and around HCMC since 2005 (referred to
Fig.3.5). The ML tree of 199 Vietnamese DENV-1 complete coding sequences generated in
this study, plus 352 DENV-I sequences available from GenBank (Accession number shown in
List 1, Appendix 2), including 176 DENV-l Vietnamese sequences sampled in Dong Thap
province (Accession number shown in Appendix 3) is shown in Fig.3.14. The tree shows 2
distinct phylogenetic relationships: the sylvatic strain (sentinel monkey isolate, Malaysia,
1972) and the human related strains consisting of genotype I (Asian countries such as
Thailand, Myanmar, China, Singapore, Japan, Cambodia, Vietnam), genotype II (Indonesia,
Japan, China, Pacific Ocean: Hawaii, French Polynesia) and genotype III (The Americas,
Caribbean, Thailand, Singapore, Myanmar). All the Vietnamese DENV-I viruses in this study
fell into genotype I and were closely related to isolations in Thailand, Myanmar
(D1.Myanmar.059/01), Cambodia (AF309641-1998), and Singapore
(DIISG/05K4621 DKII2005). This population exhibited sequence diversity with 6 clades,
herein defined as groups 1-6 evident. The percentage representation of each DENV-I
phylogenetic group is illustrated in Fig.3.15. Interestingly, there were no strong spatial
features in the ML tree, with strains sampled from patients living in and around HCMC being
phylogenetically related to strains sampled from Dong Thap (Fig.3.14). Four of the five
DENV-1 viruses sampled in 2003 clustered in group 1, one clustered in group 6. This
suggested that DENV-1 genotype I, group I was the dominant group when this serotype was
not the most prevalent in circulation.
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Fig.3.14. ML tree of complete coding sequences from 551 strains of DENV -1. Tree
includes 199 Vietnamese strains in this study and 352 complete CDS available from
GenBank (grey and black). Strains marked by color indicate Vietnamese viruses. Tree
contains 3 human-related genotypes and 1 sylvatic. All Vietnamese strains fall into
Genotype I and diverge in 6 groups labeled from 1 to 6. Groupl (n=34) appears in dark
green, group 2 is in pink (n=2), group 3 is in red (n=67), group 4 is in blue (n=25), group 5
is in green (n=6) and group 6 is in turquoise (n=65). Tip labels in black are Vietnamese
strains sampled in Dong Thap.
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G2 (1%)
Fig.3.15. Percentage contribution of each clade to the total
DENV-l virus population sampled in HCMC (n=199).
3.3.4.3. Selection pressure on DENV-l
To help understand whether positive selection acted on the DENV-l population, a selection
pressure analysis was carried out in individual genes of all groups. The mean dNldS ratios
across genes were low, ranging from 0.046 (NS3) to 0.182 (NS2A) (Table 3.5). Here, NS2A
and Capsid also exhibited higher dNldS than other genes (0.182 and 0.177, respectively). We
found no evidence for adaptive evolution in any sites, or genes in DENV -1. The overall theme
was of purifying selection.
Gene Capsid prM E NSI NS2A NS2B NS3 NS4A NS4B NS5
Length
ICN0 of aa) 114 166 495 352 218 130 619 150 249 899
Global dN/d5 0.177 0.110 0.075 0.075 0.182 0.069 0.046 0.059 0.046 0.064
Table 3.5 Selection pressure in Vietnamese DENV-l sequences (n=199) on a gene-
by-gene basis. Mean dNldS of all genes is <1, ranging from 0.046 (NS3, NS4B) to
0.182 (NS2A).
3.3.4.4. Sequence divergence at nucleotide and amino acid level amongst DENV-l groups
The overall mean sequence difference (complete CDS) amongst 6 lineages of DENV-l
genotype I was 2.02% in nucleotide sequence and 0.66% in amino acid sequence. NS2A was
the most divergent sequence with 2.6% difference at the nucleotide level and 1.2% at the
amino acid level. The least divergent in nucleotide sequence was Capsid (1.29%). At the
amino acid level, the least divergent sequence was NS4B (0.29%). Collectively, at the
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nucleotide level, some of the non-structural genes (NS2A, NSI and NS5) exhibited higher
level of divergence than structural genes (Capsid, prM and E gene). Similar to what was
observed in Vietnamese DENV-2 sequences, NS2A also exhibited the highest sequence
divergence at the amino acid level (1.2%). Sequence divergence in individual genes for
DENV-l is shown in Table 3.6.
Length Mean divergence in Mean divergence in amino
Gene (No of amino acid) nucleotide sequence (%) acid sequence (%)
Capsid 114 1.29 0.76
prM 166 2.02 0.96
E 495 2.07 0.65
NSI 352 2.22 0.89
NS2A 218 2.60 1.20
NS2B 130 1.81 0.43
NS3 619 1.94 0.29
NS4A 150 1.86 0.19
NS4B 249 1.49 0.29
NS5 899 2.13 0.84
Complete CDS 3392 2.02 0.66
Table 3.6. Sequence divergence in DENV-1 viruses sampled in HCMC at individual gene level
and complete CDS. Shown in bold is the highest sequence divergence at nt and amino acid level.
3.3.5. Sequence analysis of DENV-3
3.3.5.1. Sampling of DENV-3
DENV-3 was first detected in HCMC in 1987 [14]. It increased in prevalence in southern
Vietnam in 1994 and was the serotype associated with the 1998 DHF epidemic where it
accounted for 71% of the serotypes detected [14]. It gradually declined in prevalence in 1999.
Following was a lull in DENV-3 endemic for many years. Its prevalence slightly increased in
2007 accounting for -20% of all serotypes now. History of DENV-3 activity in southern
Vietnam and its incidence between 1996 and 2007 is shown in Fig.3.16. Thirty-one DENV-3
sequences sampled between 2006 and 2008 were analyzed hereafter, of which 25 originated in
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HCMC (Fig.3.17), 4 were from other provinces and 2 sequences were from patients of
unknown address.
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Fig.3.16. History of DENV-3 activity in southern Vietnam between 1996 -
2007. Increase in DENV-3 frequency in 1998 is associated with the
incidence inI998-outbreak. After that DENV-3 exists as minor population
(Source: Pasteur Institute-HCMC). DENV-3 frequency increased from 2007.
Fig.3.17. Distribution of DENV-3
infected patients in HCMC. Shown
in the map is the distribution of
patients addresses in HCMC from
whom DENV-3 viruses were
sampled during admission to
HCMC hospitals (n=25). Labeled
with numbers indicates amount of
10 Km patients in each district.
3.3.5.2. Phylogenetic analyses of DENV-3
The ML tree of 31 Vietnamese DENV-3 complete CDS generated in this study (Accession
numbers shown in Appendix 3) plus 203 sequences available from GenBank (Accession
numbers shown in List 1, Appendix 2) is shown in Fig.3.18. The tree shows 3 distinct
genotypes designated I, II and III. Genotype I is widely distributed in many regions across the
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Americas, Asia, and Pacific region. Genotype II viruses were commonly sampled in Asian
countries (e.g. Thailand, China, Singapore, Taiwan, Bangladesh). Genotype III segments in 2
distinct clades, with one clade common in some Asian countries (Singapore, Taiwan, Sri
Lanka) and the other clade found in the Americas (Venezuela, Brazil), Caribbean (Puerto-
Rico). All Vietnamese DENV-3 fell in genotype II and clustered together with Thai and
Taiwan isolations. To understand better DENV-3 historical phylogeny in and around HCMC,
we analyzed DENV-3 E and EINSI sequences (n=21) available from GenBank in 1996
(n=15), 1998 (n=l ), 2003 (n=2), 2004 (n=L), 2005 (n=l) and 2006 (n=l) (GenBank accession
numbers shown in List 2, Appendix 2). Phylogenetic analyses of these partial genomic
sequences by NJ method indicated that they all belonged to Genotype II (Fig.3.19). Thus
DENY-3 genotype II has circulated in and around HCMC since at least 1996.
j
Genotype I
(Brazil, Indonesia, Taiwan,
East Timor, China, Pacific
Ocean: Hawaii, French
Polynesia)
Genotype II
[Vietnam 2006-2008 (in blue)]
Thailand, China, Singapore,
Taiwan, Bangladesh)
]
Singapore, Taiwan,
Sri Lanka
The Americas,
Caribbean
Genotype
III
Fig.3.18. ML tree of complete CDS from 234 strains of DENV-3. Tree contains 31
Vietnamese DENY-3 sampled from 2006 to 2008 and 203 complete CDS available
from GenBank (in grey). Branches with different colour indicate different genotypes.
Tree contains 3 human related genotypes marked as I, II and III. Strains highlighted
in blue indicate Vietnamese DENV-3 sequences generated in this study. All
Vietnamese strains fall into Genotvoe II.
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]GenOlype I
Genotype II (Vietnamese
strains in red and blue,
199n-200R)
0.02
Fig.3.19. NJ tree of partial E gene from 77 strains of DENV-3. Thirty-one
Vietnamese DENV-3 sequences generated in this study (blue) and 21
Vietnamese sequences available from GenBank (red) sampled between 1996
and 2008 fall in genotype II. Tree was built with 25 DENV-3 references from
GenBank (grey).
3.3.5.3. Sequence divergence in nucleotide and amino acid sequence in DENV-3
Overall sequence difference (complete CDS) in 31 DENV-3 viruses was 0.70% in nucleotide
sequence and 0.24% in amino acid sequence. At the nucleotide level, NS2A, once more,
showed the highest sequence divergence (0.85%), though NS4A was the most divergent
sequence (0.67%) at the amino acid level. The least divergent in nucleotide sequence was NS 1
(0.62%) and NS4B (0.63%). At the amino acid level, the least sequence divergence was NS4B
(0.08%). Collectively, sequence difference amongst Vietnamese DENV-3 viruses was very
low at nucleotide as well as amino acid level. This could be due to sampling time of these
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viruses was relative short (spanning from September-2006 to March-2008). Sequence
divergence in nucleotide and amino acid sequence in 31 DENV-3 are shown in Table 3.7.
Length Mean divergence in Mean divergence in
Gene (No of amino acid) nucleotide sequence (%) amino acid sequence (%)
Capsid 114 0.65 0.34
M 166 0.64 0.19
E 493 0.69 0.28
NSI 352 0.62 0.41
NS2A 218 0.85 0.32
NS2B 130 0.74 0.20
NS3 619 0.68 0.14
NS4A 150 0.76 0.67
NS4B 248 0.63 0.08
NS5 900 0.70 0.16
Complete CDS 3390 0.70 0.24
Table 3.7 Sequence divergence in DENV-3 complete CDS and in individual genes based
on nucleotide and amino acid sequence. Shown in bold indicates sequence with highest
divergence in nucleotide sequence and amino acid sequence (NS2A: 0.85% and NS4A:
0.67%, respectively).
3.3.5.4. Selection pressure on DENV-3
The mean dNldS ratios across genes were low, ranging from 0.027 (NS4B) to 0.161 (Capsid)
(Table 3.8). Capsid and NS4A exhibited higher dNldS than other genes (0.161 and 0.157,
respectively). We found no evidence for adaptive evolution in all sites, or genes in DENV-3.
Gene Capsid prM E NSI NS2A NS2B NS3 NS4A NS4B NS5
Length
I(No ofaa) 114 166 493 352 218 130 619 150 248 900
Global dNldS 0.161 0.065 0.093 0.112 0.085 0.081 0.039 0.157 0.027 0.033
Table 3.8 Selection pressure in Vietnamese DENV-3 sequences (n=3l) on a gene-by-
gene basis.
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3.4. Discussion
To our knowledge, this is the largest data set of genome sequences assembled to examine the
changing evolution of DENV in a defined geographic setting and time. We report here DENV
serotype prevalence patterns over the last 10 years (1999-2008) and molecular epidemiology
of the three DENV serotypes in and around HCMC. To provide a more comprehensive and
expansive history of DENV-2 molecular epidemiology, particularly the emergence of the
Asian 1 lineage, we integrated complete DENV-2 CDS with partial CDS generated in this
study and partial Vietnamese CDS available from GenBank.
In DENV-2, a major finding was the replacement ofDENV-2 AmlAs lineage with the Asian I
lineage during 2003-2006. This event was associated with recent increased in dengue
incidence. These suggest the possibility of that OENV-2 Asian I lineage viruses have a fitness
advantage over Ami As lineage viruses. In DENV-1, an interesting finding was the extent of
within-genotype nucleotide sequence diversity present amongst viruses sampled in HCMC
(and Dong Thap Province also). This suggests the virus population fills the "sequence space"
available to it but that purifying selection removes less fit viruses in either the human or
mosquito host. In DENV-3, the limited amount of sequence information available did not
allow major conclusions beyond understanding how these Vietnamese viruses were related to
others in the region. Consistent with previous findings [l18, 132], the overall evolutionary
pressure was purifying selection.
As shown previously, NS2A consistently contained the highest levels of nucleotide sequence
divergence within each of DENV-I, DENV-2 and DENV-3 (2.58%, 10.8% and 0.85%,
respectively). At the amino acid level, NS2A was also the most divergent sequence within
DENV-I and DENV-2 serotype (1.2% and 5.2%, respectively). NS2A also had higher ratio of
dNldS than other genes. Previous studies have reported similar results in DENV-1, DENV-2
and DENV-4 [118, 122, 136]. Taken together, the results imply that NS2A was less impacted
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by purifying selection than other genes and that structural or functional flexibility is permitted
for this gene. The basis for greater flexibility in the sequence of NS2A is unclear since little is
known about the role ofNS2A in the viral life cycle or in infected hosts. It has been suggested
NS2A plays a vital role in virus assembly [145]. Thus, further research would be needed to
investigate why this gene can tolerate greater sequence diversity than others.
Regular changes in serotype prevalence are well documented in many dengue endemic
settings [9, 127, 146]. The serotype identification results from patients admitted to HTD
between 2001 and 2007 are in line with data from the Pasteur Institute virus surveillance
program that suggests DENV-l, -2 and -3 are on 6-8 year cycles in southern Vietnam.
Presumably, development of widespread herd immunity to an individual serotype is an
important event that mediates regular turnover of viral serotypes in endemic settings. Our
knowledge of what serotypes have been prevalent in previous years allows us to make
predictions about what might happen in the future. We would predict that DENV-3 will be the
next serotype to become prevalent in southern Vietnam as the last time it circulated at high
prevalence was in 1998 when it was associated with one of Vietnam's most severe DHF
epidemics. The 10-year interval since DENV-3 has circulated widely means that a
considerable number of children born in the last 10 years will have no or limited immunity to
this serotype.
The most striking feature in the DENV-2 genome dataset was the DENV-2 lineage
replacement event (Fig.3.ll). The AmlAs lineage appears to have been the only DENV-2
lineage present in southern Vietnam between 1987 (strain 24H, 57S, [119]) and 2003 when we
first sampled viruses belong to the Asian 1 lineage. Our best estimate is that between 2002-
2003, the Asian 1 lineage was introduced to Vietnam. On the basis of phylogenetic
relationship the likely sources of this introduction were Thailand, Cambodia and China. Over
the space of -4 years, the Asian 1 lineage has completely displaced the AmiAs lineage to such
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an extent that the AmiAs lineage has not been sampled from dengue patients at the HTD since
2006.
There are several potentially overlapping explanations for this replacement event. First, it
could be due to the inherent fitness of Asian 1 lineage viruses for the mosquito vector such
that they outcompete AmlAs viruses by either a) having a lower infectious dose for Ae.
aegypti mosquitoes, b) have a shorter extrinsic incubation period or c) replicate to higher titres
in salivary glands and are therefore more infectious per biting episode. Perhaps less likely is
that Asian 1 viruses confer a survival advantage to Ae. aegypti mosquitoes such that they
persist in the environment for longer. The fitness advantage may also occur in the human
whereby Asian 1 viruses might achieve higher or longer viraemias in vivo and thereby provide
more opportunity for human to mosquito transmission. In any of these scenarios, the fitness
advantage might be mediated solely by features inherent in the virus, e.g. a set of sequences in
Asian 1 viruses that confer greater infectivity to Ae. aegypti mosquitoes, or possibly, the
features of the virus and host in combination, e.g. a set of sequences in the E gene of Asian I
viruses that allow a certain level of immune escape from neutralising antibody elicited by
previous DENV-2 (AmJAs) infection. DENV-2 Asian has been proven to be fitter than the
American lineage [61]. From our epidemiological results and observed differences between
AmiAs and Asian 1, we assume that the Asian 1 genotype could have a greater potential
fitness than the AmJAs and has successfully replaced the AmlAs lineage. However, this
hypothesis has not yet been experimentally assessed in this study and needs to be examined
further.
Of the 15 amino acids that differed between Asian 1 and AmiAs and which were also different
in their physicochemical properties, 4 changes occurred in the NS5 gene, 1 in NS4B, 2 in
NS2A,2 in NSl, 5 in E, and 1 in prM. Five of the amino acid differences were in the E gene
which is exposed on the surface of the virion and associated with a number of biologic
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activities including haemagglutination [102], receptor binding [103], low-pH mediated
endosomal fusion [104]. In addition, the E protein is the major antigenic target of the humoral
immune response and neutralising antibodies map to this protein [105]. Amino acid
differences in E between the two 2 lineages could potentially result in altered binding of
neutralising antibody; particularly antibody elicited by previous DENV-2 (Am/As) infections.
These hypotheses will have to be confirmed through further experiments such as side-by-side
comparisons of the ability of antibodies (mAb and polyclonal) to neutralize Asian 1 and
Am/As lineage viruses.
An alternative explanation for DENV-2 lineage change is that this event simply resulted from
stochastic process. Irrespective of the mechanism that drives this replacement, vaccine and
drug development must take into account the increasing footprint of Asian 1DENV -2 lineages
as these viruses are now firmly rooted in Thailand [147], Cambodia and Vietnam.
Shortly after the DENV-2 Asian 1 lineage was first sampled, a change in serotype prevalence
occurred, with DENV-1 becoming the dominant serotype. Whether the change in serotype
prevalence was a consequence of DENV-2 lineage replacement remains unknown. There have
been similar previous reports of lineage turnover at times of serotype replacement in Thailand
[118]. The first time was in the early 1980s (around 1983). The predominant serotype changed
from DENV-l to DENV-4 and was associated with DENV-l genotype III replacement. The
second occasion was in the early 1990s (around 1994). DENV-l clade "1980-1994" was
replaced by clade "1990-2002", then DENV-l decreased in prevalence and DENV-4 emerged
as a dominant serotype. Similar events have been reported in Paraguay when introduction of a
new DENV-2 clade was associated with a shift of dominant serotype from DENV-3 to DENV-
2 in 2005 [127]. In the Philippines, DENV-2 Cosmopolitan genotype viruses have gradually
replaced Asian 2 genotype viruses since 1999 and this occurrence has been associated with an
increase in the number of severe cases [133].
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To our knowledge, our sequence data on DENV-I is the most comprehensive assessment of
sequence diversity in a single serotype in a single setting ever performed. DENV-I viruses
fell into 6 distinct phylogenetic clades. The large genetic diversity in DENV-I lineages could
have resulted from the introduction of foreign clades from elsewhere. For example, DENV-I
group 4 viruses were related to Japanese, Chinese and Singaporean (2005) strains; DENV-l
group 5 viruses were closely related to Thai (2001) and Chinese (2001) strains. The diversity
amongst the DENV viruses sampled here was primarily at the nucleotide level, with little
variation present at the amino acid level. Once again this suggests purifying selection is a
dominant feature of DENV-I viral evolution in and around HeMC. The existence of such
significant diversity in a single genotype of DENV-I in a single geographic location
underlines the ability of DENV to fill the allowable sequence space within the confines of
purifying selection. It will be of great interest to see how the DENV-I virus population
changes over time, particularly to see if some virus lineages have a selective advantage over
others when (inevitably) serotype turnover occurs in southern Vietnam.
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4. Dengue virus molecular epidemiology in an outbreak in Dong Thap Province in
the Mekong Delta region of southern Vietnam
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4.1. Introduction
Dengue was first recognized in southern Vietnam in 1960 and has since become a major
public health problem. Since 1963, the incidence of DHF has steadily increased in Vietnam
[14]. During the last 30 years, epidemic peaks of dengue occurred regularly at 3-4 year
intervals (1975, 1978179, 1983, 1987/88, 2001, 2005) (Source: Pasteur Institute HCMC:
http://www.pasteur-hcm.org.vnlenglisbD.In1999. the National Dengue Control Program for
southern Vietnam was established and based in the Pasteur Institute, HCMC. Dengue is
recorded all year round with peak transmission between June and November during the rainy
season.
Dong Thap Hospital (herein abbreviated to DTH) is a 750 bed general hospital in Cao Lanh
City - capital town of Dong Thap, and is the designated provincial hospital for Dong Thap
Province (162 km from south-west HCMC, Fig.4.1). Cao Lanh district is adjacent to Cao Lanh
City. Most of the patients in this study resided in these 2 areas. OUCRU has been
collaborating with DTH since 1993 and on dengue related activities since 2006.
Since 2000, the number of dengue cases has increased annually in Dong Thap (Fig.4.2.
Source: Centre of Precautionary Measures against Epidemic - Dong Thap province). In 2007,
a dengue outbreak occurred in Dong Thap resulting in 12,943 cases (773/105 population), of
which there were 1,635 DSS cases and 9 deaths. (Source: Centre of Precautionary Measures
against Epidemic - Dong Thap province). During this outbreak DTH and OUCRU enrolled
suspected dengue patients into an ongoing prospective descriptive study examining early
virological, immunological and host genetic risk factors for DSS and viral molecular
epidemiology. Study enrolment took place in the outpatient clinic of the infectious diseases
department. All study participants were admitted to DTH.
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A
15Km H
Fig.4.1. Maps of southern VN and Dong Thap province. (A) is southern Vietnam; the
shaded area is Dong Thap province. Shown in (B) is Cao Lanh district (hachured) and
Cao Lanh City (dark grey). DTH is located in Cao Lanh City (the red cross).
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Fig.4.2. Number of
uncomplicated dengue cases,
DSS cases, and the case fatality
rate (CPR) in Dong Thap
province from 2000 to 2007. An
increasing number of dengue
cases has been reported
annually, though the CPR has
declined over time, it dropped
from 0.32% (2001) to 0.07%
(2007). (Source: Report of
Precautionary Measures against
Epidemic Department - Dong
Thap province).
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4.2. Aims of the study
The aim of this study was to describe the molecular epidemiological patterns of DENV -1 and
DENV -2 from high transmission periods in 2006 and 2007 in Dong Thap Province in southern
Vietnam. We particularly focused on an outbreak in 2007 by utilizing sequence analyses of the
complete coding sequences of 176 DENV-I and 38 DENV-2. Additionally, the availability of
well documented clinical outcomes in the study population offered us an opportunity to study
the association between the viral genetic characteristics of DENV-I clades with clinical
outcome and laboratory variables (viraemia and platelet nadir). Finally, we planned to look for
any selection pressure acting on DENV-1 and DENV-2 viruses.
4.3. Patient recruitment and sampling method
Study inclusion criteria were; 1) clinical suspicion of dengue and/or NSI positive with NSI
ELISA assay, 2) history of fever less than 72 hrs and 3) written informed consent obtained.
Exclusion criteria were patients with dual acute infections, or history of fever more than 72
hrs, or lack of informed consent. Details of procedure of sample collection were described in
Chapter 2. All viral sequences were obtained from the plasma of patients enrolled in this study
at DTH between October-December/2006 and May-November/2007. Paired specimens from
enrollment and convalescence phase were tested for diagnostic IgM and IgG capture ELISA.
DENV viraemia was detected with a serotype specific TaqMan RT-PCR.
4.4. Study Methods
4.4.1. Whole genome amplification and sequencing strategies
Consensus viral genome sequences were determined directly from plasma samples using the
Broad Institute's ABI directed amplification viral sequencing pipeline. Details of these
methods are described in Chapter 2. The DENV-2 complete genome sequences generated
from this project have been logged into public databases
(http://www.ncbi.nlm.nih.gov/sites/entrez) under the accession numbers shown in Appendix 3.
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4.4.2. Sequence analyses
Sequence alignments were constructed (using Se-AI program
http://evolve.zoo.ox.ac.uklsofiware.html) for 176 DENY-1 (10176 nt) and 38 DENY-2
complete coding sequences (10173 nt). Data sets were combined with complete genome
sequence references from GenBank (176 DENY-I, 330 DENY-2) and genome sequences from
patients' blood sampled in HCMC (199 DENY-l and 156 DENY-2).
4.4.3. Mapping of households
The household of each patient who contributed a DENY genome sequence was mapped using
a hand-held global positioning system (GPS) device. Mapinfo (version 9.0 package, ESRl,
Redlands CA, USA) was used to digitalize the households onto a digital administrative map of
Vietnam. DENY sequences were then matched with household cases to investigate viral
spatial distributions.
4.5. Results
4.5.1. A dengue outbreak in 2007 in Dong Thap Province
Dong Thap province experienced a major dengue outbreak in 2007. The peak of the epidemic
was from June to October. Fig. 4.3 shows the number of dengue and shock cases admitted to
DTH in 2007 relative to the previous year and the year after. Hospitalised patients had clinical
manifestations ranging from DF to DHF and DSS. Interestingly, the number of dengue cases
declined dramatically in 2008. It is uncertain whether this was due to increased vector control
or a level of herd immunity obtained by the high levels of transmission during 2007. However,
the ratio of shock cases in 2008 was as high as in 2006 or 2007 (13.2% versus 11.8% or
13.4%, P=O.2, Fisher's exact).
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From October to December/2006 and over the 2007 outbreak, blood samples from 448 dengue
Fig.4.3. Number of dengue and % of shock cases in Dong Thap hospital in 2006, 2007,
and 2008. Total cases in 2007 (n=3787) is 1.67 fold greater than 2006 (n=2259) and
19.2 fold greater than the first nine months of 2008 (n= 197).
4.5.2. Characteristics of the study population
patients admitted to DTH were collected (74 in 2006 and 374 in 2007). Most of the patients
were j; 15 years [76.1%, n=341; median (range): 11 (2-42)]. The ratio between male and
female was 1.2:1. Of these 448 patients, DF patients accounted for 46.2%, DHF 44.2% and
DSS for 9.6%. Details of sample collection and clinical classification are described in Table
4.1.
AcuteSample characteristics Total orr' Dengue DF(%) DHF (%) DSS (%)
Sampling ,2006
8 76 2 74 24 (32.4 45 (60.8) 5 (6.7)-
2007 376 2 374 183 (48.9) 153 (41.0) 3800.2)
Overall 452 4 448 207 (46.2) 198 (44.2) 43 (9.6)--
Male (%) 55 75 55 50 54 67-- - - -
Median age (range) 11(2-42) 11(2-29) 11(2-42) 11(2-42) 11(2-34) 11(2-30)
a: Samples collected from October to December b: Other febrile illness
Table 4.1 Characteristics of samples collected in 2006 and 2007 in DTH. Acute
dengues are 448, of which 46.2% are DF, 44.2% are DHF and 9.6% are DSS.
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4.5.3. Infecting serotype prevalence
Table 4.2 shows the DENV serotypes identified in plasma samples by TaqMan-PCR. Of 448
acute dengue cases, 391 were RT-PCR positive (58 sampled in 2006 and 333 in 2007). Similar
to the recent DENV picture in southern Vietnam, DENV-I was the dominant serotype during
the sampling period accounting for 81.3% of all DENV detected. Second was DENV-2, 16.4%
then DENV-3 at 1.8% and DENV-4 was 0.5%. There were no differences in the proportion of
DF, DHF and DSS between DENV-I and DENV-2 (P=l, P=O.8 and P=O.7, respectively;
Fisher's exact). The ratio of the infecting serotype relative to disease severity is summarised in
Table 4.2.
~
OENV-I (81.3%, n=318) OENV-2 (16.4%, n=64) OENV-3 OENV-4
(1.8% n=7) 1(0.5% n=2)
r
1
OF DHF DSS OF DHF DSS DF DHF DF DHF
2006 13 35 2 2 2 3 0 0 1 0
2007 125 III 32 26 26 5 6 I 0 1
138 146 34 28 28 8
Total(%) (43.4) (46.0) (10.7) (43.7) (43.7) (12.5) 6 1 1 1
Table 4.2. Serotype prevalence relative to OF, DHF and DSS patients enrolled in the study
in Dong Thap Hospital in 2006 and 2007. The predominant serotype is DENV-I (81.3%),
then DENV-2 (16.4%). OENV-3 and DENV-4 are present at 1.8% and 0.5%. There was no
significant difference between proportion of DSS cases in DENV-2 and DENV-l (12.5%
versus 10.7%, P=O. 7, Fisher's exact).
4.5.4. Patient distributions
Using a Global Positioning System navigation device, 278 (44 were 2006 sampling, 234 were
2007 sampling) case households were plotted on a digital map. Each dot represents the
household of I patient. Forty-one percent of patients (114/278) lived in Cao Lanh city (dark
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grey), 41.4% (115/278) lived in Cao Lanh district and 17.6% (49/278) lived in neighboring
districts. Households of dengue patients are shown in Fig.4.4.
Fig.4.4. Location of mapped
households of 278 patients in
Dong Thap province. Yellow
dots are DENV-I infected
patients (n=219), turquoise
dots are DENV-2 (n=55), red
dots are DENV-3 (n=5) and
pink, DENV-4 (n=2).
4.5.5. Molecular epidemiology of DENV-I and DENV-2 in Dong Thap province
4.5.5.1. Viral genome sequences
To better reveal the accuracy of DENV molecular epidemiology patterns, efforts were made to
obtain the highest number of viral genome sequences. To this end, 288 DENV-I (90% of total
DENV-I), 55 DENV-2 (85% of total DENV-2), all DENV-3 and DENV-4 available were
attempted for the whole genome sequencing. Shown in Fig. 4.5 is a chart showing the number
of samples attempted whole genome amplification and the number of successful genomic
sequences in individual DENV serotypes.
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Viruses circulation from the study population
DENV-l DENV-2 DENV-3 DENV-4
RT-PCR(+): (n=3J8) (n=64) (n=7) (n=2)
I I I I
Number of WGA 288 55 7 2
attempted (%): (90%) (85%) (100%) (100%)
I I I I
Number of genome 176 38
representatives (%): (55%) (59%) None None
Fig.4.S. Sample selection in DTH for DENV whole genome sequencing. The chart
shows the process of sample attempts and the success rate for whole genome
sequencing in the study population. Shown in the first box line is the total of DENV
serotypes detected by RT-PCR. Numbers of individual DENV serotypes attempted
for the whole genome amplification are shown in the second box line. The overall
number of genome sequences in each DENV serotype is shown in the third box line.
The final representation of DENV-1 was 55% (n=176) and 59% for DENV-2 (n-38).
No genome sequence ofDENV-3 and DENV-4 was successfully amplified.
Finally, 214 clinical samples [74 OF, 109 DHF (grade I to grade II) and 31 DSS] comprising
176 DENV-l (representative of 55% DENV-l) and 38 DENV-2 (59%) were successful for
whole genome sequencing. Of those, 181 (85%) were ~18 years (school age group). No
DENV-3 or DENV-4 genomes were successfully recovered. Details of the number of
genomic sequences are summarised in Table 4.3. Patients who were resident in Cao Lanh city
accounted for 40% (n=86) of total sequences, 37% (n=80) from Cao Lanh district, and 23%
(n=48) from other adjacent districts. Seventy-eight percent of viral sequences (n=167) were
collected during the peak of transmission between June to the end of October/2007.
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To tal of geno m ic sequences
Year D EN V-I (n= 176) DEN V - 2 (n= 3 8) Age
Total
DF DHF DS S DF DHF DS S s 1 8 >18
2006 a 2 1 1 0 0 0 I 14 0 14
2007 54 82 27 I 8 1 6 3 167 33 200
To tal 56 93 27 18 1 6 4 1 8 1 33 214
a: October to December -2006
Table 4.3 Details of virus source and total number of genome sequences in Dong Thap
province from October/2006 to November/2007. Samples from the 2007-outbreak
represented 93% (200/214) of the total. School-age samples represented 85% (1811214)
of the total
Shown in Fig. 4.6 is a map on which the household residence of each patient from whom a
DENY genome sequence was determined. Each spot represents 1 virus.
o
o
Fig.4.6. Distribution of 214 DENY
genomes. Map showing distribution
of residential addresses of patients
from whom DENY viruses were
sequenced, Cao Lanh district (white
area), Cao Lanh city (dark grey area),
".0 and other adjacent district (grey).
Each dot corresponds to 1 virus.
Shown here are 214 households
representing 214 genome sequences.
Yellow dots are DENY-l (n=176).
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4.5.5.2. Molecular epidemiology of DENV-I
a. Sequence analyses of DENV -I in Dong Thap
Phylogenetic analysis of 176 DENV-I coding region sequences from Dong Thap, 199 from in
and around HCMC and 176 from NCBI is shown in Fig. 4.7. The maximum likelihood tree
contained 3 DENV-1 genotypes labeled as genotype I, II and 1II and was rooted by the
sylvatic virus. Each branch of the tree was supported by high bootstrap (shown on main
nodes). All DENV-I in Dong Thap (n=176) belonged in Genotype I. There was significant
diversity in Genotype I with 9 lineages represented; however viruses from Dong Thap
belonged to five of these. As shown in Chapter 3, DENV-I in HCMC diverged into 6 lineages
(or clades) in Genotype I numbered from I to 6. In order to keep the numbering consistent in
the DENV-I phylogenetic tree, 5 DENV-I lineages in Dong Thap province were numbered as
I, 2, 3, 4 and 6. No strain fell in lineage #5. InDong Thap, lineage #3 was the most prevalent
virus sampled (73.4%, 129/176). Lineage #6, which existed nearly equal to lineage #3 in
HCMC (lineage #6 versus lineage #3: 32.7% versus 33.7%), was present in Dong Thap at
15.3% (27/176) of the sampled population. Lineage #1, #2, and #4 accounted for 2.8%,
(5/176) 5.1% (9/176), and 3.4% (6/176), respectively. Lineage 1, 2, 3 and 6 were purely of
Vietnamese origin whilst lineage #4 contained DENV-I sampled from other Asian countries
(Cambodia, Singapore, China, and Japan). Amongst these lineages, lineage #3, #4 and #6
contained a number of clusters in which 2007-viruses were originally associated with 2006-
viruses. When sequences were stratified by year; lineage #3 was still the dominant lineage in
2006 (54%, 7/13), then lineage #6 (31%, 4/13) and lineage #4 (15%, 2/13). Thus, lineage #1
and #2 were either newly introduced to DT in the 2007 outbreak or existed at low frequency
before the outbreak. The ratio of each DENV-I lineage relative to the overall population is
shown in Fig. 4.8.
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: (Thailand, Myanmar,
: China. Sinzaoore strains)
: Group 1 (VN strains),, ,
: Group 2(VN strains
: Group 3
: (Vietnam strains),
Genotype I
Group 4
(VN, Cambodia,
Singapore, Japan,
Mvanmar strain )
Group 5 (VN,
China, Thailand
Group 6
(Vietnam train)
]Genotype IJ (Indo, Japan, hina,Hawaii, French Polyn ia)
]
Genotype In
(The Am ri a ,
aribbean, Thailand,
inaao re. Mvanrnar)
o.D1
Fig.4. 7. ML tree of complete coding sequence from 551 D NY-I train. The tree
includes 176 Dong Thap strains, 176 strains available from enBank (highlighted in grey)
and 199 Vietnamese strains in HCMC and other provinces (highlighted in black) that do not
belong to this study. The tree is rooted by DENV-l sylvatic genotype. oat trap upport i
shown on main nodes. Each genotype branch is painted in a different c lour and labeled
with a genotype name. All Dong Thap strain fall in Genotype I and diverge in 5 lineage
(#1, #2, #3, #4 and #6). Branches in Genotype 1 that have Dong Thap train are highlight d
in different colours corresponding to different group.
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Gl
(2.8%) G2
Fig.4.8. DENY-1 lineages sampled in Dong Thap province. Pie
graph shows the percentage of each clade relative to the overall
number of DENY-l sampled from Dong Thap province (n=176).
Lineage #3 was the most prevalent (73.4%) and then lineage #6
(15.3%). Lineage #1, #2, and #4 appear as a minority.
When the different lineages were compared to the digital map of household locations in Dong
Thap, there was no apparent spatial relatedness amongst lineages. All five lineages scattered in
Cao Lanh city, Cao Lanh district and other neighboring districts. However, within some
individual lineages, there was a number of genetically distinct clusters showing temporal and
spatial structure. These clusters are highlighted (labeled 3, b, c, d, e, f, g, h and i) and shown
in FigA.9.A. Geographical distributions of distinct clusters, details of nucleotide difference,
sampling time difference, and physical distance within clusters are also shown in Fig.4.9.B.
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• 11 Fig.4.9. Relationship between phylogenetic cluster and
temporal and spatial distribution in DENV-I lineages
in Dong Thap province. (A) is 6 lineages of DENV-l
genotype I indicated by different branch colours. Five
lineages contain viruses collected in Dong Thap (1, 2,
3, 4 and 6). Clusters highlighted in different colours
(labeled from a to i) are genetically distinct viruses
distributed within a different limitted area and
correspondingly displayed in B. Shown in (B) are
• spatial distributions of clustering viruses. Individual
clusters are indicated by different colours or symbols.
Number of nucleotide differences, physical distance,
and temp~fal distance are shown in table under (B).
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nt difference Physical distance Terrporal
(range) (range)m distance (day)
2-7 35-1200 2-17
1-4 300-000 10-17
4-6 200-5600 11-28
1-7 500-1000 3-16
1-9 150-1600 1-43
0-8 0-6000 1-48
1-14 200-6000 6-24
3-10 400-3200 8-11
0-6 100-2000 7-20
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b. Highly active transmission periods associated with a number of identical sequences
Shown in Fig.4.10.(A) are 5 pairs of identical sequences found during the peaks of
transmission (Octl2006 and Jul-Sep/2007). Pair #1 which was 10,690 nt in length (position 23-
10,712), ~200 metres apart and collected 3 days apart and sampled at the high transmission
period of 2006 (October). Pair #2 was 10,691 nt in length (23-10,713), =-lkm apart, 7 days
apart and sampled at high transmission time in the 2007 outbreak (August). The remaining 3
pairs, namely #3, #4 and #5 were 10,685 nt (position 23-10,707), 10,690 nt (23-10,712) and
10,684 nt (23-10,706) in length, respectively. All were sampled during high transmission time
in the 2007 outbreak. The identical viruses #3 were the interesting ones which were sampled
from 2 patients (7 and 15 years) living in the same house with a history of illness starting 1
day apart. The identical sequences #4 appeared 4 days apart and were -70 metres distant.
Interestingly, the identical viruses #5 were collected 27 days apart and at a distance of ~2.5km.
All patients from whom the identical sequences derived were from 7-18 years. Fig.4.10.(B)
shows numbers of cases per month and high transmission time (black bars) in DT in 2006 and
2007 at which identical sequences were collected. Collectively, the identical sequences
obtained in a restricted area over the epidemic were associated with the highest transmission
periods; particularly the twin #5 (lineage #3) collected 27 days and -2.5km apart.
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c. Selection pressure on DENV-l
Fig.4.10. Geospatial distribution of
identical DENV-1 genome sequences.
Shown in (A) is 5 pairs of identical
sequences obtained during the peaks
of tranmission in 2006 and 2007 with
different time of collection (day, d).
Pair #1 (red dots, -200 metres apart)
and #2 (green dots, -1km apart)
belonged to lineage #6. Pair #3 (Pink:,
the same location), #4 (turquoise, 70
metres apart) and #5 (black, -2.5km)
belonged to lineage #3. Shown in (B)
is number of dengue cases per month
in Dong Thap in 2006 and 2007 .
Identical sequences were obtained at
time when number of cases was
highest (black bars).
We found no positive selection in any gene or site amongst DENV-l lineages #1 and #6.
dNldS in every gene was low «1), ranging from 0.029 (NS4B) to 0,335 (Capsid). This, again,
suggested that purifying selection had a major impact on the DENV population structure.
Similar to DENV-1 virus population sampled in and around HCMC, here, Capsid and NS2A
also exhibited higher dNldS ratio than other genes (0.335 and 0.134, respectively). dNldS
results on a gene-by-gene basis are presented in Table 4.4.
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Gene Capsid prM E NSI NS2A NS2B NS3 NS4A NS4B NS5
ILength
l(Noofaa) 114 166 495 352 218 130 619 150 249 899
Global dNldS 0.335 0.110 0.101 0.099 0.134 0.052 0.030 0.068 0.029 0.053
Table 4.4 Selection pressures in DENV-1 collected in Dong Thap on a gene-by-gene
basis in DENV-1 data set (n= 176). No site is under positive selection pressure. All
dNldS ratios were < 1, ranging from 0.029 (NS4B) to 0.335 (Capsid).
d. Sequence divergence in nucleotide and amino acid sequence amongst DENV-llineages
The overall mean sequence divergence (complete CDS) amongst 5 DENV-1 clades was 1.25%
in nucleotide sequence and 0.42% in amino acid sequence. The divergence in nucleotide and
amino acid sequences on a gene by gene basis is shown in Table 4.5. Collectively, in this
virus population, Capsid and M protein showed the highest level of sequence divergence
amongst the Vietnamese viruses sampled in this study (1% and 0.81%, respectively).
Length M e and iv erg e n c e
M e and iv erg e nee
in nucleotide in a m in 0 a c id
Gene
(N 0 0 f a m in 0 a c id )
s e_qu e n c e (% ) sequence (%)
Cap sid 1 1 4 0.92 1.00
M 166 1 .59 o .8 1
E 495 1 .3 1 0.48
N S 1 352 1 .34 0.54
N S 2A 218 1.68 0.70
N S 2B 1 30 1 .3 1 0.10
N S 3 619 1 .1 7 0.1 7
N S4A 150 1.08 0.15
N S4B 249 0.88 0.52
N S 5 899 1 .24 0.52
Complete CDS 3392 1 .25 0.42
Table 4.5 Sequence divergence amongst 5 DENV-1 clades on a gene by gene basis.
Shown in bold are the genes with the highest divergence in nucleotide sequence (NS2A:
1.68%) and in amino acid sequence (M protein: 1.00%). The lowest divergence in
nucleotide sequence is NS4B (0.88%); in amino acid sequence is NS2B (0.10%). The
overall sequence divergence (complete CDS) in 5 DENV-I clades is shown in the
bottom row (1.25 and 0.42 at nucleotide and amino acid level, respectively).
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e. Investigation of the association between clinical outcome and DENV-l clades
Thirty-one patients, from whom DENV genome were sequenced, developed DSS, of which 4
cases was DENV-2 (1 sampled in 2006,3 in 2007), 27 were DENV-I (all sampled in 2007).
Though DF and DHF were found in patients infected with anyone of the 5 DENV-1 lineages,
4 of 5 lineages contained DSS patients. Lineage #3 accounted for 77.8% (21127) of total DSS;
DSS in lineage #6 was 14.8% (4/27), lineage #1 and lineage #2 was 3.7% of each (1/27). No
DSS case was associated with lineage #4. The proportion of DSS cases in each of the 5
lineages is as follows: lineage #1: 115 (20%), lineage #2: 119 (11.1%), lineage #3: 211128
(16.4%), lineage #4: 0/6 (0%), lineage #6: 4/27 (14.8%). To explore whether genetic
differences amongst 5 DENV-I clades may cause differences in clinical outcome, a further
analysis was made. Viraemia levels and platelet nadirs were compared amongst the 5 lineages
and between lineage #4 (in which no patients developed DSS) and each of the other 4 lineages
(1, 2, 3, and 6). Median viraemia values (logIO cDNA equivalents/ml) and platelet nadirs at
the time of enrolment in each of the 5 lineages were compared (Table 4.6). No significant
differences in viraemia levels or platelet nadirs were found in enrolment amongst 5 lineages
(P=0.8, and P=0.3, respectively, Kruskal-Wallis test). Paired comparison of viraemia and
platelet nadir between group 4 versus each of other 4 groups (I, 2, 3 and 6) also showed no
significant differences (P=0.2; 0.5; 0.9; 0.7 and P=0.5; 0.2; 0.2; 0.1; respectively). Summary
of laboratory variables (medium 10glOcDNA equivalents, medium platelet nadirs) and
demographic information on DENV-I clades are described in Table 4.6. Platelet nadirs and
viraemia levels in DENV-I clades are shown in Fig.4.11.
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Median
log10cDNA DOl Number
equivalents Median platelet [Median Male Median of
Clade (SD) nadirs (SD) (range)] (%) age (SD) shock
1 (n=5) 7.7 (0.82) 80,000 (60,076) 3 0-3) 8 13 (5.5) 1
2 (n=9) 8.2 (0.63) 88,000 (38,069) 3 (2-3) 66 10 (3.5) 1
3 (n=128) 8.11 (1.04) 83,750 (39,679) 3 (1-5) 54 11 (6.5) 21
4 (n=6) 8.2 (0.53) 55,500 (39,043) 2.5 (2-4) 50 10 (2.5) None
6 (n=27) 7.9 (1.01) 93,500 (54,946) 3 (1-4) 50 12 (7.5) 4
P value" 0.8 0.3 0.8
a: Kruskal-Wallis DOl: Day of illness
Table 4.6 Viraemia levels, platelet nadirs and demographic information in patients
infected with different DENV-I lineages. No association between viraemia level or
platelet nadir with a particular lineage was found.
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Fig.4.11. Viraemia levels and platelet nadirs in different DENV-I clades. Shown in A is the
median (interquartile and range) of viraemia values at the time of enrolment for each of 5
DENV-l lineages. B is platelet nadirs in 5 clades. There is no significant difference in
viraemia level and platelet nadir amongst 5 groups.
4.5.5.3. Molecular epidemiology ofDENV-2 inDong Thap
a. Phylogenetic analysis of DENV-2
DENV-2 accounted for 16.4% (64/391; 57 in 2007, 7 in 2006) of all serotypes during
sampling time. The genome sequences of 38 DENV-2 were determined. A maximum
likelihood tree of 38 DENV-2 revealed that they all belonged to the Asian 1 genotype
(Fig.4.12).
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Fig.4.12. ML tree of complete coding sequence from 524 DENV -2 strains. The tree
includes 38 Dong Thap strains, 330 strains available from GenBank (highlighted in grey)
and 156 Vietnamese strains sampled in HCMC and other provinces (highlighted in
black). The tree is rooted with DENV-2 sylvatic strains. Branches defining genotypes are
highlighted in different colours and labeled with their genotype name. Nodes that
separate branches defining different genotypes are supported with high bootstraps shown
at all main nodes. All Dong Thap strains fall into Asian 1genotype (highlighted in blue).
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When different sub-lineages within Asian 1 genotype were compared to the digital map of
household locations, a spatially and temporally clustering pattern was observed in several
genetically distinct clusters. Shown in Fig.4.13 are 3 distinct Asian 1 DENV-2 clusters (A)
and areas (B) within which these distinct clusters were distributed.
A B
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nt difference Physical distance Temporal
(range) (range) m distance Jdarl.
2-8 30-2200 1-24
1 600 5
1-6 200-2200 7-29
Fig.4.13. Temporally and spatially genetic association in DENV-2 lineages. Shown
in (A) are DENV-2 Asian 1 viruses described in the DENV-2 ML tree above.
Highlighted clusters are viruses showing temporal and spatial association (numbered
from 1 to 3). Shown in (B) is geographical distribution of distinct clusters. Different
clusters are indicated by different symbols. Shown in table under (B) is information
of nucleotide difference, physical distance and temporal distance within individual
clusters. In cluster 1, 6 of 7 viruses showed genetically temporal association and
were distributed between 30-2200m.
b. Sequence divergence in nucleotide and amino acid sequences ofDENV-2
The overall mean sequence divergence (complete CDS) in 38 DENV-2 was 0.77% in the
nucleotide sequence and 0.37% in the amino acid sequence and is summarised in Table 4.7.
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Generally, sequence divergence in this DENV-2 population is rather low, probably because
they were sampled in a short period of time in the same location and belonged to the same
genotype.
Mean Mean
Length d iv erg en c e in d iv e rg e n c e in
(N 0 of nu c le 0 tid e amin 0 ac id
Gene amin 0 acid) sequence (% ) sequence (% )
Capsid 114 0.49 0.23
M 166 0.78 0.13
E 495 0.75 0.32
N SI 352 0.77 0.43
N S2A 218 0.84 0.87
N S2B 130 0.44 0.00
N S3 618 0.86 0.27
NS4A 150 0.82 0.41
N S4B 248 1.02 0.33
N S5 900 0.72 0.45
Complete CDS 3391 0.77 0.37
Table 4.7 The sequence divergence amongst 38 DENV-2 sampled in Dong Thap.
Shown in bold are the highest divergence in nucleotide sequence (NS4B: 1.02%) and
in amino acid sequence (NS2A: 0.87%). The overall sequence divergence in
nucleotide and amino acid sequence (complete CDS) is 0.77 and 0.37%, respectively.
c- Selection pressure on DENV-2
Shown in Table 4.8 is the dNldS result on a gene-by-gene basis of DENV-2 in Dong Thap. In
the same context of the evolutionary process in DENV, the overall selection pressure impacted
on DENV-2 was that of purifying selection. dNldS ratio across genes was <1 ranging from
0.002 (NS2B) to 0.227 (NS2A). NS2A and Capsid again exhibited higher dNldS ratio than
other genes (0.227 and 0.171, respectively).
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Gene capsidlprM IE INSI INS2A INS2B INs3 INs4A INs4B INs5
Length
(No ofaa) 114 166 495 352 218 130 618 150 248 900
Global dN IdS 0.171 0.042 0.051 0.117 0.227 0.002 0.071 0.133 0.094 0.118
Table 4.8 Selection pressures on a gene-by-gene basis of DENV-2 (n=38) collected in
Dong Thap. None site is under positive selection pressure. All dNldS ratios were < I,
ranging from 0.002 (NS2B) to 0.227 (NS2A)
4.6. Discussion
All four DENV serotypes were identified during the study period (October-December/2006
and the 2007 dengue outbreak) in Dong Thap province, but DENV-I and DENV-2 were the
major serotypes associated with the outbreak. Although both mild and severe diseases have
been found to derive from anyone of the 4 serotypes, the proportion of severe disease (DHF
versus DF) in DENV-I was greater than the other DENV serotypes. With our greatest effort,
DENV-I and DENV-2 were the most easily available viruses for sequencing. This study
therefore, describes the molecular epidemiological pattern of DENV-I and DENV-2 in this
setting, covering the periods of high DENV activity, and investigates the association between
virus genetics and clinical outcome and laboratory variables.
In DENV -1, a notable finding was the extent of genetic variation (but not amino acid
diversity) within a single genotype, although these viruses were collected during a short time
in a restricted area. Purifying selection was the overall evolutionary pressure shaping the
genetic diversity in this viral population. In DENV-2, Asian 1 genotype was the unique
lineage detected over the outbreak, compatible with what was observed in and around HCMC
during this period. This, again, suggests a possibility of DENV-2 Asian I genotype having a
competitive advantage over AmiAs genotype.
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The extent of genetic diversity of DENV on a localized scale utilizing E gene sequences has
been previously measured in primary schools in Kamphaeng Phet, Thailand and showed little
evidence for in situ evolution, and that viral migration was the major mechanism shaping the
genetic diversity of DENV in the region [147, 148]. We exploited the full genome approach to
study the structure of genetic variation in this DENV population in relation to temporal and
geographic distribution on a background of households mapped within a =lOkm radius around
DTH. Our phylogenetic analysis showed that the 2007-viruses were originally associated with
2006-strains in DENV-1 lineage #3 and #6 clusters. In addition, a number of phylogenetic
clusters were observed within which genetic distances ranged from 0 to over 10 nucleotides in
samples separated by days to -rnonth of sampling and distributed in close vicinity to one
another. As such, with whole genome data derived from a large number of samples, our results
provide strong evidences for in situ evolution in this fine spatial scale. However, viral
introduction is the main mechanism shaping the genetic diversity in this study region, which is
shown by the breadth of viral lineages sampled over the study area.
Investigation of DENV molecular epidemiology at the full genome level has demonstrated the
utility of this approach in giving higher phylogenetic resolution that can be coupled with
spatial and temporal epidemiological data [137, 149]. A previous report has shown the
existence of clearly distinct spatial clusters in DENV-l and DENV-3 in Singapore [137].
Consistent with this previous study, our results revealed spatially and temporally constrained
phylogenetic clusters in both DENV-1 and DENV-2. This could be a reflection of focal
transmission patterns (e.g. within a household or between neighbouring households).
Amongst the DENV-1 population in Dong Thap, a number of pairs of identical sequences at
the level of the whole viral genome were detected. This could be a reflection of a shared
exposure between these individuals (for example an infected mosquito in the same living
accommodation, neighborhood, school, workplace or place of entertainment), or, perhaps less
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likely it just occurs by chance in a DENV population where identical sequences co-circulate
and could be revealed when a large enough number of viruses is sampled. Pairs of identical
sequences had a spatial range of 0-1,000m distance within a collection period of 1-7 days
apart. One pair of identical sequences that was detected in 2 patients living in the same house
with 1 day difference between collections strongly suggests that they were infected by the
same mosquito in their residence. Interestingly, our results show a pair of identical sequences
sampled -2.5km apart in distance and 27 days apart in time. The simplest explanation for this
is that this represents a consensus virus sequence that has not accumulated any mutations from
the consensus after going though several rounds of mosquito-human infection. A less probable
explanation is that this is a consequence of shared exposure to a long-lived infected mosquito,
since the lifespan of Ae. aegypti mosquitoes is usually only a few weeks. Also possible is
trans-ovarial transmission such that the progeny of an infected mosquito carry a virus with an
identical genome sequence. Vertical transmission has been proven previously for several
mosquito-borne viruses, such as La Crosse virus [150], West Nile virus [151] and Yellow
Fever virus [152]. Recent studies have also shown this transmission pattern occurring in
DENV [88, 94,153] but the role of it in dengue epidemics remains unknown [153,154]. It
would be particularly interesting to carry out further studies to determine how this
transmission pattern contributes to dengue epidemiology in Vietnam.
Within the DENV-l virus population in and around HeMe, viruses belonging to lineage #6
were as abundant as viruses in lineage #3 (33.7% versus 32.7%). In Dong Thap however,
lineage #6 was sampled at a much lower rate than lineage #3 (15.3% versus 73.4%) suggesting
that this lineage was first introduced into HeMC where it has become established with then
occasional introductions into Dong Thap. Alternatively, but less likely is that herd immunity
status in Dong Thap might be more favorable for lineage #3 than lineage #6 relative to
HCMe.
108
Chapter 4. Dengue virus molecular epidemiology in an outbreak in Dong Thap Province ill the Mekong Delta
region of southern Victnam
Our results indicated that the number of dengue cases in Dong Thap was relatively high
between July-December/2006 (referred to Fig.4.3). The number of cases suddenly dropped
during the first 3 months of 2007, and then the outbreak was triggered in the early rainy season
(April). Interestingly, after the 2007 outbreak, a remarkable drop in dengue cases in 2008 was
observed in Dong Thap. The basis of this phenomenon remains uncertain. A possible
explanation is that the population-wide immunity level probably has reached a threshold that
curtails DENV-1 transmisison. This could also result from the Vector Control Program having
been launched after the outbreak (Source: Dong Thap Committee of Precautionary Measures
against Epidemic). Training courses for Prevention, Management and Control of Dengue had
been organized in 2008 in Dong Thap province (Source: Dong Thap Committee of
Precautionary Measures against Epidemic).
The same genetic diversity was observed in 2006 and 2007 in that DENV-1 clade #3 was the
major lineage. In addition, sequence analyses showed no evidence for adaptive selection
impacting on this viral population over the outbreak. In summary, in agreement with previous
studies [130, l37, 155], our results imply that stochastic factors, vector control or herd
immunity or a combination of these aspects were the major contributions driving the end of
the dengue outbreak in Dong Thap province.
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5.1. Introduction
Though most DENV infections are uncomplicated and not life-threatening, accurate and
timely diagnosis is helpful for clinical management, disease surveillance and research
activities. Laboratory diagnosis for acute dengue is currently performed by many approaches:
virus isolation in mosquito cells or mammalian cells, viral RNA detection by RT-PCR, or
serological assay e.g. MAC ELISA.
Virus isolation is definitive but requires at least seven days for completion. It is expensive,
requires specialized techniques and usually accessible only in reference or research
laboratories. RT-PCR is a rapid, sensitive, and reliable assay but this technique is expensive
and not always feasible in resource poor endemic areas. Moreover, it is less sensitive around
the time of defervescence, a time when the clinical complications of vascular leakage are most
likely to manifest. The MAC ELISA assay is widely used for dengue diagnosis in many
dengue endemic laboratories. However, firstly, the interpretation of the result in some settings
is complicated due to cross-reactive antigenic determinants shared by DENV with other
flaviviruses; secondly, definitive confirmation requires paired specimens collected within the
appropriate time frame (5-7 days apart). This limits its utility, since confirmation of results
occur when the patient has recovered or even left hospital. Therefore, an accurate and sensitive
diagnostic test that differentiates dengue from other viral infections in the first few days of
illness is an important practical requirement.
DENV NSI protein becomes detectable from the first day after fever onset up to day 9 [21].
Moreover, this protein can be detected even when viral RNA becomes unmeasurable in RT-
PCR or in the presence of IgM antibodies [21, 22]. The recent introduction of commercial
ELISA assays to detect the dengue virus NS 1 antigen in human serum or plasma has provided
an additional dengue diagnostic to the existing approaches of RT-PCR, serology and less
frequently, virus isolation. Previous studies have described the sensitivity of commercial NSI
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assays in patients with dengue [25-28]. These studies have shown this antigen is a promising
diagnostic marker but further evaluation in different settings is required. Outstanding
questions exist for existing NS I assays as diagnostic tools and these include their sensitivity
across different serotypes, viral burdens and DENV reactive-IgG/IgM status.
5.2. Purposes of the study
The aims of this study was to evaluate the diagnostic utility of a commercial NS I dengue
antigen-capture ELISA test kit produced by BioRad Ltd (Platelia DENGUE NS 1 AG, herein
referred to as Platelia NS 1). Diagnostic accuracy was assessed via specificity and sensitivity
across viral burdens, different infecting serotypes, IgG/IgM status and infection status.
5.3. Methods
5.3.1. Patient recruitment
This study was performed in Vietnam as part of the DENCO study (Dengue case classification
and case management). The DENCO study was a prospective clinical study characterizing the
clinical features of dengue in patients in Asia (Thailand, Vietnam, Philippines, Malaysia) and
the Americas (Brazil, Venezuela, Nicaragua). In Vietnam, the study enrolled participants
admitted to CH #1, CH #2, or HTD from August 2006 to March 2007. Participants were
eligible for entry to the study if they had a history of fever of less than 7 days and there was a
clinical suspicion of dengue. Exclusion criteria were patients with signs and symptoms of dual
acute infections, or lack of informed consent. Clinical classifications were defined according
to WHO criteria. In this study, day of onset of illness was defined as day 0 and was self-
reported by the patient or patient's parents/guardian.
5.3.2. Sample cellectlon and study procedures
Details of procedure of sample collection are described in Chapter 2. Patients' blood samples
collected at the enrollment day (admission samples) were tested with quantitative serotypic
TaqMan RT-PCR, virus isolation using C6/36 cell line and NSI diagnostic investigations.
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Paired specimens from enrollment and convalescence phase were tested in IgM and IgG
capture ELISA assays. NSI-ELISA accuracy indexes were assessed based on sensitivity,
specificity, negative and positive predictive values (NPV and PPV).
5.3.3. The dengue diagnosis reference algorithm
No single assay can diagnose all dengue patients in the acute, febrile stage of illness.
Consequently, we use an algorithm that uses results from 3 assays- a) RT-PCR detection of
DENV RNA in plasma, b) viral culture and c) serological changes in DENV reactive IgM and
IgG levels in paired plasma specimens. A diagnosis of confirmed dengue was made if the PCR
was positive and/or virus culture positive. Acute dengue confirmed by serology if
-lgM sero-conversion was recorded (i.e. from negative to positive), or
- Rising levels of IgM were detected (IgM Units at discharge (lgM2) > 1.2 x IgM Units
at admission (IgM 1) and IgM2 > 20 Units) or
- IgG sero-conversion and positive for IgMI or IgM2,
Samples with IgM positive in a single specimen or IgM positive in paired specimens but no
significant rise in Units and no IgG sero-conversion were diagnosed as "recent dengue".
Patients with paired samples collected at least 3 days apart with the 2nd sample collected ?7
days after illness onset and with no virological or serological evidence of DENV infection
were defined as "no evidence of acute or recent dengue". A schematic showing the reference
algorithm for laboratory confirmation of dengue is shown in Fig.S.l.
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yes
8-IgG positive in GAC ELISA in SI and S2 ..... Recent flavivirus infection
I no
Paired plasma 3 or more days apart
1- RT-PCR positive
, no
2- Viral culture positive
, no
yes Lab confirmed..... acute dengue
yes Lab confirmed..... acute dengue
yes Lab confirmed..... acute dengue
yes Lab confirmed
..... acute dengue
.:. Lab confi rmed
acute dengue
3- IgM sero-conversion in MAC
ELISA from SI to S2
(IgM DENV>JEV IgM)
, no
yes
..... Recent Dengue
infection
4- IgM positive in MAC ELISA in SI and S2,
and IgM Units in S2 >20 and at Jeast=1.2xlgM
in SI and IgM DENV>IgM lEV
, no
5-IgM positive in MAC ELISA in SI or S2
and IgG sero-conversion
'no
6- IgM positive in MAC ELISA in a single
specimen OR IgM positive in paired
specimens but no significant rise in Units
and IgM DENV>IgM JEV
7-IgG sero-conversion in GAC ELISA from
SI to S2
.=. Acute flavivirus infection
(in VN this is probably dengue)
No laboratory evidence of
acute dengue
Fig.5.l. Reference algorithm for laboratory confirmed acute dengue
SI: admission sample, S2: discharge sample
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Primary and secondary dengue cases were defined according to the level of IgG ELISA Units
measured on day 6 or day 7 of illness. The IgG cut-offs for determination of primary versus
secondary dengue in this ELISA were determined separately against a well recognized
reference ELISA (Dr Sutee Yoksan, Centre for Vaccine development, Thailand). Secondary
dengue is determined in patients with IgG ELISA Units> I0.7 on day 6 of illness or > 18.4
Units on day 7 of illness.
5.3.4. Analysis
The diagnostic accuracy of the Platelia NS 1 assay was calculated relative to the final diagnosis
determined by the reference algorithm: acute dengue or other febrile illness. Platelia NS 1
results that were equivocal and remained equivocal after retesting were considered negative.
Statistical analysis was performed with Intercooled Stata 9.2 (Stata, TX, USA). Sensitivity,
specificity, PPV and NPV were calculated as described in Chapter 2.
5.4. Results
5.4.1. Characteristics of the study population
From August 2006 to March 2007, paired blood samples from 891 suspected dengue patients
were collected from hospitals in HCMC; 289 patients were from the CH #1, 302 patients from
the CH #2 and 300 patients from HTD. Of 891 patients, 732 (82.2%) had laboratory
confirmation of acute DENV infection according to the reference algorithm, of which 22.2%
(n=162) were primary dengue, 75.5% (n=553) were secondary dengue and 2.3% (n=17) were
indeterminate. Thirty-seven patients had DENV-reactive IgM and/or IgG positive in paired
plasma, but with no significant rise in ELISA Units between samples and were defined as
having had "recent dengue". There were 122 patients who had no serological or virological
evidence of acute or recent dengue and were defined as "other febrile illness" (OFl). The
median age (year) in dengue patients was 12 (range, 1-54). Of 732 acute dengue patients,
65.8% (n=482) were children «15 yrs) and 34.2% (n=250) were adults (~I5 yrs). The median
115
Chapter 5. Evaluation of the Platclia NS 1 ELISA assay for diagnosis of acute dengue
day after the onset of fever in confirmed dengue patients that enrolment samples were
collected was 4 days (range, 1-6). The characteristics of the patient population are described in
Table 5.1.
Acute Recent
Characteristics Total dengue OFI dengue
No. of patients 891 732 122 37
Sex (M %) 52 54 41 49
Age (year)
median (range) 13 (1-54) 12(1-54) 15 (I-53) 14 (2-37)
Duration of fever (days) at enrolment
DayO 2 2 0 0
Day 1 19 11 8 0
Day2 109 88 21 0
Day 3 310 263 42 5
Day4 302 266 23 13
Day 5 139 96 25 18
Day6 10 6 3 1
Day of illness
median (range) 4 (1-6) 4{l-6) 3 0-6) 5 (3-5)
Primary infection 162 (22.2%)
Secondary infection 553 (75.5%)_
Indeterminate 17 (2.3%)
Table 5.1 Baseline table summarizing mean duration of illness at enrollment, serological
profile and demographic features of the study population. 732 (82.2%) had laboratory
confirmation of acute DENY infection. OF!: Other febrile illness
The 732 confirmed acute dengue cases based on the described algorithm and the overlap of the
3 diagnostic tests (RT-PCR, virus culture and serological assays) is shown in Fig.S.2. Six
hundred forty eight cases were positive for RT-PCR, 217 were virus culture positive and 629
were confirmed by serology.
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Fig.S.2. Diagram showing dengue 1
cases and the overlap of RT-PCR,
virus culture and serology assays. I
Three cases were confirmed by culture
only, 105 by RT-PCR only and 78 by ,
serology only; Three hundred fifty six I
cases were confirmed by two assays I
(332 by serology and RT-PCR, 21 by
RT-PCR and culture, and 3 by culture I
and serology) and 190 cases were,
overlapped by 3 assays.
_..- ....." >,~ .
~ 21,.... \ .
Confirmed I."" \ .
by culture I ."" \ ...I :' ,
(n=217) -+1 f 190 I 332
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5.4.2. DENV serotype prevalence
Of 648 DENV infections identified by TaqMan RT-PCR (88.5%), DENV-l was the dominant
serotype, accounting for 53.2% of all RT-PCR confirmed infections (n=345). The second most
prevalent was DENV-2 with 35.5% (n=230), then DENV-3 with 10.2% (n=66). DENV-4 was
detected in just 1.1 % (n=7) of all RT-peR confirmed infections. Eighty-four samples (11.5%)
were of unknown serotype. A frequency of individual DENV serotype is summarised in
Fig.S.3.
DENV_4 Unknown
Fig.S.3. Chart of serotype prevalence in the study population detected by
RT-PCR positive. DENV-1 was the most prevalent serotype (53.2%);
the second most prevalent was DENV-2 (35.5%), then DENV-3
(10.2%). DENV-4 was the least prevalent (1.1%).
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5.4.3. Evaluation of the Platelia NSl accuracy for the diagnosis of dengue
Platelia NS I antigen-capture ELISA was performed on enrolment samples from all 891
patients in the study. Five-hundred twenty three samples were positive for NS 1, 341 were NS 1
negative and 27 samples were equivocal. Amongst 27 equivocal samples, 13 samples
remained equivocal and 14 samples became negative after a second run; for the purposes of
analysis equivocal samples were regarded as negative for NS 1. Of 523 NS 1 positive samples,
500 were from patients with laboratory confirmed acute dengue (273 were DENV-I, 134 were
DENV-2, 53 DENV-3, 4 DENV-4 and 36 of unknown serotype), 23 were from patients with
"recent dengue" according to the algorithm. Of 368 NS 1 negative samples, 122 were
diagnosed as OFl, 232 were acute dengue and 14were recent dengue.
The sensitivity and specificity of Platelia NS I was assessed relative to the "acute dengue"
classification by the reference algorithm. The overall sensitivity of Platelia NS 1 on enrolment
specimens was 68.3% (500/732) (95% Cl: 64.8-71.7). The NSI positivity was consistently
lower than RT-PCR when matched with day of illness (Fig.S.4). Against RT-PCR as a
reference test, the overall Platelia NS1 sensitivity was 71.7% (465/648) (95% Cl: 68.1-75.2).
None of plasma samples from patients with no laboratory evidence of acute dengue (n = 122)
were NS1 antigen positive. Specificity of Plate lia NSI in acute plasma was 100% (Table 5.2).
rca (+) Q NSI (+)
100
~ 80'>:e 60
i- 40
"t. 20
o~~~~~~~~~~~JW~~~~~~~~-~~~
DOl: 0
(N= 2
1
10
2
82
3
251
4 5
226 72
6
5
Overal
648)
Fig.S.4. PCR and NS 1 positivity by day of illness. Graph shows NSI positivity by
day of illness and overall NS1 positivity in test sample comparative to RT-PCR.
NSI positivity was consistently lower than RT-PCR. DOl: Day of illness.
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Platelia NS 1 sensitivity in samples from patients enrolled on day 0 of illness was 100% (2/2).
Sensitivity gradually declined with increasing day of illness (Table 5.2). The sensitivity,
specificity and PPV, NPV with 95% Cl of Platelia NSI assay against the reference algorithm
by day of illness is summarised in Table 5.2.
Day of Acute Sensitivity % Specificity % PPV%
NPV%
illness Dengue NSI (+) (95% Cl) (95% CI)* (95% CI)*
(95% Cl)
DayO 2 2 100 (22.3-100,0) 100.0(15.8- 100.0)
Day 1 11 10 90.9 (58.7-99.7) 100.0 (68.8-100.0) 100.0 (77.9-100.0)
88.9 (51.7-99.7)
Day2 88 68 77.3 (67.1-85.5) 100.0 (86.7-100.0) 100.0 (95.7-100.0)
51.2 (35.1-67.1)
Day3 263 181 68.8 (62.8-74.4) 100.0 (93.1-100.0) 100.0 (98.4-100.0)
33.8 (25.6-42.9)
Day4 266 179 67.3 (61.3-72.9) 100.0 (87.8-100.0)
100.0 (98.3-100.0) 20.9 (13.7-29.7)
Day S 96 58 60.4 (49.9-70.3) 100.0 (88.7-100.0) 100.0 (94.9-100.0)
39.7 (27.5-52.7)
Day6 6 2 33.3 (43.3-77.7) 100.0 (36.8-100.0) 100.0 (22.4-100.0)
42.8 (10.0-81.5)
Total 732 500 68.3 (64.8-71.7) 100.0 (97.6-100.0) 100.0 (99.4-100.0)
34.5 (29.5-39.6)
*: One-sided, 95% confidence interval
Table 5.2 Diagnostic accuracy for NSI-ELISA stratified by day of illness. Overall NSI
sensitivity ofNS1 is 68.3%.
Sensitivity of Platelia NS 1 in patients enrolled within ~ 72 hrs of illness duration were
significantly higher than in patients enrolled at later times [sensitivity (95% Cl); 79.2% (69.9-
86.6), n=101 versus 66.5% (62.7-70.2), n=631, P=O.Ol]. This difference was strongly
associated with viraemia levels, as viraemia level of test sample collected ~72hrs was
significantly greater than >72hrs [median loglO cDNA equivalents (SD); 8.12 (1.67) versus
6.47 (1.77), P<O.OOOl].
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5.4.4. NSl sensitivity in relation to viraemia levels
Of 732 acute DENV infections, viraemia, expressed as cDNA equivalents/ml plasma, was
measured in 648 samples. Viraemia was highest at day 1 of illness (n=10) then gradually
declined on the following days (2,3,4,5 and 6). The overall decreasing of viraemia level over
the acute phase of illness is illustrated in Fig.5.5.
o._~--~--~--~~--._--~--~--
DOl: 0 1 2 3 4 5 6
(n=2) (n=10) (n=82) (n=251) (n=226)(n=72) (n=5)
P=O.6 P=O.1 P=O.02 P<O.OOI P<O.OOI p-o 5
I II II II II 11-·1
Fig.5.S. Viraemia levels in test samples on enrolment day. Shown is median
(interquartile and range) viraemia level in patient samples on enrolment day. The
limit of detection of the assay is shown with a dashed line. (DOl: Day of illness)
.....••.............•.........
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We hypothesised that plasma viraemia levels would be associated with the detection of plasma
NSl, since NSI, like virions, is a product of infected cells. Accordingly, viraemia levels
were significantly higher in patients who were NS I-positive at the time of study enrolment
(n=464) versus those who were negative for NSI (n=I84) [median (SD): 7.27 (1.72) versus
5.12 (1.45), P<O.OOl, Mann-Whitney test] (Fig.5.6). Furthermore, patients who were NSI
positive were also more likely to be RT-PCR positive [ratio of RT-PCR (+) in NSI positive
patients (95% Cl); 93% (90.2 - 94.9), (n=500) versus NSI (-) patients; 79.3% (73.5 - 84.3),
(n=232), P<O.OOl, Fisher's exact].
NS 1positive
(n=464)
NS 1negative
(n=I84)
t/) 15-c:Cl)
.~ 10
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Cl)
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P<O.001
Fig.5.6. Viraemia levels by NS1 status tested by the Platelia ELISA.
Shown is the median (interquartile and range) viraemia level in NSI
positive (n=464) and NSI negative (n=I84) patients with a measurable
viraemia level at the time of study enrolment. The limit of detection of the
assay is shown with a dashed line. Viraemia levels were significantly
higher in NS 1 positive patients relative to NS 1 negative patients
(Mann-Whitney test).
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The NS I sensitivity relative to viraemia levels in test sample compared by day of illness (day
1, 2, 3, 4 and 5) was also consistently higher in NSI-positive patients (P=O.l for day I and
P<O.OOl for day 2 to day 5) suggesting that NSI sensitivity reduced concomitantly with
reduced viraemia level and with increased illness duration. Viraemia levels according to NS 1
status in dengue patients by day of illness is shown in Fig.S. 7.
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(11=9) (n=L) (11=66) (11=16) (11=175) (11=76) (n=162) (11=64) (11=48) (n=24)
122
o NS 1 negative
Fig.S.7. Viraemia levels by NSI status in dengue patients compared by day of
illness. Median viraemia level in NS 1 positive cases is consistently higher than in
NS 1 negative cases on the same day of illness. Viraemia levels at day 0 and day 6
were not shown in the graph as sample size was small for statistical analysis (n=2
and 5, respectively). (n= Number of samples in each NSI status group, DOL:Day
of illness)
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The association between NS 1 sensitivity and viraemia levels was consistently observed in
individual infecting serotypes. In patients infected with DENV-1 (n=345), DENV-2 (n=230)
or DENV-3 (n=66), viraemia levels in those who were positive for NSI were significantly
higher than in those who were negative for NSI on the enrolment day (P<O.OOl) (Fig.5.S).
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Fig.5.S. Viraemia levels by NS 1 status relative to DENV serotypes. Box and whisker plot
shows viraemia levels by NS 1 status in enrolment sampled from patients infected with each
of the 4 DENV serotypes. Viraemia in those who were NSI positive were consistently
higher than in those who were NS 1 negative. The difference is statistically significant in
patients infected with DEN-I (n-345), DENV-2 (n=230) and DENV-3 (n=66). Numbers
below the chart indicate number of samples in NS 1 positive or negative group in individual
serotypes. Hatched blocks are NS 1positive, open blocks are NS 1 negative.
5.4.5. NSl sensitivity in relation to immune response status
5.4.5.1. NSl sensitivity in primary or secondary infection
Shown in Table 5.3 is NSI sensitivity relative to immune response status. Overall, NSI
sensitivity was higher in patients with primary dengue (85.2%) than secondary dengue
(63.3%). Reduced NSI sensitivity in secondary infection was not associated with the duration
of illness, as at the time of testing, illness day in secondary cases was non-significantly greater
than primary cases (3.5 versus 3.4, P=O.4, Table 5.3). Reduced sensitivity in secondary
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infection was also not statistically associated with viraemia levels between primary and
secondary cases [secondary 10giOviraemia; 6.7 versus primary, 6.8, P=O.J, Table 5.3].
Sample Mean 001 a Viraemia a NSI sensitivity%
(SO) P value median (SO) P value NS 1 (+) (95%CI) P value bgroup
Primary
6.8 (1.9) 85.2
infection 3.4 (1.0)
(n=147)
138
(78.8-90.3)
(n= 162)
0.4 0.1 < 0.0001
Secondary
6.7 (1.7) 63.3infection 3.5 (0.9) 350
(n=553)
(n=484) (59.1-67.3)
a: Mann-Whitney test; b: Fisher's exact test; 001: Day of illness
Table 5.3 Sensitivity of Platelia assays in patients with primary or secondary infection.
Sensitivity in secondary cases is significantly lower than in primary cases (63.3% vs.
85.2%, P<O.OOOJ). This reduced sensitivity is not associated with day of illness
(secondary, 3.5 versus primary, 3.4, P=O.4) or viraemia levels in the test samples
(secondary dengue, 6.7 versus primary, 6.8, P=O.J).
5.4.5.2. Influence of IgM and IgG responses on NSI sensitivity
In general, NS I sensitivity in samples from patients with measurable DENV-lgG (in GAC
ELISA) was significantly lower than in samples from patients without measurable DENV-IgG
(39.7% versus 86.2%, P<O.OOJ, Fisher's exact), whereas IgM positivity (MAC ELISA) in test
sample was not significantly associated with NS I sensitivity [NS I sensitivity in IgM (-),
69.3% versus IgM (+), 67.5%, P=0.6, Fisher's exact]. Collectively, IgM responses did not
affect detection rate ofNSI in the Platelia assay. In contrast, NSI sensitivity was significantly
reduced in the presence of measurable DENV reactive-IgG in test sample. This significant
NSI sensitivity reduction in non-measurable DENV-IgG was consistently observed when test
sample were matched by day of illness [NSI sensitivity in IgG (+) versus IgG (-), %: 28.5
versus 55.5 for day 2; 40.8 versus 67.6 for day 3; 35.8 versus 81.6 for day 4; and 30.4 versus
85.7 for day 5; P< 0.005 for all]. No sample on day 0 or dayl was positive for IgG. Results
from day 6 were not shown because number of samples was small, n=7. Shown in Table 5.4 is
NS I sensitivity in relation to IgMlIgG response status.
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=:=~ Sensitivity % P valueTotal NS 1 (+) (95% Cl) (Fisher's exact)I p
Measurable IgM 419 283 67.5 (62.8 - 72)
Non-measurable IgM 313 217 69.3 (63.9 - 74.4) P=0.6
Measurable IgG 282 112 39.7 (34.0 - 45.7)
Non-measurable IgG 450 388 86.2 (82.7 - 89.3) P <0.00]
Table 5.4 NS I sensitivity relative to DENV -reactive IgM/lgG status in the test
samples. NS1 sensitivity in IgG (-) samples was significantly greater than in IgG (+)
samples while there is no significant difference in NS 1 sensitivity by IgM response
status.
Reduced NS 1 sensitivity in the presence of DENV-reactive IgG was also consistently
observed in the context of individual infecting serotypes. NS I sensitivity in samples from both
DENV-l and DENV-2 infected patients with non-measurable DENV-IgG was significantly
greater than in patients with measurable DENV-IgG (NS1 sensitivity in IgG (-) versus IgG
(+); DENV-I, 92.8% versus 48.1%, P<O.OO]; DENV-2; 76.5% versus 33.6%, P<O.OO]). This
difference was of borderline significance for DENV-3 (85.7% versus 66.6%, P=O.09). Result
for DENV-4 was not shown as the sample size was inadequate for statistic analyses (n=7). An
illustration of influence ofIgG response status on NSI sensitivity in DENV-I, DENV-2, and
DENV-3 is shown in Fig.S.9.
Fig.S.9. NSI sensitivity by DENV-
IgG status in individual serotypes.
Shown is NS1 sensitivity by DENV-
IgG status in test sample across
individual infecting serotypes. NS 1
sensitivity in IgG (-) samples is
consistently higher than in IgG (+)
in 3 DENV-l, -2 and DENV-3. (n:
18) Number of samples in each IgG
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5.4.6. Influence of infecting DENV serotype on sensitivity of Platelia NSI
The DEN V serotype was characterized in 88.5% (6481732) of acute dengue patients. Detection
rate ofNSl in DENV-3 or DENV-l infected patients was significantly higher than in DENV-2
infected patients (Fig.5.10.A, Fisher's exact). NSI sensitivity in DENV-4 was also non-
statistically lower than DENV-l or DENV-3 (P=O.l, Fig.5.10.A, Fisher's exact). One possible
explanation for this difference was the immune status in these individuals. To investigate this
assumption, we analysed proportion of secondary and primary infection in individual
serotypes. The proportion of secondary infection in patients infected with DENV-2 (88%) was
statistically higher than either DENV-I (65%) or DENV-3 (74%), [Fig.5.10 D, Fisher's exact].
There was also a statistically greater proportion of DENV -2 infected patients having
measurable IgG in the test samples than either DENV-I or DENV-3 (Fig.5.10.C, Fisher's
exact). Proportion of secondary cases in DENV-4 was also higher than DENV-I or DENV-3,
though this was not statistically significant [Fig.5.10 D, (P=O./ and P=O.06, Fisher's exact)].
Moreover, the percentage of patients infected with DENV -4 having measurable reactive IgG
was significantly greater than DENV-I or DENV-3 (P=O.OOl, Fig.5.10.C, Fisher's exact).
This lower NSI sensitivity in DENV-2 and DENV-4 was associated with viraemia levels, as
viraemia levels in DENV-2 or DENV-4 was lower than DENV-I or DENV-3, though this was
not statistically significant. [logIOviraemia, median (SD): DENV-2: 6.48 (1.79), DENV-4:
6.13 (1.75), DENV-I: 6.80 (1.86), and DENV-3: 6.68 (1.69), P=O.2, Kruskal-Wallis test].
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Fig.S.IO. NSI sensitivity in relation to immune response status. Shown in (A) is NSI
sensitivity in test samples at the enrollment in individual infecting serotypes. NSI detection
rate in DENV-2 is significantly lower than in DENV-l or DENV-3. Proportion of secondary
cases (B) or patients with DENV reactive-IgG measurable (C) in DENV-2 infected patients is
significantly greater than DENV-l or DENV-3. NSI detection rate in DENV-4 (57%) is also
lower than DENV-l or DNEV-3, though this is not statistically significant.
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However, low NSI sensitivity in DENY-2 or DENY-4 was not affected by the difference in
the duration of illness at the time of sampling, as mean illness day in DENY-2 infected
patients was significantly shorter than either DENY-lor DENY-3 [DENY-2 illness day; mean
(SD), 3.28 (0.88) versus 3.50 (0.96), P=O.008 or 3.52 (0.91), P=O.03]; and illness day in
DENY-4 infected patients was non-significantly longer than either DENY-lor DENY-3 [3.71
(1.25) versus 3.50 (0.96), P=O.7 or 3.52 (0.91), P=O.8]. Thus, reduced sensitivity in DENY-2
or DENY -4 infected patients was probably due to an increased proportion of patients having
DENY -reactive IgG in their test samples (indicative of secondary infection). Furthermore,
there would be other factor impacting on lower NSI sensitivity in DENY-2. To test this
hypothesis, we analyzed Platelia NS I sensitivity relative to DENY serotype in patient samples
that satisfied 2 conditions: primary infection and negative for DENY-reactive IgG. This
further analysis revealed that the detection rate for NSI in DENY-2 (n=20) was significantly
lower than either DENY-I (n=99) or DENY-3 (n=14) [DENY-2 NSI sensitivity (95%CI):
56.5% (34.5-76.8) versus DENY-I: 92.6% (86.0-96.7) or DENY-3: 73.3% (44.8-92.2),
P<O.OOOl, Pearson test]. No primary case belonged to DENY-4. In brief, besides immune
response status, probably the mAb used for capture and detecting NS I had lower affinity to
DENY-2 NS I which contributes to lower NS I sensitivity in DENY-2.
S.4.7. Relative associations with NSI antigenaemia in test sample
Since Platelia NSI sensitivity was associated with many factors in univariate analysis; IgG
status in test sample, viraemia level, infecting serotype, and number of day of illness; we then
further investigated the influence of these variables on the NS I sensitivity via logistic
regression analyses (expressed with odds ratio - OR). Shown in Table S.S are positive and
negative associations with NS 1 antigenaemia. The absence of DENY reactive IgG from test
sample was strongly positively associated with NSI sensitivity [IgG (-): OR (95% Cl), 9.97
(6.05-16.39), P<O.OOI versus IgG (+): 0.1 (0.07-0.15), P<O.OOl], whereas IgM showed no
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influence on NSI sensitivity (OR IgM (-) (95% Cl) versus IgM (+), 1.08 (0.79-1.49), P=0.6
versus 0.92 (0.67-1.26), P=O.6). To a lesser extent, primary infection and higher viraemia
levels were also positively associated with NSI sensitivity. In contrast, secondary infection
and duration of illness prior to test sample collected were negatively associated with NS I
sensitivity. In relation to infecting serotypes, DENV-2 [OR (95% Cl), 1.86 (1.12-3.08),
P=O.Ol] showed less positive association with NSI sensitivity than DENV-I and DENV-3
[OR (95% Cl), 5.05 (3.05-8.36), P<O.OOl and 5.43 (2.58-11.44), P<O.OOl; respectively].
DENV -4 was not included in the logistic regression as the sample size of DENV-4 infected
patients was small (n=7).
Positive and negative associations with NSI antigenaemia
Variables Odds Ratio 95%Cl P value
IgO (-) 9.97 6.05 - 16.39
IgO (+) 0.1 0.07 - 0.15 <0.001
IgM (-) 1.08 0.79 - 1.49
IgM (+) 0.92 0.67 - 1.26 0.6
Primary infection 3.33 2.09 - 5.32
Secondary infection 0.29 0.18 - 0.48 <0.001
Viraemia level 2 1.68 - 2.17 <0.001
PCR(+) 5.65 3.09 - 10.34 0.001
DENV-I 5.05 3.05 - 8.36 <0.001
DENV-2 1.86 1.12 - 3.08 0.01
DENV-3 5.43 2.58 - 11.44 <0.001
Number of illness days 0.77 0.65 - 0.91 0.002
Table S.S Positive and negative associations with NS I antigenaemia.
Shown are factors with associations with NS 1 sensitivity in test
sample. Absence of IgO from test sample, host primary infection and
viraemia are factors associated with increased NSI sensitivity.
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5.5. Discussion
In this study, we report the assessment of diagnostic accuracy of Platelia NS I assay conducted
in children and adults admitted to HCMC hospitals from August 2006 to March 2007. This
assessment includes sensitivity and specificity spanning across different serotypes, host
infection status; viraemia levels, and duration of illness. The results from this study show that
NS I detection by means of Platelia NS 1 assay provides a highly specific (100%) and
satisfactorily sensitive approach to dengue diagnosis using a single specimen.
In univariate and multivariate analysis, we demonstrated NS 1 sensitivity was associated with
viraemia level detected by TaqMan RT-PCR. Patients who were NSI negative had
significantly lower median viraemia levels than NS 1 positive patients with the same duration
of illness history. In particular, patients who presented within :::72hrs and who were NSI
positive had viraemia levels much greater than in those who were NS I negative. These data
suggests that NSI antigenaemia is the reflection of the viraemia levels.
The assessment of NS I sensitivity using the Platelia NS I assay relative to day of illness has
been conducted in both children and adults in Thailand and showed no association between the
sensitivity and patient's duration of illness for Platelia NSI [26]. Unlike this previous study,
our results show that NSI detection rate decreases with increased duration of illness. This
probably because NS I decays over the infection time, leading to decreased NS I level in the
blood stream. Another possible explanation is that increased Igs in the blood stream over acute
phase may reduce free plasma NS I due to Igs-sequestered NS 1. In fact, Libraty et al. have
shown plasma sNS 1 concentration peaking at day 3 to day 4 of illness then declining to
undetectable at day 7 to 8 in both DF and DHF secondary sera [23].
In agreement with previous studies [26, 29], the results of this study demonstrate that the
Platelia NS I assay is less sensitive in secondary dengue cases. This is also consistent with our
finding of reduced NSI sensitivity in test sample with a measurable level of anti-DENY IgG
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antibodies. Furthermore, as reported in previous studies [21, 29, 140], unlike DENV-IgG
antibodies, detection of NSI antigen was not influenced by the presence of DENV-IgM
antibodies in the test sample. Study of the profiles of NS I-specific antibody in primary and
secondary patient's sera has revealed a higher level of NS I specific-antibody in secondary
sera than primary sera [156]; thus, a possible explanation for reduced NSI sensitivity in
secondary immune response is that plasma NS 1 is sequestered in immune complexes and that
target epitopes are not accessible to either the plate-bound or probe mAb in the NS I ELISA.
Indeed, efforts to dissociate immune complexes can enhance the sensitivity of the Platelia NS I
assay [26, 140].
Studies of the sensitivity and specificity of the Platelia ELISA have been previously conducted
in different settings [24, 26-30, 157], some of these assessments (French Guiana [28, 30];
Malaysia [27]) have reported a relatively higher sensitivity for Platelia NSI (88% and 93%)
than the results reported in this study. Given that the sensitivity was affected by infection
status, it is possible that the lower NS I sensitivity for Platelia reported here was partly due to
high proportion of secondary infection in this hospitalized-based study (76% secondary
dengue cases in the study population), concomitant with greater proportion of samples with
measurable DENV-reactive IgG. Our study is more consistent with the reported sensitivity of
Platelia NSI (63%) from Thailand where most cases were secondary dengue [26].
The Platelia NS I assay showed higher sensitivity for DENV-l or DENV-3 than DENV-2. It is
possible that the higher proportion of secondary cases with DENV-2 is the cause of this result.
However, this cannot be the only reason for low Platelia NS I sensitivity in our DENV-2 study
population. Our further assessment of Platelia NS I sensitivity in the test sample from cases
with primary infection and negative for DENV-IgG in the test sample revealed lower rates of
NS I detection for DENV-2. An inherent lower sensitivity for DENV-2 NS I was supported by
the logistic regression analysis in which the odds of being NS I positive was lowest even after
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including other factors such as day of illness, viraemia and serological status in the test
sample. A possible explanation for lower sensitivity in DENV-2 infections could be lower
avidity of the mAbs in the assay for the target epitope(s) in DENV-2 NSI. This serotype-
related difference in sensitivity may reduce the utility of this assay in investigations of DENV-
2 endemic or epidemic areas.
Another study conducted in Puerto Rico has shown lower NSI sensitivity for DENV-4 for
Platelia NS I [29]. This is consistent with our finding of low Platelia -NS1 sensitivity for
DENY -4, although the number of samples was inadequate for statistic analyses, because
DENY-4 was present at a very low frequency in this study.
Similar to previous studies [21, 140]. we demonstrated that NSI can be detected in patients
whose blood sample is negative by RT-PCR. The most likely explanation for this is that
bloodstream NS I clearance kinetics is different to those of the RNA genome.
In summary, our study confirms that as no single diagnostic assay is adequately sensitive and
specific enough to diagnose all acute cases of dengue at every time point during the acute
illness. DENV-NSI antigen detection based on ELISA principle provides an alternative tool to
diagnosis for acute dengue. The ease of this assay and relatively modest cost (- $5 per sample)
make it feasible to perform in most routine hospital laboratories in southern Vietnam. NS I
detection would be a diagnostic choice for improving dengue diagnosis in the first few days of
illness before DENV IgM is measurable. Importantly, our results suggest very high specificity
for the Platelia NSI assay. Though results from this study reveal a high specificity for the
Platelia assay; other brands of NS I assay also need to be evaluated. Such evaluations of NS I
sensitivity and specificity should be conducted on a wide range of patients in different settings
in order to recognize the strengths and weaknesses of these tests.
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6. Assessment of the utiUty of NSI-LFRT versus Platella NSI ELISA for diagnosis of
acute dengue virus infection
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6.1. Introduction
Timely, sensitive, and specific diagnosis of DENV infection can assist in patient management.
Prompt diagnosis of index cases can also facilitate vector control activities in the
community so as to mitigate further transmission. The availability of commercial ELISA
assays to detect the DENV NS I protein in acute plasma provides an additional dengue
diagnostic tool to the existing approaches ofPCR, serology and, less frequently, virus isolation
[25-30, 157]. The assessment ofNSl assays as a diagnostic tool across a wide range of patient
populations and viral serotypes is an important part of the process of identifying where these
assays may fit into existing dengue diagnostic algorithms.
In dengue epidemic areas, a convenient, rapid, and reliable diagnosis for acute dengue will
bring a quick and appropriate point-of-care decision. RT-PCR, with a required-stringent
workflow, is not widely accessible. The NSI-antigen ELISA has shown to be suitable for early
diagnosis with considerably high sensitivity, (83.2% [29]; 93.4% [27]) and specificity (100%
[27, 28]), and could be considered as first-line testing for acute dengue diagnosis in a single
serum sample [27, 28] but it can only be carried out in well-equipped healthcare services. In a
primary healthcare center with minimal laboratory apparatus, an accurate, rapid and simple
diagnosis is an important strategy for acute dengue diagnostic. Rapid tests provide an
alternative in such a setting. The most significant advantage of this system is ease of
application and they are the least time-consuming.
The sensitivity and specificity of NSI-LFRT assay have been previously assessed in several
settings [30, 158]. These studies have shown this approach is an improvement for a rapid and
accurate diagnosis for acute dengue, and could be used in routine clinical practice. However,
further evaluation of this assay in different settings and different ethnic profiles is needed. In
this context, the purpose of this study was two-fold. First, to compare the sensitivity and
specificity ofa lateral flow rapid test (NSI-LFRT) versus the Platelia ELISA, in the context
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of different viral serotypes, viral burdens, day of illness, and clinical presentations in
Vietnamese patients. Second, to assess the specificity of these NSI assays in patients with
other confirmed infections.
6.2. Materials and Methods
6.2.1. Patient enrolment
A series of prospective clinical research studies on dengue are in progress at the Hospital
for Tropical Diseases (HTD) in Ho Chi Minh City, Vietnam. Patients greater than 2 years
of age admitted to one of the intensive care units (adult or paediatric) or to one of the general
wards with a clinical suspicion of dengue as their primary diagnosis are eligible for enrolment
following written informed consent by the patient or guardian. In this study, day of onset of
illness was defmed as day I and was self-reported by the patient or patient's parents/guardian.
All studies have received approval from the Ethics Committee of the HTD and from
the Oxford Tropical Research Ethics Committee. All patients in these studies are assessed
daily by a study physician and have serial haematocrit and platelet estimations
performed, as well as appropriate sampling for diagnostic serology and virology. Other
investigations and clinical management are at the discretion of the attending physicians. After
discharge each patient is classified using the current WHO criteria for DF, DHF and DSS.
Patients with history of DENV infection later than 6 days or patients with dual acute infections
of dengue or lack of written informed consent were excluded from the study.
Plasma samples from patients with another confirmed diagnosis (malaria, enteric fever, JE or
leptospirosis) were obtained from stored specimens collected as part of other prospective
studies at HTD between 2001-2008. The diagnosis of Plasmodium falciparum malaria was
made by blood smear. Enteric fever was diagnosed by blood culture of S. Typhi or S.
paratyphi. Leptospirosis was diagnosed by positive serology (microscopic agglutination
test). Japanese encephalitis was diagnosed by capture JgM and IgG ELISA assays.
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6.2.2. Study procedures
To confirm dengue infection, plasma from all suspect dengue cases were sampled at admission
and tested with quantitative serotypic TaqMan RT-PCR. Paired specimens from enrollment
and convalescence phase were tested for serologic MAC and GAC ELISA. To evaluate the
sensitivity and specificity ofNSl-LFRT, all admission samples were blindly tested for dengue
NSI antigen by NSI-LFRT and Platelia ELISA according to the manufacturer's instructions.
Both NS 1 tests were performed with freshly collected acute plasma samples from each patient.
Samples that were defined as equivocal in the NS 1 Platelia ELISA assay were repeated. If
they were still equivocal they were regarded as being negative. Samples that were defined as
equivocal in the NSI-LFRT were considered as being negative. Details of NSI-LFRT assay
are described in Chapter 2. Shown in Fig.6.1 is an example of aNSI LFRT result. Each assay
strip was independently assessed twice.
Sample
loading pad Fig.6.1. An example of NSI-LFRT
read. (A): negative result, with only
Control Line. (B): positive result,
with Control Line and Test Line.
A
B
Test line
6.2.3. Dengue diagnostics and result analysis
Diagnostic results for dengue were as described in Chapter 5. Sensitivity, specificity, PPY,
and NPY analyses were as described in Chapter 2. The interpretation of primary and
secondary serological responses was also as described in Chapter 5.
6.3. Results
6.3.1. Characteristics of the study population
From November 2007 to January 2008, we prospectively tested 138 consecutive acute plasma
samples from all children and adults enrolled in these studies. The mean duration of illness
prior to the test plasma sample being collected was 3 days (range; 1-6). Patients with a breadth
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of disease severities were represented in the study, including patients with DSS. There were
117 patients diagnosed with "acute dengue", and 8 cases diagnosed as "recent dengue"
according to the laboratory reference algorithm. Of the "recent dengue" cases, 118had OHF
and 7/8 had established OSS. Since the clinical picture was so clear in these patients, and was
supported by highly suggestive serology (IgM positive in MAC ELISA in acute and early
convalescent plasma samples and IgG titre rising, but not 4-fold rising), we included these
patients in the "acute dengue" category, for a total of 125 acute dengue patients. Of 125 acute
dengue cases, 11 cases were diagnosed by PCR alone, 14 were diagnosed be serology alone,
and 100 were diagnosed by both peR and serology. There were 13 patients in whom there was
no evidence of acute or recent dengue. The baseline characteristics of the study population are
shown in Table 6.1.
Acute dengue (0=125)
Sample Claical severity Serologicalstatus OFl
characteristics Indeter Overall
OF DHFI DHFII OHF III Primary Secondary minate
Nwnberof 49 16 40 20 24 93 8
cases (39.2%) (12.8%) 1(32.0010)(16.0010) (19%) (74%) (6%) 125 13
Male/Female 1:2.1 1.7:1 1:1.2 1.5:1 2:1 1:1 1:1.2 1:1.2
Median age
in year
I(range) 20 (7-41) 15(1~2' 14(6-40' 11(4-31' 13(6-39\ 17(4-42) 16(4-42' 12
Mean day
of illness
(range) 2.8 (1-5) 3.1 (2-5) 3.5 (1-6) 4.6 (3-6) 3.3 (1-5) 3.6 (1-6) 3 (1-6) 3
OENV-l 29 8 21 5 14 44 5 63
DENV-2 5 3 8 4 3 17 20
DENV-3 11 5 6 3 6 16 3 25
OENV-4 2 0 1 0 3 3
Serotype not
defined 2 4 8 1 13 14
Table 6.1 Summary of key clinical, viral and demographic information on the study population
OF!: Other febrile illness
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6.3.2. Infecting serotype prevalence
DENV serotype was characterized in 111 samples, of which 63 samples were DENV-I, 20
samples were DENV-2, 25 samples were DENV-3, and 3 samples were DENV-4. Fourteen
samples were not defined for infecting serotype. A frequency of individual DENV serotype is
shown in Fig.6.2.
Unknown serotype
DENV-3
22.5%
DENV-l
56.8%
DENV-2
18 %
Fig.6.2. Frequency of infecting serotype in the study population
6.3.3. NSI result description
Platelia NSI antigen-capture ELISA and NSI-LFRT were completed on 138 patient samples
at admission. One-hundred and four samples were positive for Platelia NSI-ELISA, 91
samples were positive for NSI-LFRT. Samples that were equivocal in the Platelia NSI assays
on first testing (n=2) were re-tested; one sample was negative whilst the other remained
equivocal and thereafter was regarded as negative. During the study, there were no examples
of discordance in the interpretation of any NSI-LFRT. None of plasma samples that had no
laboratory confirmation for acute dengue infection (n = 13) reacted with NS] antigen in both
tests. Results ofNSl assay in both assays in 138 samples are summarised in Table.6.2.
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Acute Dengue infection
OFI Total
DENV- DENV- DENV- DENV- Unknowns I 2 3 4 serotype
ELISA- NSI (+) 62 11 24 3 4 0 104
NSI
NSI (-) I 9 1 0 10 13 34
LFRT- NSI (+) 56 7 22 3 3 0 91
NSI
NSI (-) 7 13 3 0 II 13 47
Table 6.2 NSI results in 138 study samples from NSI-LFRT and Platelia NSI
assays. 104 samples are positive with Platelia NS 1, 91 samples are positive with NS 1-
LFRT. None of patient specimens in OFI (n=13) is NSI reactive in both NSI assays.
6.3.4. Overall sensitivity of NSI-LFRT versus NSI-ELISA
Overall, the NSI-ELISA assay was more sensitive than the NSI-LFRT test for the diagnosis
of acute dengue relative to the reference algorithm (83% versus 73%, P=O.047; Table 6.3).
Against RT-PCR, the sensitivity of the NSl-ELISA was also greater than the NSI-LFRT
(90% versus 79%, P=O.025; Table 6.3). There were 4 and 3 patients who were positive in the
NSI ELISA assay and NSI-LFRT respectively who were negative in the RT-PCR.
NS 1 sensitivity against reference algoritlun
Total Acute NSI Sensitivity % Specificity % PPV% NPV(%)
NSI assays analysis dengue positive (95%0) (95I'loal (95%at (951'/00) Pvalue
PlateIia7MNSI 138 125 104 83.2(75.5- 89.3) lOO(86.7-HXlO)100(97.2-100.0)38.2(22.2- 56.4)
0.047
LFRT-NSI 138 125 91 72.8 (64.1- SO.3)100(91.6-100) 100(96.7- 100.027.6(15.6- 42.6)
NSI sensitivity against RT-PCR
Platelia7MNSI 138 III lOO 90.1 (83.0- 95.0) lOO(76.2-100.0) lOO(97.~IOO.O)71.1(54.1-84.6)
0.025
lFRT-NSI 138 III 88 79.3 (71.0- 86.3) 100(87.8-100) 100(96.7-100.0 54.0(39.3- 68.1)
a one-sided, 95% Confidence Interval
Table 6.3 Diagnostic accuracy for each NSI assay against the reference algorithm and RT-PCR.
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6.3.5. Sensitivity of NSl tests by day of illness
The sensitivity of both NSI ELISA and LFRT tests was influenced by the patient's duration of
illness prior to study entry (Fig.6.3). Thus, both the ELISA and NSI-LFRT were significantly
more sensitive in test sample collected within 3 days of illness onset versus those collected at
later times, P=0.002 and O.OJ, (Table 6.4). The reduced sensitivity of NSl assays in patients
presented after 72hrs was associated with viraemia levels in test sample [Viraemia level in
patients presented within 72 hrs, loglOcDNA (SD); 8.5 (1.3) versus viraemia level after 72
hrs, 6.9 (1.2), P<O.OOOJ, Mann-Whitney, (Fig.6.4)].
NSI-ELISA P NSI-LFRT P
Sample group NSI (+) sensitivity (95%CI) value
a sensitivity (95%CI) NSI (+) value a
< =3 day (n=75) 69 92.0 (83.4 - 97.0) 0.002 81.3 (70.6 - 89.4) 61 0.01
> 3 day (n=50) 35 70.0 (55.4 - 82.1) 60.0 (45.2 - 73.5) 30
a: Fisher's exact test
Table 6.4 Sensitivity ofNSl assays in plasma samples collected within 3 days
of illness onset versus those collected at a later time.
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Fig.6.3. Relationship between day of illness and NSI sensitivity. (A) Shown is
percentage of positive Platelia ELISA and (B) LFRT assays by day of illness in
patients with confirmed dengue (n=125).
140
Chapter 6. Assessment of the utility of LFRT -NS I versus Platelia NS 1ELISA for diagnosis of acute dengue
virus infection
<= 3d > 3d
Fig.6.4. Viraemia level in samples
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6.3.6. NSI sensitivity in primary or secondary infection
In general, NSI detection was higher in patients with primary dengue (n=24) than secondary
dengue (n=93) (Table 6.5). This difference was statistically significant for the NSI-LFRT
(P=O.Ol) and of borderline significance for the ELISA (P=O.07). The difference in sensitivity
between primary and secondary dengue was not significantly associated with the illness day at
the time of testing [mean illness day (SD) of primary dengue versus secondary dengue: 3.3
(1.0) versus 3.7 (1.3), P=O.2)]. Reduced NSI sensitivity in secondary infection was also not
associated with viraemia levels between primary and secondary dengue cases [median 10gi0
viraemia (SD), primary versus secondary: 8.3 (1.4) versus 7.7 (1.5), P=O.2].
Sample Platelia % NSI-LFRT %
NSI status (95%CI) P value
a (95% Cl) P value agroup
Primary NSI (+) 23
22
infection NSI (-) 1 2
(n=24)
NS 1 sensitivity 95.8 (78.9 - 99.9) 91.7 (73.0 - 98.9)
0.07 0.01
Secondary NSl(+)
73 61
infection NSI (-) 20 32
(n=93)
78.5 (68.8 - 86.3) 65.6 (55.0 - 75.1)NSI sensitivity
a Fisher's exact
Table 6.5 Sensitivity of NSI assays in patients with primary and secondary serological
profiles. Sensitivity in primary is greater than in secondary cases in both test kits, but the
significant difference is only in NSI-LFRT (P=O.Ol).
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As shown in Chapter 5, NSI sensitivity has reverse association with DENVs-reactive IgG. To
assess the consistency of this occurrence, we analysed NSI detection sensitivity in the context
of DENV -reactive IgG and IgM antibody in the test samples in both assays. Consistent with
our report in Chapter 5, the presence of measurable DENV -reactive IgG in the test samples
was associated with a significant reduction (P<O.OOJ) in NSI sensitivity in both assays (Table
6.6). DENV-reactive IgM was also associated with a reduction in NSI-LFRT sensitivity and
was statistically significant in the ELISA assay (P=O.03) (Table 6.7).
S NSI-Platelil NSI-LFRT Sensitivity% (95% enTotal NegativePositiveNegative NSI-Platelia NSI-LFRTPositivea
IgG positive 38 23 15 18 20 60.5 (43.4 - 76.0 47.4 (31.0 - 64.2)
IgG negative 87 81 6 73 14 93.1 (85.6 - 97.4 83.9 (74.5 - 90.9)
Pvalue P < 0.001 P < 0.001
a: IgG in test sample
Table 6.6 Sensitivity of each NS1 assay in the presence or absence of measurable
DENV-reactive IgG in test samples.
cs:: NSI-Platelia NSI-LFRT Sensitivity% (95% Cl)Total Positive Negative NSI-Platelia NSI-LFRTPositive Negatives
IgM positive 35 25 10 23 12 71.4 (53.7 - 85.3) 65.7 (47.8 - 80.9)
IgM negative 90 79 11 68 22 87.7 (79.2 - 93.7) 75.5 (65.4 - 84.0)
Pvalue P=O.03 P=O.26
a: IgM in test sample
Table 6.7 Sensitivity of each NSI assay in the presence or absence of
measurable DENV-reactive IgM in test samples.
142
Chapter 6oAssessment of the utility of LFRT-NS I versus Platelia NSI ELISA for diagnosis of acute dengue
virus infection
6.3.7. NSl sensitivity in relation to viral serotype
In line with the results from previous Chapter, NSl sensitivity in DENV-2 was lower than
DENV-l or DENY-3 in both NSl-Platelia (Fig.6.S.A) and LFRT-NSl (Fig.6.S.B). The
reduced sensitivity in DENY-2 was non-statistically associated with the serological response
in these individuals. Secondary dengue in DENY -2 infected patients was greater than either
DENV-! or DENY-3 (85% versus 75% and 76%, P=O.6, Pearson chi square test). A relatively
greater proportion of DENV-2 infected patients had measurable DENV reactive IgG,
(Fig.6.6.A, Pearson chi square test), rather than IgM (Fig.6.6.B, Pearson chi square test) in the
test sample.
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Fig.6.S. Sensitivity of NSl detection in Platelia ELISA CA) and LFRT (B) in the
enrolment samples according to the infecting serotype identified by real-time RT-
peR. NSI detection in DENV-2 infected patients was significantly lower [55% CA)
and 35% CB)] than for DENV-l [98% CA) and 87% CB)] or DENV-3 [96% CA) and
88% CB)] in both Platelia ELISA [P<O.001, (A)] and LFRT [P<O.OOl, (B)]. Results
for DENY-4 not shown as the sample size was small (n=3).
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Fig.6.6. DENY reactive IgG and IgM status by serotypes. Proportion of patients with
detectable DENV-reactive IgG (A) or IgM (B) antibodies (measured by capture
ELISAs) in the test sample was also related to the infecting serotype. Test sample from
DENV-2 infected patients were more likely to have measurable levels of DENV-
reactive IgG but not IgM, though this was not statistically significant.
Again, the reduced sensitivity of NSI detection in DENV-2 infected patients was non-
statistically associated with lower viraemia level in the test sample from DENV-2 infected
patients [DENY-2 median logIOcDNA (SD); 7.4 (1.7) versus DENV-I; 7.9 (1.5) or DENV-3;
7.8 (1.5), P=O.3, Kruskal-Wallis test]. The mean duration of illness at the time of sampling
showed no association with lower NSI sensitivity in DENV-2 also (DENY-I: mean 3.3 days;
DENV-2: mean 3.4 days; DENV-3: mean 3.3 days, P=O. 7, Kruskal-Wallis test). In brief, NSI
detection was a robust diagnostic test in DENV-I and DENV-3 infections, but was less
sensitive in DENV-2 infections in part because test sample from these patients were generally
more likely to have a concomitant DENV-IgG response, suggestive of secondary infection.
6.3.8. NSI sensitivity in relation to clinical profile
In general, NSI sensitivity in DF patients was higher than in DHF for both NSI-ELISA and
LFRT [(92% versus 78%, P=O.049) and (80% versus 68%, P=O.22, respectively)]. Lower
NS 1 sensitivity in DHF was associated with greater illness days and lower viraemia levels in
DHF patients relative to DF (Table.6.8). Reduced NSI sensitivity in DHF was also associated
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with measurable OENV-IgG in test sample [IgG (+) in OHF versus OF: 39% versus 18%,
P=0.009, Fisher's exact].
NS I assay and
other variables DF (n=49) DHF (n=76) P value
Platelia sensitivity
% (95%CI) 91.8 (80.4 - 97.7) 77.6 (66.6 - 86.4) 0.049 a
LFRT sensitivity
% (95%CI) 79.6 (65.7 - 89.8) 68.4 (56.7 - 78.6) 0.22 a
Mean day
of illness(SO) 2.87 (0.12) 3.97 (0.15) <0.001 b
Median viraemia
(SO) 8.13 (0.22) 7.53 (0.20) 0.04 b
a Fisher's exact test b: Mann-Whitney test
Table 6.S. Sensitivity of each NS I assay in OF and OHF patients. NS I
sensitivity in OHF patients who presented later and had lower viraemia than DF
patients is lower than NSI sensitivity in OF patients for both NSI-ELISA and
LFRT (92% and 80% versus 78% and 68%, respectively).
6.3.9. NSI specificity in patients with other confirmed diagnoses
Since the number of patients with no evidence of acute dengue was small (n= 13) in this study
(Table.6.1), further effort was made to assess the specificity of dengue NSI assays in patients
with other infectious diseases whose transmission geographically overlaps with dengue. To
this end, frozen acute (within 10 days of illness onset) plasma samples from patients with
culture confirmed enteric fever (S. typhi; n=25 and paratyphi, n=25), smear positive P.
Jalciparum malaria (n=52), serological-proven Japanese encephalitis (n=ll) and Leptospirosis
(n=12) were tested in parallel by both NSI-ELISA and NSI-LFRT. In all cases, NSI tests
were negative in these samples.
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6.4. Discussion
An accurate, early and convenient laboratory diagnosis for acute dengue is still problematic in
most dengue endemic areas, particularly where laboratories are poorly equipped and have
limited resources. Approaches currently used for laboratory dengue diagnosis such as DENV-
antibody detection (IgMlIgG ELISA), or less frequently, viral isolation and viral nucleic acid
amplification assays require skilled staffs and well-equipped laboratories. The dengue
immunochromatographic test for detection of dengue specific IgMlIgG, despite its advantage
for obtaining results within 7 minutes [159], has similar limitations to serology by ELISA,
since antibody detection is not sensitive in the very early stages of disease. It strictly requires
paired specimens for definitive laboratory determination and lacks specificity (IgG) because of
cross-reactivity with other flaviviruses. In this study, we compared the accuracy of NS l-LFRT
assay and NSI-ELISA, performed in parallel on the same day, in a group of paediatric and
adult patients encompassing a broad range of dengue disease severities and considered the
results in the context of viral burden and humoral immune response. A number of issues have
been raised by this study.
In general, sensitivity of NSI-LFRT was consistently lower than NSI-ELISA when matched
in the first 3 days of illness (81% versus 92%) or after 3 illness days (60% versus 70%). The
NSI antigenaemia test marketed as Dengue NSI Ag STRIP (LFRT) has proven to be a
promising first-line test in the field when only a single specimen is available [30]. Results
from our study showed that NSI-LFRT sensitivity (73%) was consistently lower than in
previous reports (81.5%, French Guiana [30], 90.4%, Malaysia [158]). The observed lower
sensitivity was probably due to higher ratio of secondary infections in the study population
(79%).
In agreement with other studies [27, 30, 158] and our previous report for NSI-ELISA, we
observed that NSI-ELISA and LFRT were less sensitive in secondary dengue cases. This is
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also consistent with our fmding of substantially decreased sensitivity in test sample with a
measurable level of anti-DENY IgG. Previous studies have reported contradictory findings on
the influence of DENV-reactive IgM on NSI detection [21, 22, 24, 27, 29, 140, 160J. In our
study, NSI sensitivity was also affected by the presence of measurable IgM and this was more
clearly observed in Platelia ELISA (P=O.03) than in LFRT (P=O.26). If the NS I sensitivity is
truly affected by both DENV-rneasurable IgM and IgG, immune-complex dissociation must be
considered to increase the utility of the test, regardless of whether test samples are collected
from primary or secondary infection patients.
In line with previous study [157], detection rate of positive NSI was higher in DF patients
rather than in DHF for both LFRT and ELISA. This could result from lower viraemia levels
likely related to being present late in DHF patients.
Overall, though the NSI-LFRT assay was modestly less sensitive than the Platelia NSI-
ELISA in this study (73% versus 83%) but importantly, retained high specificity (100%). The
attraction of the NSI-LFRT relative to the NSI ELISA is its ease of use and speed (IS minutes
versus 2 hrs), though this comes at a greater cost per test (-$10 versus $5). An obvious setting
in which to use this assay format is in primary health care clinics for testing of febrile patients
presenting early in their illness. In our hospital-based setting, the sensitivity of the NS l-LFRT
was 81% in patients admitted within 3 days of illness onset which is acceptable for a
diagnostic test. The ongoing development of specific anti-viral drugs for dengue [46, 47]
makes the availability of accurate rapid tests, such as the NSI-LFRT even more important
since diagnosing patients quickly and early will provide the greatest window of opportunity
for an anti-viral drug to be delivered with clinical benefit.
A weakness of the current study is that relatively few of the patients in the prospectively
assessed patient population were negative for dengue. We compensated for this by including a
large number of patients with known alternative diagnoses. The strengths of the current study,
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and point of difference from published studies, are that we included patients with severe
clinical presentations and investigated the relationship between NSI positivity, viraemia
levels, illness history and Ig responses. The finding that viraemia levels are (in previous
Chapter also), on average, higher in NS I-positive patients is a novel finding in the context of
these commercial assays. The significance of this observation is tied to the widely accepted
view that high viraemia levels are associated with disease severity [36, 161]. Thus, NSI
detection may be biased towards detecting those patients who, generally, have the highest
viraemias and with relatively higher risks of developing complications during their illness.
Future studies should measure the prognostic value of early NS 1 measurements for predicting
patients at risk of developing severe complications, e.g. DSS.
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Dengue is a globally important public health problem. There is no vaccine or anti-viral drug
available for dengue at the moment. Vector control programs are complicated and not always
sustainable [162] and thus a vaccine would be the most effective control strategy. Dengue
viruses, like other RNA viruses, possess an RNA-dependent RNA polymerase that lacks
proofreading activities leading to high mutation rates and genetic diversity. Thus, in moving
towards designing vaccines or developing anti-viral drugs against dengue, an understanding of
DENV genomic diversity is of crucial importance. Moreover, knowing how the changes in
serotype or lineage prevalence relate to dengue epidemics would be useful for better dengue
control. In addition, an accurate and timely diagnosis to differentiate dengue infection from
other viral infections in the first few days of illness is also an important practical requirement
because it is helpful for clinical management, disease surveillance and research activities.
Against this background, this study was carried out to; 1) investigate molecular epidemiology
of the 3 most prevalent DENV serotypes over the last 10 years in Southern Vietnam (HCMC
and surrounding provinces); 2) examine molecular epidemiology of DENV-I and DENV-2 in
a Mekong delta province during a dengue outbreak in 2007; and 3) assess the utility of two
commercial NS 1 antigen detection assays in the contexts of viraemia, infecting serotype, host
immune response and duration of fever. This section will discuss what implications for
vaccine/drug targets can be drawn from results of this study; how our results could contribute
to dengue prevention and a control strategy; and how results from the evaluation of NS I
commercial test kits could contribute to improving this diagnostic assay. Finally, additional
future research directions will be proposed.
7.1. Co-circulation of multiple DENV lineages and the emergence of DENV-2 Asian 1:
implication for the current dengue vaccine/drug effort
The most challenging issue for dengue vaccine developers is making a safe vaccine that elicits
broad and durable protective immune responses against all four serotypes of DENV. The
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results of this study highlight the extent of sequence diversity within individual serotypes of
DENV (notably, DENV-l and DENV-2) and thus the importance of providing broad coverage
against all of the discrete virus lineages within each serotype. For example, we demonstrate
that 3 different DENV-2 genotypes have been circulating in HCMC; American!Asian, Asian 1
and Cosmopolitan genotypes. Differences in amino acid sequence between the DENY-2
genotypes were low for the complete CDS (2.6%); however, divergence varied from gene to
gene, for example, 5.2% for NS2A; 4.2% for Capsid; 3.9% for NSI and M protein. Whilst the
amino acid differences in the E proteins of viruses from these different lineages were small
(2.4%), it is plausible that even subtle changes could provide for immune escape from
vaccine-elicited neutralising antibodies. We also showed that DENV-2 Asian 1 replaced the
American/Asian genotype in southern Vietnam. The DENV-2 Asian 1 lineage is probably the
most prevalent lineage of DENV-2 in SE Asia, suggesting vaccine developers must at least
ensure that their vaccines can elicit protective immunity against this lineage. Similarly, drug
developers should be using members from this lineage as reference DENV-2 viruses.
Furthermore, the Asian 1 genotype could potentially become widely distributed
geographically in many DENY endemic areas and particularly the Americas where currently
Am/As DENV-2 viruses are prevalent (shown in Fig.3.7).
The large genetic diversity in DENV-l genotype I viruses (6 distinct lineages with sequence
divergence ranging from 0.1-1.17 %) suggests southern Vietnam has sufficiently high
transmission levels to support substantial genetic (but not amino acid) diversity in this single
genotype of DENV-1 viruses. The concept of virus reservoirs has been suggested for
influenza, with tropical regions of Asia being nominated as reservoirs for new influenza
subtypes or lineages [163]. Conceivably Vietnam and other countries in SE Asia act as
geographic reservoirs that cultivate multiple lineages of DENV of which the fittest find new
niches for transmission in other neighbouring countries or globally. However, overriding
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evolutionary mechanism acting on DENV is purifying selection, as exemplified by the limited
amino acid diversity in the DENV-l genotype I viruses sampled in this study.
7.2. Signs to indicate a dengue epidemic and potential precautionary measures
Results from this study showed no evidence for the temporal coincidence between DENV-2
lineage replacement and serotype change as in other previously reported studies [118, 127].
However, the DENV-2 lineage replacement was associated with increased DENV-2 incidence
occurring in 2003, 2004 and 2005 (Fig.3.l2). Previous studies have shown lineage shifts are
either coincidental with an increase in severe cases or precede a dengue outbreak [130, 133].
For example, DENV-l lineage replacement in Myanmar (1998-2000) resulted in an outbreak
in 2001 [130]. In our research, results from DENV epidemiology investigation have shown
that multiple DENV serotypes co-circulate in Southern Vietnam and serotype shifts have
continually occurred. Notably, the conclusion drawn from a dengue surveillance program in
Southern Vietnam over the last 12 years showed that DENV serotype shifts are temporally
associated with increased dengue incidence in years during which the serotype change
occurred (for example 1998,2004 and 2007). Taken together, our results suggest that genetic
diversity is temporally linked to increased disease incidence. As a consequence, monitoring
shifts in lineages or serotypes could provide a warning of potential outbreaks of dengue.
7.3. NSl antigen as a candidate for early dengue diagnosis
Our evaluation of commercial NSI assay kits (Platelia ELISA and NSI-LFRT) has
consistently shown that NS l-positivity is higher in patients with high viraemia levels than in
those who have lower viraemia levels. For both NSI tests, the NPVs have a wide range of
values [20-88%, depending on the day of illness (Platelia ELISA)]. It is critical that laboratory
staff and clinicians understand that a negative result for NS 1 does not exclude dengue as a
diagnosis. Clearly rapid point of care tests could be very useful for diagnosis of dengue in
outpatient or primary care level facilities. Similarly, they could be useful for intensive care
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facilities where the differential diagnosis of a patient with shock could include sepsis or other
syndromes. As drugs for dengue advance down development pathways, rapid tests that can
diagnose dengue early will be valuable for identifying those patients who might benefit from
an anti-viral therapy.
Future NS I test possibilities could include serotype specific NS 1 tests that would be useful for
research purposes. Itmight also be possible to configure semi-quantitative NS I rapid tests that
could be evaluated for their diagnostic and prognostic accuracy. Data from my colleague, Miss
Than Ha Quyen suggests that early NS 1 levels in plasma could be useful as a prognostic
marker of DSS.
It would be a useful aid to rational development of antibody tools that have equal sensitivity
and specificity for the DENV serotypes. Our sequencing results in Chapters 3 and 4 have
contributed to NS 1 test developers as it suggests there is limited amino acid diversity in NS I
sequences from the same serotype.
7.4. Future directions
The most interesting questions emanating from this thesis and for future research are:
1. Why do Asian 1 DENV-2 viruses have a fitness advantage over American/Asian
genotype viruses in southern Vietnam?
2. Are there measurable biological phenotypic differences amongst the different DENV-l
lineages we have detected here, and what will happen to the various lineages in the
DENV-1 population during the next shifts in dominant serotype?
3. Do the current dengue vaccines that are in development, many of which are based on
viruses that circulated >20 years ago, elicit antibodies capable of neutralising the
currently circulating viruses from southern Viet Nam?
4. Can NSI be used as a prognostic marker ofDSS?
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The first question, on the fitness of Asian I DENV-2 viruses, could be addressed by virus-host
studies in A. aegypti mosquitoes. One reasonable hypothesis is that Asian I viruses have a
fitness advantage over American!Asian viruses in the mosquito vector by having a shorter
extrinsic incubation period or a lower infectious dose. An alternative possibility is that Asian -
I viruses have a fitness advantage because there are more susceptible hosts in the population,
This could be explored by measuring neutralising antibody titres to both Asian 1 and
American! Asian viruses in plasma from healthy community cohort samples collected between
2001-2005 in southern Vietnam by the OUCRU.
There may not be a measurable clinical phenotype to each of the DENV-l or DENV-2
lineages we have measured here. If there was, it would be fascinating as it would suggest
much more subtle relationships between virus sequences and "virulence" than previously
appreciated for dengue. One way of looking at this is by a careful investigation of clinical and
virological findings in the patients in whom we have recovered a genome sequence. Of note,
as of end-July 2009, our group has sequenced 590 DENV-I genomes from patients with a
breadth of disease severities in whom the viraemia levels in daily specimens are currently
being determined. With such numbers, it might be possible to link a genotype to a virological
or clinical phenotype. These ongoing studies will also allow us to see how the DENV-I
population structure changes as the prevalence of DENV-I inevitably decreases to be replaced
by a different serotype.
It is very important that dengue vaccines offer immunity to contemporary viruses that are in
circulation, and that vaccine development keeps pace with ongoing changes in viral diversity.
Protective value of vaccines under development could be assessed by measuring titres of
neutralising Ab against the viruses we have sampled here. Although neutralising antibody is
not a confirmed surrogate of immunity, it would be re-assuring to see that these vaccines elicit
antibodies capable of neutralising representative contemporary strains.
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The possibility of using NSI to predict clinical outcomes has been suggested but not
confirmed [23]. An obvious next step for NSI assays is to make them quantitative and
evaluate them in very large prospective cohort studies. A simple diagnostic and prognostic
marker for severe dengue would be a very valuable aid to clinicians in dengue endemic
countries such as Vietnam.
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Fig.3.9. NJ phylogenetic tree of239 DENV-2 EINSl sequences (240 nt) including 83
strains available from GenBank (21 are Vietnamese strains highlighted in red) and
156 Vietnamese strains generated from this study. All Vietnamese strains sampled in
1987, 1995 and 1996 fall in American! Asian genotype.
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O.OO9Q
Asian 2genotype
Asian! genotype
(2003-2008)
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American/Asian
genotype
(2001-2006)
Fig.3.10. NJ phylogenetic tree of 502 DENV-2 NS5 sequences (78nt) including 11
reference sequences from GenBank, 156 sequences derived from whole genome
sequences (38 from Dong Thap province) and 335 attempted sequences. The
American!Asian genotype contains sequences sampled from 2001-2008 (n= 130),
Asian 1 genotype contains sequences sampled from 2003-2008 (n=354), and
Cosmopolitan comprises sequences sampled in 2006, 2007, and 2008 (11=7).
Bootstrap values are shown at main nodes.
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List 1: Full genome sequences available from GenBank used in this study
No Country Accession No Year Serotype
1 Malaysia EF457905 1972 DENV-1
2 Cote d'voire AF298807 N/A DENV-1
3 Brunei EU179860 2005 DENV-l
4 Singapore AY762084 N/A DENV-I
5 Thailand AY732474 1990 DENV-l
6 Thailand AY732476 1990 DENV-1
7 Myanmar AY713473 1971 DENV-I
8 Myanmar AY722801 1976 DENV-l
9 Myanmar AY722802 1996 DENV-1
10 Myanmar AY722803 1998 DENV-1
11 Singapore EU081258 2005 DENV-1
12 Argentina AY277665 N/A DENV-1
13 Brazil AF311957 N/A DENV-1
14 Brazil AF311958 N/A DENV-l
15 Brazil AF513110 N/A DENV-l
16 Brazil AF311956 N/A DENV-l
17 Brazil FJ384655 N/A DENV-l
18 Brazil AF226685 1990 DENV-1
19 Nicaragua EU482615 2005 DENV-I
20 Nicaragua FJ432720 2005 DENV-1
21 Nicaragua FJ024485 2005 DENV-1
22 Nicaragua EU482617 2005 DENV-1
23 Nicaragua EU596502 2005 DENV-1
24 Nicaragua FJ024478 2005 DENV-1
25 Nicaragua FJ43272I 2005 DENV-1
26 Nicaragua EU482619 2005 DENV-l
27 Nicaragua EU482618 2005 DENV-I
28 Nicaragua EU596503 2005 DENV-l
29 Nicaragua FJ024480 2005 DENV-l
30 Nicaragua EU596504 2005 DENV-l
31 Nicaragua FJ024481 2005 DENV-1
32 Nicaragua FJ024479 2006 DENV-1
33 Nicaragua EU482616 2005 DENV-1
34 Nicaragua FJ024423 2005 DENV-1
35 Nicaragua FJ024484 2005 DENV-1
36 Nicaragua FJ024482 2005 DENV-1
37 Nicaragua FJ024483 2005 DENV-1
38 Nicaragua EU596501 2004 DENV-I
39 Puerto Rico EU482591 2006 DENV-l
40 Venezuela EU482610 2007 DENV-I
41 Venezuela EU482611 2007 DENV-l
42 Venezuela EU482609 2007 DENV-l
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43 French Guiana AF226686 N/A DENV-l
44 French Guiana AF226686 N/A DENV-l
45 French Guiana EF122231 N/A DENV-l
46 French Guiana EF122232 N/A DENV-l
47 Puerto Rico FJ410186 1992 DENV-l
48 Puerto Rico FJ410188 1996 DENV-l
49 Puerto Rico FJ478457 1996 DENV-l
50 Puerto Rico FJ410184 1993 DENV-l
51 Puerto Rico EU482567 1998 DENV-l
52 Puerto Rico FJ410183 1993 DENV-l
53 Puerto Rico FJ410181 1995 DENV-l
54 Puerto Rico FJ410185 1993 DENV-l
55 Puerto Rico FJ410190 1987 DENV-l
56 Puerto Rico FJ410175 1994 DENV-l
57 Puerto Rico FJ410180 1995 DENV-I
58 Puerto Rico FJ410174 1995 DENV-I
59 Puerto Rico FJ410182 1996 DENV-I
60 Puerto Rico FJ410189 1996 DENV-l
61 Puerto Rico FJ478458 1987 DENV-l
62 Puerto Rico FJ410179 1994 DENV-l
63 Puerto Rico FJ390379 1998 DENV-l
64 Puerto Rico FJ390374 1995 DENV-I
65 Puerto Rico FJ410187 1992 DENV-I
66 Puerto Rico EU482592 1998 DENV-l
67 Puerto Rico FJ390378 1998 DENV-l
68 Puerto Rico FJ390380 1998 DENV-I
69 Puerto Rico FJ410173 1998 DENV-l
70 Argentina AY277664 N/A DENV-I
71 Argentina AY277666 N/A DENV-l
72 Brunei EU179861 2006 DENV-l
73 Hawaii DQ672564 2001 DENV-l
74 Nauru Island U88535 1974 DENV-I
75 Nauru Island U88536 N/A DENV-I
76 Nauru Island U88537 N/A DENV-I
77 China EF025110 N/A DENV-l
78 Indonesia AB189121 1998 DENV-I
79 China EF032590 N/A DENV-l
80 Japan AB195673 N/A DENV-I
French
81 Polynesia DQ672556 N/A DENV-I
French
82 Polynesia D_Q_672557 N/A DENV-l
French
83 Polynesia DQ672559 N/A DENV-l
French
84 Polynesia DQ672560 N/A DENV-I
85 Hawaii OQ672561 2001 OENV-l
86 Hawaii OQ672562 2001 OENV-l
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87 Hawaii DQ672563 2001 DENV-1
French
88 Polynesia DQ672558 N/A DENV-1
89 Indonesia AB189120 1998 DENV-1
90 Indonesia AB074761 1988 DENV-1
91 Japan AB204803 N/A DENV-l
92 Cambodia AF309641 N/A DENV-l
93 China DQ193572 N/A DENV-l
94 Singapore EU081277 2005 DENV-I
95 Singapore EU081226 2005 DENV-I
96 Singapore EU081252 2005 DENV-l
97 Singapore EU081269 2005 DENV-I
98 Singapore EU081270 2005 DENV-1
99 Singapore EU081274 2005 DENV-I
100 Singapore EU081267 2005 DENV-I
101 Singapore EU081275 2005 DENV-1
102 Singapore EU081227 2005 DENV-l
103 Singapore EU081228 2005 DENV-1
104 Singapore EU081245 2005 DENV-I
105 Singapore EU081229 2005 DENV-I
106 Singapore EU081231 2005 DENV-I
107 Singapore EU081233 2005 DENV-I
108 Singapore EU081236 2005 DENV-1
109 Singapore EU081240 2005 DENV-1
110 Singapore EU081250 2005 DENV-I
111 Singapore EU081251 2005 DENV-1
112 Singapore EU081246 2005 DENV-I
113 Singapore EU081256 2005 DENV-I
114 Singapore EU081253 2005 DENV-1
115 Singapore EU081242 2005 DENV-l
116 Singapore EU081243 2005 DENV-1
117 Singapore EU081244 2005 DENV-l
118 Singapore EU081261 2005 DENV-I
119 Singapore EU081264 2005 DENV-l
120 Sinzanore EU081271 2005 DENV-l
121 Singapore EU081259 2005 DENV-I
122 Singapore EU081268 2005 DENV-I
123 Singapore EU081272 2005 DENV-l
124 Sinzanore EU081279 2005 DENV-l
125 Singapore EU081273 2005 DENV-I
126 Singapore EU081234 2005 DENV-I
127 Singapore EU081237 2005 DENV-I
128 Singapore EU081265 2005 DENV-l
129 Singapore EU081254 2005 DENV-I
130 Singapore EU081266 2005 DENV-I
131 Singapore EU081232 2005 DENV-l
132 Singapore EU081241 2005 DENV-1
133 Singapore EU081248 2005 DENV-1
183
9. Appendix 2
134 Singapore EU081249 2005 DENY-l
135 Singapore EU081247 2005 DENY-I
136 Singapore EU081263 2005 DENY-l
137 Singapore EU081230 2005 DENY-I
138 Singapore EU081238 2005 DENY-I
139 Singapore EU081280 2006 DENY-I
140 Singapore EU081281 2006 DENY-I
141 Singapore EU081239 2005 DENY-l
142 Singapore EU081257 2005 DENY-l
143 Singapore EU081278 2005 DENY-l
144 Singapore EU081235 2005 DENY-I
145 Singapore EU081260 2005 DENY-I
146 Singapore EU081255 2005 DENY-I
147 Singapore EU081262 2005 DENY-l
148 China EU359008 N/A DENY-l
149 Singapore EU081276 2005 DENY-l
150 Japan AB178040 N/A DENY-I
151 Myanmar AY708047 N/A DENY-l
152 Myanmar AY726549 2001 DENY-l
153 Myanmar AY726551 2001 DENY-l
154 Myanmar AY726553 2002 DENY-l
155 Myanmar AY726554 1998 DENY-l
156 Myanmar AY713476 2001 DENY-l
157 China AY835999 N/A DENY-l
158 Thailand AY732479 2001 DENY-l
159 Thailand AY732482 2001 DENY-l
160 China EU280167 N/A DENY-l
161 Singapore M87512 1990 DENY-l
162 Thailand AY732475 1994 DENY-I
163 Thailand AY732480 1994 DENY-l
164 China.GZ/80 AF350498 1980 DENY-l
165 Djibouti AF298808 1998 DENY-l
166 Thailand AY732477 1991 DENY-l
167 Thailand AY732478 1991 DENY-I
168 Myanmar AY713474 2001 DENY-l
169 Myanmar AY726552 2002 DENY-l
170 Myanmar AY713475 2001 DENY-I
171 Myanmar AY726550 2001 DENY-l
172 Myanmar AY726555 1998 DENY-l
173 Thailand AY732481 1982 DENY-I
174 Thailand AY732483 1981 DENY-l
175 Hawaii EU848545 1944 DENY-l
176 Japan AB074760 N/A DENY-l
177 Ivory Coast EFI05381 1980 DENV-2
178 Ivory Coast EFI05380 1980 DENV-2
179 Ivory Coast EFI05383 1980 DENV-2
180 Burkina Faso EFI05382 1980 DENV-2
181 Burkina Faso EFI05386 1980 DENY-2
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182 Guinea EFI05378 1981 DENV-2
183 Senegal EFI05390 1999 DENV-2
184 Senegal EFI05389 1999 DENV-2
185 Senegal EF457904 1991 DENV-2
186 Nigeria EFI05387 1996 DENV-2
187 Nigeria EFI05388 1996 DENV-2
188 Senegal EF105385 1974 DENV-2
189 Senegal EFI05384 1970 DENV-2
190 Malaysia EFI05379 1970 DENV-2
191 Colombia AY702040 1986 DENV-2
192 Peru EU056811 1995 DENV-2
193 Tonga AY744147 1974 DENV-2
194 Puerto Rico EU056812 1977 DENV-2
195 China AF119661 1985 DENV-2
196 Thailand DQ181801 1990 DENV-2
197 Colombia EU854294 2005 DENV-2
198 Colombia FJ024473 2005 DENV-2
199 Colombia FJ024475 2005 DENV-2
200 Colombia FJ024474 2005 DENV-2
201 Venezuela EU482604 2007 DENV-2
202 Venezuela EU482606 2007 DENV-2
203 Venezuela EU482605 2007 DENV-2
204 Venezuela EU482608 2007 DENV-2
205 Colombia FJ024477 2004 DENV-2
206 Venezuela EU482607 2007 DENV-2
207 Venezuela EU726775 1996 DENV-2
208 Nicaragua EU482444 2006 DENV-2
209 Nicaragua EU482755 2005 DENV-2
210 Nicaragua EU482768 2005 DENV-2
211 Nicaragua EU482754 2005 DENV-2
212 Nicaragua EU482763 2005 DENV-2
213 Nicaragua EU482771 2005 DENV-2
214 Nicaragua EU482597 2005 DENV-2
215 Nicaragua EU482600 2005 DENV-2
216 Nicarazua EU482632 2005 DENV-2
217 Nicaragua EU482633 2006 DENV-2
218 Nicaragua EU482636 2005 DENV-2
219 Nicaragua EU482637 2005 DENV-2
220 Nicaragua EU482749 2005 DENV-2
221 Nicaragua EU482758 2005 DENV-2
222 Nicaragua EU596484 2005 DENV-2
223 Nicaragua EU482770 2005 DENV-2
224 Nicaragua EU482629 2007 DENV-2
225 Nicaragua EU482639 2006 DENV-2
226 Nicaragua EU482760 2005 DENV-2
227 Nicaragua EU482688 2006 DENV-2
228 Nicaragua EU482753 2005 DENV-2
229 Nicaragua EU482767 2005 DENV-2
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230 Nicaragua EU482769 2005 DENV-2
231 Nicaragua EU482750 2005 DENV-2
232 Nicaragua EU482756 2005 DENV-2
233 Nicaragua EU569699 2007 DENV-2
234 Nicaragua FJ410291 2007 DENV-2
235 Nicaragua EU482599 2005 DENV-2
236 Nicaragua EU482602 2005 DENV-2
237 Nicaragua EU482631 2005 DENV-2
238 Nicaragua EU482681 2005 DENV-2
239 Nicaragua EU482761 2005 DENV-2
240 Nicaragua EU482695 2005 DENV-2
241 Nicaragua EU482598 2005 DENV-2
242 Nicaragua EU482680 2005 DENV-2
243 Nicaragua EU482759 2005 DENV-2
244 Nicaragua EU482752 2005 DENV-2
245 Nicaragua EU482765 2005 DENV-2
246 Nicaragua EU482762 2005 DENV-2
247 Nicaragua EU482635 2005 DENV-2
248 Nicaragua EU482601 2007 DENV-2
249 Nicaragua EU482638 2007 DENV-2
250 Nicaragua EU482690 2006 DENV-2
251 Nicaragua EU482621 2007 DENV-2
252 Nicaragua EU482622 2007 DENV-2
253 Nicaragua EU569697 2007 DENV-2
254 Nicaragua EU482624 2007 DENV-2
255 Nicaragua EU482626 2007 DENV-2
256 Nicaragua EU482628 2007 DENV-2
257 Nicaragua EU482625 2007 DENV-2
258 Nicaragua EU569692 2007 DENV-2
259 Nicaragua EU569698 2007 DENV-2
260 Nicaragua EU596498 2007 DENV-2
261 Nicaragua EU569700 2007 DENV-2
262 Nicaragua EU569701 2007 DENV-2
263 Nicaragua EU660406 2007 DENV-2
264 Nicaragua EU482627 2007 DENV-2
265 Nicaragua EU482630 2007 DENV-2
266 Nicaragua EU569694 2007 DENV-2
267 Nicaragua EU569695 2007 DENV-2
268 Nicaragua EU569696 2007 DENV-2
269 Nicaragua EU596495 2007 DENV-2
270 Nicaragua EU596497 2007 DENV-2
271 Nicaragua EU621672 2007 DENV-2
272 Nicaragua EU660404 2007 DENV-2
273 Nicaragua FJ478459 2007 DENV-2
274 Nicaragua EU482623 2007 DENV-2
275 Nicaragua EU569693 2007 DENV-2
276 Nicaragua EU569702 2007 DENV-2
277 Nicaragua FJ373300 2007 DENV-2
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278 Nicaragua EU596496 2007 DENV-2
279 Nicaragua EU596499 2007 DENV-2
280 Nicaragua EU660405 2007 DENV-2
281 Nicaragua EU482684 2006 DENV-2
282 Nicaragua EU482685 2006 DENV-2
283 Nicaragua EU482686 2006 DENV-2
284 Nicaragua EU482772 2006 DENV-2
285 Nicarazua EU482773 2006 DENV-2
286 Nicaragua EU482694 2007 DENV-2
287 Nicaragua EU482620 2006 DENV-2
288 Nicaragua EU482683 2006 DENV-2
289 Nicaragua EU482691 2006 DENV-2
290 Nicaragua EU482692 2006 DENV-2
291 Nicaragua EU596483 2006 DENV-2
292 Nicaragua EU482766 2005 DENV-2
293 Nicaragua EU596500 2007 DENV-2
294 Nicaragua EU482682 2006 DENV-2
295 Nicaragua EU482687 2006 DENV-2
296 Nicaragua EU482751 2005 DENV-2
297 Nicaragua EU482764 2005 DENV-2
298 Nicaragua FJ478455 2005 DENV-2
299 Nicaragua EU482603 2007 DENV-2
300 Nicaragua EU482748 2005 DENV-2
301 Nicaragua EU482634 2006 DENV-2
302 Nicaragua EU482689 2006 DENV-2
303 Nicaragua EU482757 2005 DENV-2
304 Nicaragua EU482693 2006 DENV-2
305 Nicaragua EU482696 2006 DENV-2
306 Cuba AY702034 1997 DENV-2
307 Cuba AY702035 1997 DENV-2
308 Cuba AY702036 1997 DENV-2
309 Cuba AY702037 1997 DENV-2
310 Cuba AY702038 1997 DENV-2
311 Cuba AY702039 1997 DENV-2
312 Martinique AF208496 1998 DENV-2
Dominican
313 Republic AB122020 2001 DENV-2
Dominican
314 Republic AB122021 2001 DENV-2
315 Puerto Rico EU687216 2005 DENV-2
Dominican
316 Republic AB122022 2001 DENV-2
317 Puerto Rico EU482726 2006 DENV-2
318 Puerto Rico EU48273I 2005 DENV-2
319 Puerto Rico EU596491 2007 DENV-2
320 Puerto Rico EU687217 2005 DENV-2
321 Puerto Rico EU677145 1999 DENV-2
322 Puerto Rico EU687212 1998 DENV-2
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323 Puerto Rico EU482546 1998 DENV-2
324 Puerto Rico EU482560 1998 DENV-2
325 Puerto Rico EU677142 1999 DENV-2
326 Puerto Rico EU482545 1998 DENV-2
327 Puerto Rico EU482734 1998 DENV-2
328 Puerto Rico EU482735 1998 DENV-2
329 Puerto Rico EU482544 2006 DENV-2
330 Puerto Rico EU482548 2006 DENV-2
331 Puerto Rico EU482549 2006 DENV-2
332 Puerto Rico EU482719 2006 DENV-2
333 Puerto Rico EU596490 2007 DENV-2
334 Puerto Rico EU596488 2007 DENV-2
335 Puerto Rico EU482725 2006 DENV-2
336 Puerto Rico EU726770 2005 DENV-2
337 Puerto Rico EU482551 2006 DENV-2
338 Puerto Rico EU482720 2006 DENV-2
339 Puerto Rico EU596489 2007 DENV-2
340 Puerto Rico EU529693 2004 DENV-2
341 Puerto Rico EU687213 2004 DENV-2
342 Puerto Rico EU482552 2006 DENV-2
343 Puerto Rico EU781135 2005 DENV-2
344 Puerto Rico EU482724 2005 DENV-2
345 Puerto Rico EU687235 2003 DENV-2
346 Puerto Rico EU482553 2006 DENV-2
347 Puerto Rico EU687215 2004 DENV-2
348 Puerto Rico EU482556 2005 DENV-2
349 Puerto Rico EU687214 2004 DENV-2
350 Puerto Rico EU687244 2004 DENV-2
351 Puerto Rico EU687242 2004 DENV-2
352 Puerto Rico EU687243 2004 DENV-2
353 Puerto Rico EU687245 2005 DENV-2
354 Puerto Rico EU687199 2003 DENV-2
355 Puerto Rico EU687236 2003 DENV-2
356 Puerto Rico EU687237 2003 DENV-2
357 Puerto Rico EU687238 2003 DENV-2
358 Puerto Rico EU687241 2003 DENV-2
359 Puerto Rico EU482593 2001 DENV-2
360 Puerto Rico EU482723 2002 DENV-2
361 Puerto Rico EU677146 2004 DENV-2
362 Puerto Rico EU677147 2004 DENV-2
363 Puerto Rico EU687240 2003 DENV-2
364 Puerto Rico EU687230 2001 DENV-2
365 Puerto Rico EU687228 2001 DENV-2
366 Puerto Rico EU687229 2001 DENV-2
367 Puerto Rico EU687231 2001 DENV-2
368 Puerto Rico EU482722 2002 DENV-2
369 Puerto Rico EU687227 2001 DENV-2
370 Puerto Rico EU687232 2001 DENV-2
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371 Puerto Rico EU687224 2000 DENV-2
372 Puerto Rico EU687222 2000 DENV-2
373 Puerto Rico EU687223 2000 DENV-2
374 Puerto Rico EU687225 2000 DENV-2
375 Puerto Rico EU482557 1999 DENV-2
376 Puerto Rico EU482730 1999 DENV-2
377 Puerto Rico EU482732 1998 DENV-2
378 Puerto Rico EU677143 1999 DENV-2
379 Puerto Rico EU596487 1998 DENV-2
380 Puerto Rico EU660400 1998 DENV-2
381 Puerto Rico EU569715 1997 DENV-2
382 Puerto Rico EU482547 1998 DENV-2
383 Puerto Rico EU569720 1997 DENV-2
384 Puerto Rico EU482565 1998 DENV-2
385 Puerto Rico EU569711 1998 DENV-2
386 Puerto Rico EU569717 1997 DENV-2
387 Puerto Rico EU569703 1996 DENV-2
388 Puerto Rico EU482721 2006 DENV-2
389 Puerto Rico EU529706 2006 DENV-2
390 Puerto Rico EU482727 1998 DENV-2
391 Puerto Rico EU482738 1998 DENV-2
392 Puerto Rico EU482729 1999 DENV-2
393 Puerto Rico EU569718 1997 DENV-2
394 Puerto Rico EU569719 1997 DENV-2
395 Puerto Rico EU482728 1998 DENV-2
396 Puerto Rico EU482733 1998 DENV-2
397 Puerto Rico EU482739 1994 DENV-2
398 Puerto Rico EU529700 1994 DENV-2
399 Puerto Rico EU569706 1995 DENV-2
400 Puerto Rico EU482550 1998 DENV-2
401 Puerto Rico EU482554 1998 DENV-2
402 Puerto Rico EU569716 1997 DENV-2
403 Puerto Rico EU596486 1996 DENV-2
404 Puerto Rico EU569709 1996 DENV-2
405 Puerto Rico EU677141 1996 DENV-2
406 Puerto Rico EU569712 1998 DENV-2
407 Puerto Rico EU677144 1999 DENV-2
408 Puerto Rico EU569713 1997 DENV-2
409 Puerto Rico EU569710 1996 DENV-2
410 Puerto Rico EU569714 1997 DENV-2
411 Puerto Rico EU596485 1996 DENV-2
412 Puerto Rico EU529695 1994 DENV-2
413 Puerto Rico EU569708 1995 DENV-2
414 Venezuela EU687220 1996 DENV-2
415 Puerto Rico EU482561 1996 DENV-2
416 Puerto Rico EU482741 1994 DENV-2
417 Puerto Rico EU482736 1994 DENV-2
418 Puerto Rico EU482737 1994 DENV-2
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419 Puerto Rico EU569705 1993 DENV-2
420 Puerto Rico EU529694 1994 DENV-2
421 Puerto Rico EU569707 1995 DENV-2
422 Puerto Rico EU660399 1995 DENV-2
423 Puerto Rico EU482594 1992 DENV-2
424 Puerto Rico EU482585 1989 DENV-2
425 Puerto Rico EU482562 1989 DENV-2
426 Puerto Rico EU482581 1989 DENV-2
427 Puerto Rico EU482743 1989 DENV-2
428 Puerto Rico EU482582 1989 DENV-2
429 Puerto Rico EU482578 1988 DENV-2
430 Puerto Rico EU482740 1994 DENV-2
431 Puerto Rico EU482579 1988 DENV-2
432 Puerto Rico EU482742 1988 DENV-2
433 Puerto Rico EU482747 1988 DENV-2
434 Puerto Rico EU482588 1990 DENV-2
435 Puerto Rico EU482589 1993 DENV-2
436 Puerto Rico EU482586 1990 DENV-2
437 Puerto Rico EU482587 1990 DENV-2
438 Puerto Rico EU660398 1989 DENV-2
439 Puerto Rico EU482745 1989 DENV-2
440 Puerto Rico EU482746 1989 DENV-2
441 Puerto Rico EU482569 1987 DENV-2
442 Puerto Rico EU482583 1989 DENV-2
443 Puerto Rico EU482584 1989 DENV-2
444 Puerto Rico EU482744 1989 DENV-2
445 Puerto Rico EU482590 1990 DENV-2
446 Puerto Rico EU482571 1987 DENV-2
447 Puerto Rico EU482573 1987 DENV-2
448 Puerto Rico EU482574 1987 DENV-2
449 Puerto Rico EU482575 1987 DENV-2
450 Puerto Rico EU482568 1986 DENV-2
451 Puerto Rico EU482576 1987 DENV-2
452 Puerto Rico EU482577 1987 DENV-2
453 Puerto Rico EU569704 1986 DENV-2
454 Puerto Rico EU482570 1987 DENV-2
455 Puerto Rico EU482572 1987 DENV-2
456 Puerto Rico EU482580 1989 DENV-2
457 Puerto Rico EU529701 1991 DENV-2
458 New Guinea M29095/M19727 1944 DENV-2
459 Thailand AF022434 1993 DENV-2
460 Thailand DQ181798 1999 DENV-2
461 Thailand EU687246 1994 DENV-2
462 Thailand DQ181800 1995 DENV-2
463 Thailand DQ181797 2001 OENV-2
464 Thailand OQ181799 1998 DENV-2
465 Thailand DQ181803 1985 OENV-2
466 Thailand AF022435 1993 OENV-2
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467 Thailand AF022436 1993 DENV-2
468 Thailand AF022441 1993 DENV-2
469 Thailand AF022440 1993 DENV-2
470 Thailand AF169678 1993 DENV-2
471 Thailand AFI69679 1993 DENV-2
472 Thailand AFI69680 1993 DENV-2
473 Thailand AFI69682 1993 DENV-2
474 Thailand AF169686 1993 DENV-2
475 Thailand AF169684 1993 DENV-2
476 Thailand AFI69685 1993 DENV-2
477 Thailand AFI69683 1993 DENV-2
478 Thailand AF169687 1993 DENV-2
479 Thailand AF169688 1993 DENV-2
480 Thailand AF169681 1993 DENV-2
481 Thailand AF022437 1993 DENV-2
482 Thailand AF022438 1993 DENV-2
483 Thailand AF022439 1993 DENV-2
484 Thailand EU726767 1994 DENV-2
485 Thailand 00181802 1988 DENV-2
486 Thailand DQ181805 1979 DENV-2
487 Thailand D()181804 1984 DENV-2
488 Thailand OQ181806 1974 DENV-2
489 Thailand NC 001474 1964 DENV-2
490 China AF276619 N/A DENV-2
491 Burkina Faso EU056810 1983 DENV-2
492 China EF051521 2001 DENV-2
493 Taiwan AY776328 N/A DENV-2
494 Indonesia AB189122 1998 DENV-2
495 Indonesia AB189123 1998 DENV-2
496 Indonesia AB189124 1998 DENV-2
497 Australia AY037116 1993 DENV-2
498 Brunei EU179857 2005 DENV-2
499 Brunei EU179858 2005 DENV-2
500 China EU359009 N/A DENV-2
501 Indonesia AY858036 2004 DENV-2
502 Indonesia AY858035 2004 DENV-2
503 Singapore EU081177 2005 DENV-2
504 Singapore EU08ll78 2005 DENV-2
505 Singapore EU081179 2005 DENV-2
506 Singapore EU081180 2005 DENV-2
507 Bangladesh AY496871 2002 DENV-3
508 Bangladesh AY496874 2002 DENV-3
509 Bangladesh AY496873 2002 DENV-3
510 Bangladesh AY496877 2002 DENV-3
511 Bangladesh DQ401689 N/A DENV-3
512 Bangladesh D0401691 N/A DENV-3
513 Bangladesh 00401692 N/A DENV-3
514 Bangladesh OQ401693 N/A DENV-3
191
9. Appendix 2
515 Thailand AY676352 1987 DENV-3
516 China EU367962 N/A DENV-3
517 Thailand AY676348 1998 DENV-3
518 Taiwan DQ675521 1998 DENV-3
519 Taiwan DQ675523 1998 DENV-3
520 Taiwan DQ675522 1998 DENV-3
521 Taiwan DQ675524 1998 DENV-3
522 Taiwan DQ675525 1998 DENV-3
523 Taiwan DQ675526 1998 DENV-3
524 Taiwan DQ675527 1998 DENV-3
525 Taiwan DQ675528 1998 DENV-3
526 Taiwan DQ675529 1998 DENV-3
527 Taiwan DQ675530 1998 DENV-3
528 Taiwan DQ675531 1998 DENV-3
529 Taiwan DQ675532 1998 DENV-3
530 Thailand AY676349 1998 DENV-3
531 Thailand AY923865 1994 DENV-3
532 Thailand AY676350 1993 DENV-3
533 Thailand AY676351 1993 DENV-3
534 Thailand AY876494 1994 DENV-3
535 Indonesia DQ675520 1998 DENV-3
536 Thailand AY676353 1987 DENV-3
537 Singapore AY766104 1995 DENV-3
538 Brazil EF629370 N/A DENV-3
539 China AF317645 N/A DENV-3
540 strain H87 M93130 N/A DENV-3
541 East Timor AB214879 2005 DENV-3
542 East Timor AB214880 2005 DENV-3
543 East Timor AB214881 2005 DENV-3
544 East Timor AB214882 2005 DENV-3
545 Indonesia AB189125 1998 DENV-3
546 Indonesia AY858042 2004 DENV-3
547 Indonesia AY858048 2004 DENV-3
548 Indonesia AY858047 2004 DENV-3
549 Singapore EU081221 2005 DENV-3
550 Singapore EU081223 2005 DENV-3
551 Indonesia AY858040 2004 DENV-3
552 Indonesia AY858037 2004 DENV-3
553 Indonesia AB189126 1998 DENV-3
554 Indonesia AB189127 1998 DENV-3
555 Indonesia AY858039 1998 DENV-3
556 Indonesia AY858041 2004 DENV-3
557 Indonesia AY858044 2004 DENV-3
558 Indonesia AY858045 2004 DENV-3
559 Indonesia AY858046 2004 DENV-3
560 Indonesia AY858043 2004 DENV-3
561 Indonesia AB189128 1998 DENV-3
562 Indonesia AY858038 1988 DENV-3
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563 Taiwan DQ675519 1995 DENV-3
French
564 Polynesia AY744677 1989 DENV-3
French
565 Polynesia AY744678 1989 DENV-3
French
566 Polynesia AY744682 1992 DENV-3
French
567 Polynesia AY744683 1992 DENV-3
French
568 Polynesia AY744684 1992 DENV-3
French
569 Polynesia AY744685 1994 DENV-3
French
570 Polynesia AY744680 1990 DENV-3
French
571 Polynesia AY744681 1990 DENV-3
French
572 Polynesia AY744679 1990 DENV-3
573 Indonesia AY648961 N/A DENV-3
574 Taiwan AY776329 N/A DENV-3
575 Indonesia DQ401690 N/A DENV-3
576 Philippines AY496879 1997 DENV-3
577 Indonesia DQ401694 N/A DENV-3
578 Philippines DQ401695 N/A DENV-3
579 Brazil AY679147 2002 DENV-3
580 Brazil EF629366 N/A DENV-3
581 Brazil EF629367 N/A DENV-3
582 Brazil EF629369 N/A DENV-3
583 Martinique AY099337 1999 DENV-3
584 Puerto Rico EU482555 2006 DENV-3
585 Puerto Rico EU482564 2003 DENV-3
586 Puerto Rico EU529692 2006 DENV-3
587 Puerto Rico EU529696 1999 DENV-3
588 Puerto Rico FJ024468 2004 DENV-3
589 Puerto Rico FJ024469 2004 DENV-3
590 Puerto Rico FJ024467 2004 DENV-3
591 Puerto Rico FJ390372 2003 DENV-3
592 Venezuela EU529691 2001 DENV-3
593 Puerto Rico EU529703 1998 DENV-3
594 Puerto Rico EU529704 2004 DENV-3
595 Puerto Rico FJ024471 2004 DENV-3
596 Puerto Rico FJ024470 2004 DENV-3
597 Venezuela EU854292 2005 DENV-3
598 Puerto Rico EU482558 1998 DENV-3
599 Puerto Rico EU482559 1998 DENV-3
600 Puerto Rico EU726771 1998 DENV-3
601 Puerto Rico EU482563 1998 DENV-3
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602 Puerto Rico EU529697 2000 DENV-3
603 Puerto Rico EU596492 2007 DENV-3
604 Puerto Rico EU596493 2007 DENV-3
605 Puerto Rico EU596494 2007 DENV-3
606 Puerto Rico EU529698 2006 DENV-3
607 Puerto Rico FJ390371 2003 DENV-3
608 Puerto Rico FJ373302 2004 DENV-3
609 Puerto Rico FJ024466 2004 DENV-3
610 Puerto Rico EU687198 2003 DENV-3
611 Puerto Rico EU687239 2003 DENV-3
612 Puerto Rico FJ478456 2002 DENV-3
613 Puerto Rico EU687233 2002 DENV-3
614 Puerto Rico FJ024465 2004 DENV-3
615 Puerto Rico EU687219 1999 DENV-3
616 Puerto Rico EU482566 1998 DENV-3
617 Puerto Rico EU781137 1999 DENV-3
618 Puerto Rico FJ390376 1999 DENV-3
619 Puerto Rico FJ390377 1999 DENV-3
620 Puerto Rico EU482595 2003 DENV-3
621 Puerto Rico EU529702 2003 DENV-3
622 Puerto Rico FJ373306 2002 DENV-3
623 Puerto Rico EU529705 2004 DENV-3
624 Puerto Rico EU687234 2002 DENV-3
625 Puerto Rico EU726768 2000 DENV-3
626 Puerto Rico EU726769 2003 DENV-3
627 Puerto Rico EU726773 1999 DENV-3
628 Puerto Rico EU687196 2002 DENV-3
629 Puerto Rico EU687221 2000 DENV-3
630 Puerto Rico FJ410178 2002 DENV-3
631 Puerto Rico FJ390373 2002 DENV-3
632 Puerto Rico FJ410176 2000 DENV-3
633 Puerto Rico FJ410177 2000 DENV-3
634 Puerto Rico EU726774 1999 DENV-3
635 Puerto Rico FJ390375 1999 DENV-3
636 Venezuela EU482612 2001 DENV-3
637 Venezuela EU482613 2001 DENV-3
638 Venezuela EU529689 2001 DENV-3
639 Venezuela EU529684 2001 DENV-3
640 Venezuela EU529683 2007 DENV-3
641 Venezuela EU529686 2001 DENV-3
642 Venezuela EU569690 2001 DENV-3
643 Venezuela FJ373304 2004 DENV-3
644 Venezuela EU529690 2001 DENV-3
645 Venezuela EU569691 2001 DENV-3
646 Venezuela EU569688 2001 DENV-3
647 Venezuela EU854291 2004 DENV-3
648 Venezuela EU569689 2001 DENV-3
649 Venezuela EU660420 2001 DENV-3
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650 Venezuela EU529687 2001 DENV-3
651 Venezuela EU482614 2001 DENV-3
652 Venezuela EU529685 2001 DENV-3
653 Venezuela EU529688 2001 DENV-3
654 Venezuela FJ373303 2001 DENV-3
655 Puerto Rico EU687197 2003 DENV-3
656 Puerto Rico EU854298 2002 DENV-3
657 Puerto Rico EU726772 1998 DENV-3
658 Puerto Rico EU687218 1998 DENV-3
659 Puerto Rico EU781136 1999 DENV-3
660 Puerto Rico EU529699 2006 DENV-3
661 Puerto Rico EU687226 1999 DENV-3
662 Puerto Rico EU482596 1998 DENV-3
663 Singapore AY662691 N/A DENV-3
664 Singapore EU081181 2004 DENV-3
665 Singapore EU081182 2005 DENV-3
666 Singapore EU081184 2005 DENV-3
667 Singapore EU081186 2005 DENV-3
668 Singapore EU081190 2005 DENV-3
669 Singapore EU081200 2005 DENV-3
670 Singapore EU081215 2005 DENV-3
671 Singapore EU081224 2005 DENV-3
672 Singapore EU081225 2005 DENV-3
673 Singapore EU081185 2005 DENV-3
674 Singapore EU081195 2005 DENV-3
675 Singapore EU081196 2005 DENV-3
676 Singapore EU081203 2005 DENV-3
677 Singapore EU081183 2005 DENV-3
678 Singapore EU081189 2005 DENV-3
679 Singapore EU081193 2005 DENV-3
680 Singapore EU081194 2005 DENV-3
681 Singapore EU081216 2005 DENV-3
682 Singapore EU081201 2005 DENV-3
683 Singapore EU081205 2005 DENV-3
684 Singapore EU081206 2005 DENV-3
685 Singapore EU081208 2005 DENV-3
686 Singapore EU081217 2005 DENV-3
687 Singapore EU081187 2005 DENV-3
688 Singapore EU081188 2005 DENV-3
689 Singapore EU081197 2005 DENV-3
690 Singapore EU081198 2005 DENV-3
691 Singapore EU081220 2005 DENV-3
692 Singapore EU081191 2005 DENV-3
693 Singapore EU081199 2005 DENV-3
694 Singapore EU081192 2005 DENV-3
695 Singapore EU081202 2005 DENV-3
696 Singapore EU081207 2005 DENV-3
697 Singapore EU081210 2005 DENV-3
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698 Singapore EU081211 2005 DENV-3
699 Singapore EU081212 2005 DENV-3
700 Singapore EU081218 2005 DENV-3
701 Singapore EU081219 2005 DENV-3
702 Singapore EU081222 2005 DENV-3
703 Singapore EU081204 2005 DENV-3
704 Singapore EU081209 2005 DENV-3
705 Singapore EU081214 2005 DENV-3
706 Singapore EU081213 2005 DENV-3
707 Taiwan DQ675533 1999 DENV-3
708 Sri Lanka Ne 001475 2000 DENV-3
709 Sri Lanka AY099336 2000 DENV-3
196
